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DEVELOPMENT OF METASTATIC
HETEROGENEITY IN MALIGNANT
TUMOURS. I. R. HART, Cancer Metastasis
and Treatment Laboratory, NCI-Frederick
Cancer Research Facility, Frederick, Maryland
21701 U.S.A.
The process of metastasis selects for meta-
static subpopulations of cells that pre-exist
within the primary tumour. Regardless of
whether the parent neoplasm is unicellular or
multicellular in origin, it can become hetero-
geneous with regard to the metastatic
phenotype within a short time. Metastatic
cells appear to be less stable genetically and
phenotypically than benign cells; this may
account for the ability of metastatic cells to
survive under strong selection pressures, such
as those imposed during tumour spread, and
to emerge as progenitors of secondary
growths. Tumour cell subpopulations of
clonal origin are phenotypically less stable
than polyclonal populations, perhaps because
an equilibrium exists among these hetero-
geneous subpopulations; a situation which
would tend to limit further diversification.
The development of metastatic heterogeneity
in malignant tumours and the selective nature
of the metastatic process have profound
implications for biological studies of tumour
spread.
BIOLOGICAL AND CLINICAL STUD-
IES OF CLONOGENIC HUMAN
TUMOUR CELLS. S. E. SALMON, Uni-
versity of Arizona Cancer Centre, Tucson,
Arizona 85724, U.S.A.
Since 1975, our group has worked on the
development of an in vitro clonogenic assay
for fresh biopsy samples, apply the technique
to biological diagnostic studies as well as
chemosensitivity testing. We have explored
host-tumour cell interactions in vitro and
found that the endogenous adherent macro-
phages were responsible for most of the
prostaglandin production as well as modula-
ting tumour growth. Adherent phagocytic
macrophages often appear to stimulate the
clonal proliferation ofthe tumour cells in this
culture system. Evidence that cells being
tested in vitro have relevance to tumour stem
cells in vivo has also been found. In a series of
4000 in vitro tests with standard cytotoxic
agents, significant activity against TCFU was
seen in 5-2000 of tumours tested, with
variation among tumour types. We have
conducted a series ofprospective clinical trials
of the assay in relation to clinical response
and survival. Overall, for a number oftumour
types, the assay predicts drug sensitivity with
60-70% accuracy, and drug resistance with
9500 accuracy. Accurate prediction of re-
sponse in melanoma is somewhat less com-
mon, unless "mixed" responses are included.
In both myeloma and ovarian cancer,
survival is better in patients who are sensitive
in vitro than in those who are resistant. The
assay also has major applications to chemo-
sensitivity testing with new agents for "in
vitro Phase II trials", and can be used to
target tumour types as well as to predict
required plasma concentrations for new
agents. The National Cancer Institute is also
exploring the application ofthis assay system
for pre-clinical use, in screening for entirely
new types of anticancer drugs.
GROWTH FACTORS FOR CULTURED
MAMMARY AND FIBROBLASTIC
CELLS. P. S. RUDLAND & J. A. SMITH,
Ludwig Institute, Royal Marsden Hospital,
Sutton, Surrey
The growth of the mammary gland is
controlled by a series of interacting mammo-
trophic hormones. However these hormones
are inactive compared with serum or novel,
semi-purified growth factors (GF) in stimula-
ting cell proliferation of cultured rat
mammary-gland epithelial cells. These GFs
are of 2 types, a pituitary GF exerting
systemic control, and GFs from surrounding
cells which may exert local control of
mammary epithelial-cell proliferation. The
effects ofthe GFs can be amplified by certain
mammotrophic hormones (e.g. insulin (I) and
hydrocortisone (HC)). As in the mammary
gland, GFs such as FGF, EGF, PGF2a can
stimulate DNA synthesis in quiescent 3T3
fibroblasts, which can be modified with I and
HC. To explain the kinetics obtained with
PGF2a and FGF, 2 operational signals are
postulated, signal (1) initiates a lag phase and
signal (2) determines the magnitude of the
rate of cellular entry into the S phase of the
cell cycle. Usually the rate of entry into S
governs the rate of cell division, but when
serum is completely removed, additional
components (e.g. transferrin) are required.
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During the lag phase the pathways generated
by signal (1) and signal (2) have to interact,
causing increases in hypothetical protein(s)
inside the cell. One ofthe altered properties of
virally transformed cells is their lack of
response to GFs. In the 2 cases examined by
other groups the viral transforming proteins
directly act on the putative intracellular
pathways, leading to increased cell-prolifer-
ation rates. This does not rule out the
possibility of autocrine stimulation by GFs in
other systems, but suggests that some of the
intracellular steps are the more vulnerable to
alterations Awhich lead to uncontrolled pro-
liferation of potentially neoplastic cells.
MURINE T-LYMPHOCYTE CLONES:
DERIVATION, CHARACTERIZATION
AND APPLICATION TO THE STUDY
OF ALLOGRAFT AND TUMOUR
IMMUNITY. H. R. MACDONALD, H. D.
ENGERS, R. K. LEES, A. L. GLASEBROOK, A.
KELSO, B. SORDAT, J.-C. CEROTTINI & K. T.
BRITNNER, Ludu?ig Institute for Cancer Re-
search, Lausanne Branch, and Dept. Immuno-
logy, ISREC, Epalinges, Switzerland
Clones of murine T-lymphocytes specific for a
variety of soluble and cell-bound antigens can
now be established and grown in the presence
ofT cell grow%th factor (TCGF). We have used
this cloning technology to study the immune
response to alloantigens and to murine
leukaemia virus (MoLV)-associated antigens.
T-lymphocyte clones in both antigenic sys-
tems were found to have various functional
phenotypes, as defined by cytolytic activity,
and the production of lymphokines such as
TCGF, interferon, macrophage-activating
factor (MAF), and granulocyte/macrophage
colony stimulating factor (GM-CSF).
Two approaches were used to investigate
the possible role of T-lymphocyte clones in
allograft and tumour immunity in vivo. In one
experimental model, cloned cytolytic T-
lymphocytes (CTL) were injected i.p. together
with dissociated suspensions of 131ldU-
labelled tumour target cells bearing relevant
alloantigens or MoLV-associated antigens.
In both cases, efficient tumour-cell destruc-
tion was obtained; bowever, when cloned
CTL were injected i.v., only certain clones
were capable of recirculating and destroying
tumour cells in the peritoneal cavity. In a
second model better simulating the com-
plexity associated with solid tumours in vivo,
multicellular spheroids of mammary tumour
cells were implanted i.p. and exposed to
cloned CTL. Again a destruction of tumour
spheroids by some (but not all) CTL clones
was noted. Taken together, these data
indicate that cloned T-cells warrant serious
consideration as an immunologically specific
therapeutic tool in allograft and tumour
immunity.
NATURAL CELL-MEDIATED CYTO-
TOXICITY AS A POSSIBLE ANTI-
TUMOUR SURVEILLANCE MECHAN-
ISM. 0. STUTMAN, Cellular Immunology
Section, Memorial Sloan-Kettering Cancer
Center, New York, N. Y., U.S.A.
Natural cell-mediated cytotoxicity (NCMC) is
detected in normal animals as the capacity of
their lymphoid cells to lyse a variety of
tumour cells in vitro. Based on surface-anti-
gen characteristics, genetic control as well as
other properties, 2 major types of effector
cells have been described: natural killer (NK)
and natural cytotoxic (NC) cells. Both types
do not appear to belong to any conventional
lymphoid or haemopoietic cell lineage. One of
the original differences, i.e. the preference of
the former for lymphoid tumours and of the
latter for solid tumours, is not that general,
since using either resting or boosted (with
poly-IC) effector cells, almost all the possible
permutations can be detected if enough
targets are studied (i.e. solid tumours lysed
exclusively by resting or boosted NK cells,
solid tumours lysed by resting NC and
boosted NK, etc.) This is not surprising since
"NK susceptible" and "NC susceptible"
targets share "antigenic" determinants based
on either cold-target inhibition studies or by
the capacity of monosaccharides to block
NCMC in vitro. The fact that NCMC exists at
relatively high levels in normal animals and
does not need time-consuming activation like
the more conventional immune responses,
that the system can deal preferentially with
small numbers of tumour cells and that it is
independent of conventional "tumour-
associated" antigens, make NCMC a likely
candidate for exerting immunosurveillance in
vivo, in the sense defined by Burnet.
Unfortunately, examples which support and
negate such interpretation are available.
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COMPARISON OF CLONOGENIC
ASSAY METHODS ON PLASTIC FOR
MEASURING DRUG SENSITIVITY IN
VITRO. P. J. HEPBURN, J. R. W. MASTERS &
B. T. HILL, Institute of Urology and Imperial
Cancer Research Fund, London
Although clonogenic assays provide an estab-
lished method for measuring in vitro drug
sensitivity, little is known concerning the
intercomparability of the various methods.
The purpose of this study was to investigate
some of the variables, including (a) com-
parison of transferring cells immediately
(CFE) or 25 h after drug treatment (CFE/24)
with leaving colonies to develop in situ (CFA),
(b) effect of feeder cells (3T3) and (c)
differences between cells in logarithmic (Exp)
and "Pre-Exp" phase growth. The effect of
these variables on sensitivity to a class II
(methotrexate) and a class III (adriamycin)
drug were compared using a continuous cell
line from a human bladder cancer, RT112.
Classic in vitro patterns of sensitivity were
found using exponentially growing cells
transferred immediately on to plastic follow-
ing drug exposure. However, using other
methods, the concentration required to
reduce survival by 50% (ID50-see Table)
extended over a 150- and 5-fold range,
respectively, for methotrexate and adri-
amycin. In conclusion we confirmed that
significant differences in the pattern of drug
sensitivity in vitro can result from variations
in clonogenic assay procedure.
CFE
CFE/24
CFA
CFE-3T3
CWE/24
CFA-3T3
ID50
(mg/ml)
Pre-Exp
MTX Exp
0 3 11-4
40-9 15-9
45-4
4-1 18-2
40-9 25-0
15-9
ID50
(mg/ml)
Pre-Exp
ADR Exp
11*0 7.4
4-4 7.3
17 4
14-5 5-8
5-8 17-4
1*8
CLONING OF HUMAN TUMOUR
STEM CELLS. SUCCESS OF DRUG
SENSITIVITY TESTING. A. P. SIM-
MONDS & E. C. MCDONALD, Biochemistry
Department, RoyalMaternityHospital, Glasgow
The in vitro stem-cell assay system (Ham-
burger & Salmon, 1977 Science, 197, 461) has
been used to grow ovarian tumour material
and effusions from breast and gastric cancer,
also osteosarcoma, melanoma and mesothel-
ioma. Predictive testing for drug sensitivities
(Salmon et al., 1978, N. Engl. J. Med., 298,
1321) has been done using cis-platin, adri-
amycin, methotrexate and vindesine. 88% of
samples in the ovarian group, comprising 60
patients and 88 samples, were cultured
successfully, and significant results for cis-
platin response achieved for 37 patients. Five
of these were also tested against ADR. Only
12 patients received drugs of test, of whom
6/7 at present evaluated clinically show good
correlation between test and outcome. Effu-
sions from other malignancies (8 breast, 2
mesothelioma and 1 each of gastric, osteo-
sarcoma and melanoma) were cultured suc-
cessfully, and correlation between test and
outcome found in 6/7 cases evaluated so far.
Failure to obtain drug results is due to (a)
paucity ofsample, or (b) low plating efficiency
in culture. Clearly this method needs further
evaluation as part ofa clinical trial, where the
drugs ofchemotherapy are known at the time
of assay. Although 13 of the 60 ovarian
patients received no chemotherapy, it should
be possible to test 3 drugs which a patient
might receive.
IN VITRO DRUG SENSITIVITY OF
HUMAN OVARIAN TUMOUR CELLS
TO CIS-DICHLORODIAMMINE PLAT-
INUM (CDDP). A. P. WILSON C. E.
NEWMAN, C. H. J. FORD & A. HOWELL, Dept.
of Obstetrics & Gynaecology, Clinical Research
Block, Withington Hospital, Manchester
28 human ovarian tumours have been
assessed for their sensitivity to CDDP in a
monolayer assay using depression of 3H-
leucine incorporation as an index of cell
death. At 1 ,tg/ml ofCDDP tumours could be
divided into 3 categories (i) sensitive, <35%
of control, (ii) intermediate, 34-45% of
control, (iii) resistant, >450 of control.
Clinical data are available for 4 previously
untreated patients and 7 receiving 5 courses
of 100 mg/M2 CDDP. In the untreated group,
2 patients with sensitive tumours and one
patient with an intermediate tumour had
complete responses to CDDP treatment,
whilst one patient with an intermediate
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tumour had progressive disease after 2 courses
of CDDP. In the treated group one tumour
was sensitive and 3 were intermediate,
suggesting that full resistance to CDDP had
not developed. Comparison between sensitiv-
ity to CDDP and other drugs in the same
assay system revealed a marked correlation
between CDDP and Cyclophosphamide (CY)
sensitivity. 93%0 (12/13) of tumours resistant
to CDDP were also resistant to CY whilst
53% (8/15) which were sensitive to CY.
Similar trends were observed with melphalan,
bleomycin, chlorambucil and vinblastine, but
not with 5-fluorouracil or adriamycin. The
unique sensitivity of some tumours to CDDP
was a notable finding.
CLONOGENICITY OF HUMAN GLIA
IN SUSPENSION. R. I. FRESHNEV & E.
HART, Department of Oncology, University of
Glasgow
Macpherson and Montagnier (Virology 1964,
23, 291) demonstrated that polyoma virus-
induced malignant transformation ofhamster
fibroblasts was accompanied by a substantial
increase of cloning efficiency in soft agar.
Unfortunately, short-term cell cultures
derived from human tumours do not clone in
suspension with the high efficiency of trans-
formed rodent fibroblasts, making this a less
satisfactory criterion ofmalignancy. We have
shown, moreover, that the capacity to form
colonies in suspension may be found in some
normal solid tissue cells also.
Cells from a number ofshort-term cell lines
were plated between 5 x 104 and 5 x 105 per
35 mm dish or 103-104 per well in microtitra-
tion plates. A methocel upper layer and agar
lower layer was used at varying concentra-
tions, and optimal cloning was obtained in
microtitration dishes with a 0.5% agar
underlayand0.8% methoceloverlay. Success-
ful cloning was achieved with several lines of
normal glia and fibroblasts as well as with
glioma and melanoma using a lower limit of
32 cells per colony. Optimization of the
conditions did not discriminate between
cultures derived from normal or malignant
tissue.
We conclude that for certain types of cell,
at least, the formation of colonies in
methocel/agar does not correlate with their
malignancy.
COLONY GROWTH AND CHEMO-
SENSITIVITY OF HUMAN MELANO-
MAS IN A SOFT-AGAR ASSAY. K. M.
TvEIT, S. VAAGE, S. GUNDERSEN & A. PIHL,
Norsk Hydro Institutefor Cancer Research and
The Norwegian Radium Hospital, Oslo,
Norway
The ability of human melanoma cells from
patients' metastases to form colonies in soft
agar was examined using the method of
Courtenay & Mills (Br. J. Cancer, 1978, 37,
261). Relatively high plating efficiencies (PEs)
were obtained. Thus, in a study of 150
metastases, 27% ofthe tumours gave PE 1%,
44%0 gave PEs of 0-1-0.9%, and 11% gave
0.01-0.09%. In 17% of the cases, colony
formation was not observed. The PEs were
not correlated with the degree of pigmenta-
tion or with the clinical course. The reason for
the high PEs was shown to be the presence of
rat erythrocytes and the low 02 used. The
data confirm that the soft-agar method
provides good culture conditions for human
melanoma cells.
The usefulness of the Courtenay colony-
forming assay in predicting individual clinical
responses to chemotherapy was examined.
Evaluable chemosensitivity data in vitro were
obtained on 104 metastases from 83 melan-
oma patients. For all 6 drugs studied the
observed sensitivity in vitro (1/ID50) was
converted into the same in vivo unit, viz. the
expected growth delay (EGD) by means of
the calibration curves obtained on melanoma
xenografts. A clear correlation was found
between the in vitro chemosensitivity and the
clinical response to chemotherapy. Thus,
tumours from patients with partial response,
mixed response or stable disease after prior
progression, all had rather high in vitro
sensitivity to the drug used (EGD>2.0);
whereas patients with progression had lower
sensitivity. In a few cases, chemotherapy
regimen was chosen on the basis of in vitro
sensitivity, and objective clinical responses
were obtained. The in vitro soft-agar assay
here used seems promising in aiding clinicians
in tailoring chemotherapy to individual
patients.
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DIFFERENTIAL RESPONSES OF
MURINE AND HUMAN-TUMOUR
CELL LINES TO ANTI-TUMOUR
DRUGS BEFORE AND AFTER EXPO-
SURE TO RADIATION. A. S. BELAMMY
& B. T. HILL, Laboratory of Cellular Chemo-
therapy, Imperial Cancer Research Fund,
London WC2A 3PX.
The influence of several fractions of X-
irradiation (DXR) on subsequent response to
chemotherapeutic agents has been investi-
gated in mammalian tumour-cell lines in
vitro. Details ofDXR-pretreatment ofmurine
L5178Y lymphoma cells and a human line,
HN-1, derived from a head and neck
squamous-cell carcinoma have been described
previously, together with a characterization
of these sub-lines (Bellamy & Hill, 1981, Br.
J. Cancer, in press). Survival of parent and
DXR-treated tumour cells after 24h drug
exposures was assayed by colony formation in
soft agarose.
Results w,ith L5178Y cells indicate greater
sensitivity of DXR-pretreated cells to bleo-
mycin, cis-platinum and dibromodulcitol
than untreated cells: IC10 values being
decreased 4-, 2- and 2-fold respectively.
Responses to VP-16-213 and vincristine were
considerably reduced by DXR-pretreatment,
wi-ith survival plateauing at 50 and 950/,
respectively. However, the cytotoxicity of
adriamycin and 5-fluorouracil appears to be
unchanged.
Preliminary results with the human HN-1
lines, indicate that DXR-treatment also
causes changes in sensitivity to cis-platinum,
bleomycin and VP-16-213. In contrast to
results with the murine cells, 5-fluorouracil
shows increased cytotoxicity on DXR-pre-
treated cells over untreated parent cells.
It is hoped that this information may be of
value in designing more effective drug
therapies for human tumours recurring after
DXR, since several types, including head and
neck tumours (Price & Hill, 1980, J. Laryngol.
Otol., 94, 89) show- a significantly reduced
response to subsequent chemotherapy.
THE SURVIVAL OF HUMAN MELAN-
OMA CELLS TAKEN DIRECTLY
FROM PATIENTS AND TREATED
WITH LOW DOSES OF y-RADIATION.
V. D. COURTENAY & J. MILLS, Institute of
Cancer Research. Sutton, Surrey
Cell survival data from established cell lines of
human melanoma irradiated in vitro
(Barranco et al., 1971, Cancer Res., 31, 830;
Guichard et al., 1977, J. Natl Cancer Inst., 18,
1967) have tended to show relatively large
shoulders to the survival curves. Such results
have provided a theoretical basis for the
introduction of larger dose fractions in
radiotherapy regimes for the treatment of
melanomas.
Our objective in the present studies was to
take melanoma cells directly from patients
and to measure their response to radiation at
doses in the shoulder region of the dose/
response curve. The dose range up to 7 Gy
covered the range ofdose likely to be given as
a single fraction in fractionated radiotherapy.
Single-cell suspensions from the disaggregated
tumours were exposed in vitro to the y-
radiation from a 60Co source under oxic
conditions. Cell survival was assayed in a
replenishable soft-agar colony technique
(Courtenay & Mills, 1978, Br. J. Cancer, 37,
261). Colonies of more than 50 cells were
counted and PEs of 2-10% were obtained.
Survival curves showed little difference
between 1 tumour and another and exhibited
a characteristic shape continuously bending
from an initial slope. The curve was best fitted
by the linear quadratic equation ln f=
- (xD+gD2). These melanomas were also
maintained as xenografts in CBA mice or
cultured for several weeks as monolayers.
Over the same dose range, cells from
xenografts or cultures gave curves indistin-
guishable from those from the original
tumours.
These results suggest that a wide shoulder
to the survival curve is a common and stable
characteristic of human melanoma cells.
PROLIFERATIVE RESPONSES OF
HUMAN PROSTATIC NEOPLASIA
AND RAT PROSTATE IN ORGAN
CULTURE. A. C. RICHES, D. MISTRY, L.
BUCHANAN, G. DATTANI & J. P. A. WEAVER,
Department of Anatomy and Experimental
Pathology, University of St Andrews, and
Department of Urology, Dundee Royal
Infirmary
In an attempt to provide a model for
investigating hormone responsiveness and
sensitivity to chemotherapy of prostatic
464ABSTRACTS
neoplasia, the proliferative responses of
human and rat prostate have been followed in
organ culture using 125JdU uptake to monitor
DNA synthesis. In serum free cultures,
testosterone induced a marked increase in
DNA synthesis in prostates from 4-6-month-
old rats, reaching maximal levels after 4 days
in culture, after which the uptake decreases to
control unstimulated levels. This proliferative
response is dose dependent and is maximal at
testosterone concentrations of 4 x 10-9 M to
4 x 10-6AI, whereas in prostates from 12-
month-old rats the response was less marked.
Human benign prostatic hyperplasia showed
a minimal response to testosterone, a similar
pattern to that seen in the older rats. The
proliferative response of human benign pro-
static hyperplasia increases up to Day 3-4 in
culture, and then declines in both control and
hormone-treated groups, and may represent
repair processes which appear to be hormone
dependent. Explants from prostatic carcin-
oma were well maintained in organ culture,
but had to be carefully selected using frozen
sections to obtain cellular areas in the trans-
urethrally resected tissue samples. No
marked changes in the histological appear-
ance of the prostatic-carcinoma explants was
found in the presence of testosterone, Estra-
cyt or oestradiol. Testosterone exhibited some
stimulatory effects in 125IdU uptake, whereas
both Estracyt (oestramusine phosphate) and
estradiol were weakly inhibitory. Thus,
explants of prostatic neoplasia are well
maintained in organ culture and provide a
model for investigating the effects oftherapy.
HUMAN BLADDER TUMOURS IN
SHORT-TERM ORGAN CULTURE.
A. H. LAWSON, A. C. RICHES & J. P. A.
WEAVER, Department of Anatomy and Experi-
mentalPathology, University ofSt Andrews and
Division of Urology, Dundee Royal Infirmary
Transitional cell tumours of the urinary
bladder present a problem in management
because of their tendency to recur. The
tumours may be completely cured after
resection, may recur at the same grade and
stage or may recur at a worsening grade and
stage. There is no way ofpredicting behaviour
on histological appearance alone. Treatment
may be by resection, radiotherapy, total
cystectomy, intravesical chemotherapy or
systemic chemotherapy. Diffuse papillary
carcinomas are particularly difficult to treat
by resection, but total cystectomy or radio-
therapy carries a high morbidity for a low-
grade tumour. These may be treated by
instilling anti-cancer agents into the bladder.
Human bladder tumours have been main-
tained in organ culture and their kinetic
properties and responses to anti-cancer agents
in vitro have been studied. Proliferative
behaviour is studied using 125IdU uptake in
combination with histology, vincristine meta-
phase arrest and autoradiography with
[3H]dT. Drug treatment is mimicked by
immersing the explants for 1 h, washing and
then studying recovery. Different behaviour
is seen in different grades of tumour, and
different tumours respond differently to
different drugs. Correlation between in vitro
and in vivo behaviour remains to be estab-
lished. If a method of identifying tumours
liable to rapidly progress could be established,
it would enable urologists to embark on much
more radical treatment at an early stage of
the disease. Similarly a method of testing
tumours for drug sensitivity would enable one
to tailor treatment for each individual
patient.
GROWTH OF HUMAN BLADDER-
CANCER BIOPSIES IN IMMUNE-
DEPRIVED MICE. J. H. HAY*T, A. BUSUT-
TILt, C. M. STEELt & W. DUNCAN*, *Univer-
sity Department of Clinical Oncology,
IDepartment ofPathology, and tMCR Clinical
and Population Cytogenetics Unit, Western
General Hospital, Edinburgh
A series of serially transplantable xenografts
has been successfully established from
biopsies of transitional-cell carcinoma of the
bladder. These are now being used for chemo-
therapeutic and radiobiologial studies.
CBA/Lac mice were prepared by thymec-
tomy and whole-body irradiation after pre-
treatment with 200 mg/kg of Arg-C (Millar et
al., 1978, Cell Tissue Kinet, 11, 543). The mice
received 7-5 Gy of 250 kV X-rays, which is
the LD50 of untreated mice from our colony.
All biopsy material has been collected from
primary bladder tumours; no metastatic
tumour has been used.
To date, a total of 4/33 transitional-cell
carcinoma biopsies have taken and success-
fully passaged. 0/8 well differentiated (GI),
2/12 moderately differentiated (G2) and 2/13
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poorly differentiated (G3) tumours have
taken. One squamous carcinoma and one
mixed transitional-cell and adenocarcinoma
have failed to grow. 3/4 successful takes have
been from tumours recurring after surgical
resection, the 4th was from a previously
untreated patient. 3/4 ofthe xenografts grow
subcutaneously as spherical tumour nodules,
the 4th maintains the sessile pattern com-
monly seen in the bladder. The histological
appearances of all the xenografts are similar
to those of their parent tumours. No
successful takes have occurred from biopsies
taken when the bladder was irrigated with
water or from biopsies taken with the
resectoscope.
CORRELATION OF ANTITUMOUR
ACTIVITY OF HEXAMETHYLMEL-
AMINE ANALOGUES WITH THEIR
IN VITRO CYTOTOXICITY AND
METABOLISM. S. P. LANGDON, D. Ross,
A. GESCHER, J. A. HICKMAN & M. F. G.
STEVENS. C.R.C. Experimental Chemotherapy
Group, Department ofPharmacy, University of
Aston, Birmingham B4 7ET
The degree of antitumour activity of HMM
and its analogues in mice correlates with the
extent of their in vitro biotansformation to
formaldehyde (F) and formaldehyde pre-
cursors (FP) (Rutty, C. J. et al., 1977,
Biochem. Pharmacol., 26, 2385). In an attempt
to explain the exceptions to this correlation
(e.g. the chloro analogue of HMM, IV) we
investigated the in vitro cytotoxicity and
metabolism of 3 melamine analogues (I, II,
III) which have shown activity and three
compounds (IV, V, VI) devoid of activity.
These results suggest that in vitro cyto-
toxicity correlates with in vitro biotrans-
formation, whilst the antitumour activity of
these analogues correlates with plasma levels
ofFPgenerated bymetabolism.
METABOLISM OF MONOMETHYL-
TRIAZENES. J. K. HORTON, P. FARINA*,
A. GESCHER, J. A. HICKMAN & M. F. G.
STEVENS. CRC Experimental Chemotherapy
Group, University of Aston, Birmingham B4
7ET, and *Istituto Mario Negri, Milan, Italy
(I) R = Me, RI = Ac
Rlq ,N; R (II) R = H, RI = Ac
\ /N-N (III) R = H, RI =CN
Me (IV) R = H, R' = N02
Antitumour 1-aryl-3,3-dimethyltriazenes
(DMT) show cytotoxic activity in vitro to
TLX5 lymphoma cells only after metabolic
activation. Products of their demethylation
(the monomethyltriazenes MMT) have been
posulated to be the active antitumour species
by a number of workers, but we have
questioned this because MMTs were found to
be equitoxic in vitro to TLX5 cells sensitive or
resistant to DMTs in vivo (Gescher etal., 1981,
Biochem. Pharmacol., 30, 89). Under condi-
tions where DMTs are known to be activated
in vitro (ibid) the DMTs (I) (500 ,tg/ml)
produced < 10 ,tg/ml of (II) as measured by
HPLC. This was below the level necessary to
account for the cytotoxicity and it was
considered possible that either MMTs are
activated further, or they are not relevant to
cytotoxicity. Under these activation condi-
tions (9000 g fraction of mouse liver homo-
genate and cofactors) 90% of the MMT (II)
Cytotoxicity in
vitro (% inhibn.t) Biotrans-
Peak FP levels * formation
R Rl in plasma (/,M)* - + in vitro
I NMe2 NMe2
II NHMe NMe2
III NH2 NMe2
IVC1 NMe2
V NHNH2 NMe2
VI NHMe NHMe
93
243
101
16
33
51
0
0
0
63
24
0
97
99
60
96
11
3
100
98
38
113
13
6
* After i.p. administration of 0-48 mmol/kg drug. Method of Sawicki et al., 1961, Anal. Chem., 33, 93),
adapted to distinguish between F and FP.
t 2h incubation of 106 PC6A cells with 5 mM drug in the absence (-) or presence (+) of a liver micro-
somal activating system (LMAS).
t Metabolism on incubation with LMAS as measured by the appearance of F and FP according to Nash,
1953, Biochem. J., 55, 416); % relative to HMM.
R
NA
R'1 NJ'
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(4 ,ug/ml) was shown by HPLC to have
disappeared in 30 min, whereas <3000 dis-
appeared in controls (e.g. boiled liver). Similar
results were obtained whenthe MMT (III) and
(IV) were used. An in vitro assay of
cytotoxicity of the MMT (II) ± liver fraction
and cofactors, suggested that metabolism of
this MMT is a deactivating process and thus
that some other metabolite ofDMTs is likely
to be responsible for their antitumour effect.
PHARMACOKINETIC STUDIES OF N-
METHYLFORMAMIDE (NSC 3051) IN
MICE. C. BRINDLEY, A. GESCHER, E. S.
HARPUR & J. A. SLACK, CRC Experimental
Cancer Chemotherapy Group, University of
Aston, Birmingham B4 7ET.
N-Methylformamide (NMF) is an agent with
antitumour activity against a number of
murine tumours, and is currently undergoing
Phase I clinical evaluation. As part of a pre-
clinical investigation of its pharmacological
properties, its pharmacokinetics in mice were
studied. 400 or 80 mg/kg NMF was admin-
istered i.v., i.p. ororally to male CBA CA mice
(20-25 g). When these doses of NMF were
given repeatedly to mice tumour growth was
inhibited (Langdon et al., 1981, Br. J. Cancer,
44, 277). Blood samples (20 dul) were taken at
intervals from the tip ofthe tail for 24 h after
drug administration. The plasma concentra-
tion of unchanged NMF was measured by
gas-liquid chromatography. After i.v. admin-
istration, the plasma concentration vs time
curves (AUC) were 5325 + 1270 ,tg.h/ml
(n=5) for the high dose and 1399 + 276 ug.h/
ml (n=4) for the low dose. The corresponding
AUCs for oral administration were 5360 +
1117 ug.h/ml (n=8) and 1058 +201 /tg.h/ml
(n=3). After i.p. administration, the route
used in the antitumour tests, 400 mg/kg
NMF gave a AUC of 5452 + 783 ug.h/ml
(n=5). These AUCs show that the systemic
availability of NMF in mice after i.p. or oral
administration was equivalent to that after
i.v. administration.
The disappearance ofNMF from plasma, at
least at high concentrations, appeared to
follow zero-order kinetics. Our current invest-
igations of the disposition of NMF may
provide an explanation forits apparently non-
linear pharmacokinetic behaviour.
THE PHARMACOKINETICS OF ORAL
AND IV TREOSULFAN. J. WELSH*,
J. F. B. STUART*t, M. SOUKOPt, D. CUN-
NINGHAMt, R. BLACKIE*, G. SANGSTER*, &
K. C. CALMAN, *Department of Clinical
Oncology, University of Glasgow, tDepartment
of Medicine, Royal Infirmary, Glasgow, tDe-
partment of Pharmacy, University of Strath-
clyde, Glasgow
Treosulfan (L-threitol 1,4-bismethanesul-
phonate) is itself inactive. Its conversion to
the active epoxides is not enzymatically
dependent, the transformation being depend-
ent on temperature and pH; this has been
shown in vitro (Feit, 1970, J. Med. Chem.,
13, 1173). Treosulfan is conventionally pre-
scribed at low doses e.g. 500 mg b.d. for 2-4
weeks followed by a rest period of 2-4 weeks
dependent on haematological parameters.
The chiefrole oftreosulfan is in the treatment
of ovarian cancer. Treosulfan has been shown
to have a short half-life in animal studies.
This alkylating agent may thus be suitable
for high dose regimens involving autologous
marrow replacement. This study was des-
igned to determine the pharmacokinetics and
haematological toxicity of moderate dose
treosulfan (200 mg/kg). Seven patients were
studied, 4 of whom received the drug i.v.
and orally, the other 3 receiving the drug
i.v. only. Samples of plasma, tears, saliva,
urine and in one case bile, were obtained and
immediately frozen at -20°C until analysis.
The analytical technique was a gas-liquid
chromatographic method. The bioavailability
of oral treosulfan approaches that of i.v.
treosulfan, and tear and saliva measure-
ments closely follow plasma levels. Treo-
sulfan was also detected in bile and urine.
Peak plasma levels of 0 7 mg/ml were ob-
tained and the ty for oral treosulfan was
1-8h, compared to a tj of 1-5h for i.v.
drug. In conclusion, it would appear that
treosulfan in the dose of 200 mg/kg is reason-
ably well tolerated, and that its kinetics
suggest that it would be suitable for use in
high dose in association with autologous
marrow replacement.
PHARMACOKINETIC AND TOXICITY
STUDIES WITH CB 3717. D. R. NEWELL,
Z. H. SIDDIK, K. G. MCGHEE, ANN L.
JACKMAN, A. H. CLAVERT & K. R. HARRAP.
Dept Biochem. Pharmacol., Inst. Cancer Res.,
Sutton, Surrey
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CB 3717 (N - (4 - (N - ((2 - amino -4 - hydroxy-
6 - quinazolinyl)methyl)prop - 2 - ynylamino)-
benzoyl)-L-glutamic acid) is a folate-based
inhibitor ofthymidylate synthetase (TS) cur-
rently undergoing clinical tria]. Pharmaco-
kinetic studies have been made in mice at
100 mg/kg i.p., a dose which is curative
against the L1210 leukaemia on a daily x 5
schedule. This dose produced peak plasma
levels (71 +8 ,ug/ml) of CB 3717, achieved
within 2 h. This concentration was main-
tained for a further 2 h after which levels
decayed with a half-life of 81 + 8 min.
Within 24 h 55 + 11% of the administered
dose was present in the faeces and 14+10%
excreted in the urine. NoCB 3717metabolites
have been detected significant activityagainst
TS. In tissue distribution studies, 6-5 + 1.2%
of the administered dose was present as the
unchanged drug in the kidney 24 h later.
With repeated daily administration this is
associated with an increase in kidney wet
weight, whilst at lethal doses (300 mg/kg/
day) animals died from renal failure. Co-
administration of NaHCO3 (2.1 g/kg/day)
prevents the precipitation of CB 3717 in the
kidney and the associated increase in kidney
wet weight. The presence of CB 3717 in the
faeces is suggestive of biliary excretion. This
was confirmed in the rat, where at low doses
(1-10 mg/kg i.v.) >70%o of the dose was
excreted unchanged in the bile within 4 h.
At a higher dose (40 mg/kg i.v.) CB 3717
precipitation in the bile duct and a reduced
bile flow was observed. This effect consist-
ently occurred when plasma CB 3717 levels
exceeded 10 ,ug/ml. These studies indicate
that renal and hepatic toxicities may be
anticipated in man. However, with appro-
priate scheduling, these side-effects can be
avoided.
EARLY CLINICAL STUDIES WITH
THE QUINAZOLINE CB 3717. DAWN L.
ALISON, D. R. NEWELL, A. H. CALVERT &
K. R. HARRAP, Dept Biochem. Pharmacol.,
Inst. Cancer Res. and Royal Marsden Hosp.,
Sutton, Surrey
CB 3717 is a cytotoxic antifolate currently
undergoing early clinical trials. Two dose
schedules are being used involving lh infus-
ions (single dose or daily x 5) repeated at
3-week intervals. 24 patients have undergone
treatment so far. Renal toxicity, which
might have been anticipated from the
preclinical studies, has not been seen. Several
patients, however, have displayed abnormal-
ities of hepatic function, with raised trans-
aminase levels. This followed plasma levels
ofCB 3717 which would be expected to cause
biliary precipitation of the drug in rats. It
has been possible to overcome the liver
disturbance in 2 patients by infusing the same
dose ofdrug over 12-24 h. A variety ofrashes
has been seen in 6 of the patients, one dis-
playing a diffuse erythematous reaction at the
sites of previous irradiation. Marrow sup-
pression has occurred in 4 patients, with
neutropoenia and thrombocytopoenia de-
veloping 10-12 days after starting the 5-day
treatment. Pharmacokinetic studies have
shown that the renal excretion of CB 3717
varies 10-80%. Results suggest that the
maximum tolerated dose will be in the range
140-200 mg/m2/day for the 5-day schedule,
achieving plasma levels above 10 ,ug/ml is the
cytotoxic level in vitro. With the single-dose
schedule 330 mg/M2 has been tolerated in 3
patients so far, one of whom has attained
peak plasma levels of 54 jug/ml and has also
had an objective response to treatment.
THE PHARMACOKINETICS OF S.C.
INFUSIONS OF AraC. M. L. SLEVIN,
E. M. PIALLt, G. W. AHERNEt, A. JOHN-
STONt & T. A. LISTER*, *ICRF Dept of
Medical Oncology, St Bartholomew's Hospital,
London, Dept of Biochemistry. University of
Surrey, Guildford, tDept of Clinical Pharma-
cology, StBartholomew's Hospital, London
The therapeutic advantages of continuous
infusion of AraC have to be balanced against
the disadvantages of hospitalization and the
medical and nursing supervision required to
establish and maintain i.v. therapy. S.c.
bolus AraC has been used as an alternative
to i.v. infusion. However, s.c. bolus AraC is
rapidly absorbed and then declines with a
half life similar to that of i.v. AraC, and
within a few hours plasma AraC levels are
+ 10% of steady state infusion levels (Slevin
et al., 1981, BJCP, 12, 507). This within-
patient study compared the pharmaco-
kinetics of s.c. infusions of AraC (100 mg/M2
over 12 h) with the same dose given by con-
tinuous i.v. infusion in 6 patients with acute
myelogenous leukaemia. The mean plasma
concentration of AraC reached a plateau
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within 2 h, and the plasma concentrations
and the area under the curve (AUC) were
similar for both methods of administration.
The mean AUC was 1147 + 230 for the i.v.
infusions, and 1017 + 238 ng/h/ml for the
s.c. infusions. There was a relatively large
inter-patient difference in the plasma levels
during the infusions. Furthermore, there was
also a >2-fold variation in the plasma con-
centrations ofAraC within individual patients
after the plateauhadapparentlybeenreached.
The variable plasma concentrations during
the so-called "steady state" need to be taken
into account in any attempt to correlate
steady-state AraC levels with therapeutic
outcome. This study demonstrates that s.c.
infusion of AraC is a feasible alternative, and
comparable to i.v. infusion. It may allow the
patient the benefit of out-patient therapy
while preventing unnecessary thrombophle-
bitis.
THE COMBINATION OF CYTOTOXIC
DRUGS WITH CLINICALLY RELE-
VANT DOSE REGIMES OF MISONI-
DAZOLE. P. R. TWENTYMAN & P. WORK-
MAN, MRC Clinical Oncology and Radio-
therapeutics Unit, Cambridge
A number ofgroups, including our own, have
demonstrated that the effectiveness of vari-
ous cytotoxic drugs against mouse tumours
may be enhanced by the addition of the
nitroimidazole radiosensitizer, MISO to the
drug treatment. In some, but not all, of
these studies a therapeutic gain is claimed,
in that enhancement of tumour response is
greater than the increase in normal tissue
toxicity. Almost all of these investigations
have used large single doses of MISO in the
range 2-5-5 mmol/kg, which produce plasma
levels 5-10 x those seen after the maximum
clinical dose of the drug (3 g/m2). The half-
life of MISO is, however, much longer in
man than in the mouse, and this factor
may compensate for the reduced peak levels.
We have now carried out a series of experi-
ments in mice in which repeated injections
of MISO at 30 min intervals have main-
tained plasma levels at 100 ,g/ml for either
7 or 16 h. In C3H mice bearing the KHT
sarcoma, the tumour response to the nitro-
sourea CCNU was enhanced only nominally
when the CCNU was administered at 4 h
into the 7h regime. The enhancement was
greatest at lower doses of CCNU, and was
less than that for a large single dose ofMISO.
A similar regime of repeated MISO admin-
isteration produced little if any increase in
the response of the RIF-1 sarcoma to cyclo-
phosphamide (CY) and chlorambucil, in
melphalan. Data for the 16h regime of MISO
administration indicate greater enhance-
ment of CY response than seen for the 7h
regime.
STUDIES ON THE FORMATION OF
AN AFLATOXIN B1-8,9-OXIDE CON-
JUGATE WITH GLUTATHIONE AFB1-
GSH IN VITRO AND IN VIVO. R. C.
GARNER, P. J. HERTZOG & J. R. LINDSAY-
SMITH, Cancer Research Unit, University of
York, Heslington, York YO1 5DD
Incubation of aflatoxin B1 (AFB1) and (14C)-
labelled glutathione with either a rat or
mouse liver post-mitochondrial supernatant
(PMS) and subsequent reversed-phase HPLC
of the metabolites revealed the formation of
an AFB1-GSH conjugate. This metabolite
eluted prior to other AFB: metabolites such
as AFM1 and AFP1. Mouse PMS produced
more of this metabolite than rat PMS. UV
spectra of AFB1-GSH indicated that linkage
ofGSH to AFB1 was through a sulphur rather
than a nitrogen group. Acid hydrolysis (N
HCI at 100°C for 60 min) of AFB1-GSH
released the glutamic residue, to leave an
AFB1 conjugate that was not AFB1-8, 9-diol.
A metabolite with an identical retention time
on reversed-phase chromatography to AFB1-
GSH was also found in the bile of cannulated
rats administered AFB1. Despite the forma-
tion of this GSH conjugate in vitro and in
vivo, addition of GSH to the top-agar of a
Salmonella/microsome assay of AFB1 does
not inhibit mutagenicity.
MONOCLONAL ANTIBODIES TO
AFLATOXIN-DNA ADDUCTS. P. J.
HERTZOG,J. LINDSSAY-SMITH & R. C. GARNER,
Cancer Research Unit, University of York,
Heslington, York
Aflatoxin B1 is a probable human liver
carcinogen found in high levels in certain
countries. The potential of antibodies to
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aflatoxin B1 DNA (AFB1-DNA) adducts is
important since5they would reflect not only
exposure, but actual levels of damage, and
permit, to some extent, the much needed
study of carcinogenesis in humans.
We have raised such antibodies using the
guanine open-ring (ro) form of AFB1-
reacted DNA (ro AFB1-DNA) coupled to
methylated keyhole-limpet haemocyanin as
immunogen. Spleen cells from immunized
mice were fused with myeloma cells by
conventional methods and hybridomas sel-
ected in HAT medium. Specific antibody-
secreting hybridomas were detected by
enzyme-linked immunosorbent assay
(ELISA) using microtitre plates with wells
coated with ro AFB1-DNA. Positive hybri-
domas were cloned twice by limiting dilution,
then grown in ascites, for the production of
high-titre (1:105) ascites fluid for use in
immunoassays.
In standard competition assays, dilute
ascites fluid was preincubated with or with-
out an inhibitor (e.g. DNA, AFB1-DNA),
followed by incubation on the plate. The
monoclonal antibodies produced reacted
specifically with AFB:-DNA, rather than
DNA, and could detect adducts at the levels
found in liver DNA from animals dosed with
aflatoxin B1.
USE OF MONOCLONAL ANTIBODIES
TO INVESTIGATE THE CELLULAR
EVENTS ASSOCIATED WITH HEPA-
TOCARCINOGENESIS. C. H. HOLMES,
B. GuNN, E. B. AuSTIN & M. J. EMBLETON,
Cancer Research Campaign Labs., University
of Nottingham, Nottingham NG7 2RD
Monoclonal antibodies to rat hepatocytes
were prepared by conventional techniques,
involving fusion of hepatocyte-immune
spleen cells from BALB/c mice with the mouse
myeloma, P3-NS1. One of these antibodies,
RL23/36, showed preferential reactivity
with adult rat hepatocytes, while a second
antibody, RL24/72, was much less specific
and showed cross-reactivity with a number
of other cell types. Both monoclonal anti-
bodies were specific for hepatocytes within
the liver, and showed no reactivity with
hepatic sinusoidal cells. In addition, a third
monoclonal antibody, RL24/106, which was
produced in the same way, showed reactivity
with connective-tissue components in both
liver and other tissues.
The expression of both hepatocyte-ex-
pressed antigens is profoundly affected during
hepatocarcinogenesis, the RL23/36-defined
antigen especially being reduced in a number
ofdimethylamino-azobenzene (DAB)-induced
hepatomas.
The cellular composition of a range of
lesions induced in the liver by feeding dietary
DAB was examined immunohistochemically,
using these 3 monoclonal antibodies in con-
junction with several commercially available
monoclonal antibodies directed against rat
lymphocytes. Cells within these lesions
exhibited considerable heterogeneity with
respect to both expression of antigens
(identified by RL23/36 and RL24/72) and
also the degree and type of infiltrating cells
observed. Overall, there was a trend towards
a loss of liver-associated antigens in hepato-
cyte-derived cells and, in some cases, an
increase in the number of infiltrating host
cells.
THE ULTRASTRUCTURE OF DMBA-
INDUCED DYSKERATOSIS. F. H.
WHITE, R. M. CODD, N. J. SMITH & K.
GOHARI*, Departments of Human Biology and
Anatomy and *Oral Pathology, University of
Sheffield
The development of malignancy in keratin-
ized stratified squamous epithelia in both
humans and experimental animals is accom-
panied by the development of a variety of
histological changes known collectively as
epithelial dysplasia. One of these features,
dyskeratosis, is characterized by the pro-
duction of keratin in abnormal sites, i.e. in
areas other than on the surface of the tissue.
The present report describes the ultra-
structural features of dyskeratotic regions
from lesions produced in the hamster cheek
pouch epithelium by the chemical carcinogen
DMBA. Following DMBA application to
cheek pouches of male Syrian golden ham-
sters for a minimum of7 weeks, tissue samples
were removed and processed for electron
microscopy. Many individual dyskeratotic
cells within the spinous layer were seen. They
possessed a central, often pyknotic, nucleus
around which whorls of tonofibrils were
present; between the tonofibrils, mitochon-
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dria in various stages of degeneration,
vacuoles and lipid droplets were seen, and
these were often densely packed around the
nucleus. Keratin pearls consisted of a central
whorl of either ortho- or parakeratinized
cells around which granular cells were
present; these often contained small round
keratohyaline granules and abundant, often
reticular, tonofibril networks. Our observa-
tions suggest that dyskeratosis begins with
the keratinization of an individual cell or
group of cells. Adjacent cells subsequently
undergo flattening and whorling around this
nidus until a keratin pearl is formed.
BLOOD-VESSEL FREQUENCY DUR-
ING EXPERIMENTAL EPIDERMAL
CARCINOGENESIS. F. H. WHITE &
B. AL-AZZAWI, Department of Human Biology
and Anatomy, University of Sheffield, Shef-
fieldS10 2TN
The vascularization of tumours seems to be
essential for their continued growth and
development, but there is relatively little
information on the way the vessels develop
in the vicinity of neoplasms. Using morpho-
metric methods, we have previously reported
progressive increases in the volume of blood
vessels during experimental skin carcino-
genesis. These methods enable the generation
of objective data from histological sections.
Estimates of volumetric alterations are
limited, in that they do not provide a com-
plete description of the changes. In the pres-
ent report, we have estimated blood vessel
frequency (number per unit section area)
which will enable us to determine whether
the changes are a result of blood-vessel
dilatation or of new blood-vessel production.
Male Syrian golden hamsters were treated
3 times weekly wNith DMBA in liquid paraffin.
Two groups of animals were used as controls,
one of which w-as untreated and the other
receiving topical applications of liquid par-
affin for 10 weeks. Histological sections wiere
prepared and, using an image analyser, the
number of vessels per unit section area of
dermis and hypodermis was quantified. There
were progressive and significant increases in
the frequency of blood vessels during skin
carcinogenesis. In combination with our
32
previous findings, the results indicate that in
this experimental system, vascular altera-
tions are produced by the generation of new
blood vessels as well as by dilatation of
existing ones.
THE REGIONAL LYMPH NODE (RLN)
RESPONSE TO CHEMICAL CARCINO-
GENESIS IN THE HAMSTER CHEEK
POUCH (HCP). G. T. CRAIG, University of
Sheffield, Department of Oral Pathology, Shef-
fieldS10 2TA
The prognostic significance attributable to
morphological changes in RLN draining sites
of human primary cancer is somewhat
variable and often contradictory. Data
obtained from a variety of experimental
models are of questionable value, given the
predilection for the use of transplanted
tumours in heterotopic sites and the short
durations studied. Few reports have docu-
mented the in situ RLN response to the
development of induced primary carcinomas
with proven metastatic potential. The pres-
ent study used stereological (Craig, 1977,
J. Dent. Res., 56, 116) and histochemical
(Craig, 1980, J. Dent. Res., 59, 70) techniques
to monitor the morphological response of
RLN to DMBA carcinogenesis in the HCP
over a 24 week period. The early response
(0-2 wk), in both node and pouch, is con-
sistent with the induction of contact hyper-
sensitivity to DMBA; the associated and
marked paracortical (PC) expansion persisted
throughout the stages of carcinogenesis (i.e.
hyperplasia, dysplasia, carcinoma). Coinci-
dent with the emergence of exophytic tum-
ours (8-12 wk) the RLN shoxved prominent
follicular cortical (FC) activity and plasma
cell production. This pattern of FC prolifera-
tion was superimposed on the notably
expanded but relatively inactive PC com-
partment during the period from 12-24 wk)
The results suggest that the RLN response to
DMBA carcinogenesis in the HCP is charac-
terized by a sustained T-cell expansion,
attributable initially to contact sensitization
and subsequently to cell-mediated immunity
against presumptively immunogenic exo-
phytic tumours, and a later B-cell prolifera-
tion attributable either to non-specific ulcera-
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tion of tumours or humoral immunity to
shed tumour antigens.
HISTOGENESIS OF BILE-DUCT CAR-
CINOMA ARISING IN OPISTHORCHIS
VIVERRINI INFECTED HAMSTERS
GIVEN A SINGLE ORAL DOSE
OF DIMETHYLNITROSAMINE. D. J.
FLAVELL, Dept of Medical Helminthology,
London School of Hygiene and Tropical
Medicine, St Albans
Intrahepatic bile-duct carcinoma appears to
be associated with Opisthorchis viverrini
infection in man (Sonakul et al., 1978, S.E.
Asian J. Trop. Med. Pub. Hlth., 9, 215).
Long-term superinfections in hamsters for
up to 20 months duration do not yield
hepatic tumours (Favell, unpublished obser-
vations). Thamavit et al., 1978, Cancer Res.,
38, 4634) however, produced a 100% inci-
dence of cholangiocareinomas by administer-
ing 0.00250o DMN to 0. viverrini infected
hamsters. In this study, a dose of DMN
expected to induce a low incidence of chol-
angiocarcinoma in hamsters was chosen.
Control hamsters and hamsters receiving 50
0. viverrini metacercariae 40 days pre-
viously, were each given 1 6 mg DMN orally
(Tomatis & Cefis, 1967, Tumori, 53, 447).
Results include observations on animals
dying over 40 weeks after DMN treatment.
Mortality was significantly higher in the
group receiving both DMN and parasites.
Intrahepatic cholangiocarcinomas were found
only in animals receiving both parasites and
DMN. All tumours were mucin secreting and
goblet-cell metaplasia was a common feature.
Tumours with an acinar type pattern coni-
tained an abundant connective-tissue stroma,
and parasite egg grmnulomas were occasion-
ally found in this stroma. Cholangiofibrosis
and cystic cholangiomas were common in
both groups, though cholangiofibrosis was
more extensive in the group receiving both
parasites and DMN. Cholangio-carcinomas
appeared to arise either from hyperplastic
processes in the bile-duct wall, or from areas
of cholangiofibrosis distinct from major bile
ducts. In both cases a range of transitional
stages between hyperplasia and carcinoma
were seen. Cholangiocarcinoma and cystic
cholangioma were frequently seen in close
proximity, and appeared to have their origin
in adjacent areas of cholangiofibrosis.
LIKELY MECHANISMS BY WHICH
CARCINOGENS INDUCE ADRIAMY-
CIN RESISTANCE IN RAT HEPATO-
CYTES. I. CARR & D. B. LANGLEY, Depart-
ment of Medical Oncology, City of Hope
National Medical Center, Duarte, California,
91910, U.S.A.
Administration of the hepatocarcinogen 2-
acetylaminofluorene (AAF) to rats induces a
resistance in their hepatocytes to doses of
adriamycin (Ad) that are cytocidal to normal
hepatocytes after incubation in vitro in
primary monolayer culture (Carr & Laishes
1981, Br. J. Cancer, 44, 567). To investigate
the mechanism of this carcinogen-induced
resistance, sensitive (normal) and resistanit
(2-AAF altered) hepatocytes were incubated
with Ad-1 8 x 10-5M for periods up to 24 h.
No differences were seen in the cellular
uptake, efflux, DNA-binding, %DNA nicks,
or 0/ inactive Adraglycone metabolites
between sensitive and resistant cells. How-
ever, only 500/ of the fluorescing material
was organic extractable. Examination of the
aqueous non-extractable material revealed
that this was 13% ofthe total cellular fluores-
cence in the sensitive cells and 340 in the
resistant cells. It contained mainly highly
polar metabolites, presumably water-soluble
conjugates. Administration of Adr 5 mg/kg
i.v. to normal or 2-AAF-treated rats pro-
duced in similar concentrations of Adr and
0/ fluorescence in the non-toxic aglycone
metabolites. No Adr OH was found. The
differences in susceptibility to Adr induced
toxicity presumably reside therefore in the
generation of free radicals or in the ability
to scavenge them, to produce exeretable
polar compounds.
IS DYEING OF BAIT A CARCINO-
GENIC HAZARD FOR ANGLERS AND
THEIR SUPPLIERS? C. E. SEARLE &
J. TEALE, Cancer Research Campaign Labor-
atories, Department of Cancer Studies, The
MedicalSchool, Birmingham B15 2TJ
Chrysoidine (2,4-diaminoazobenzene), once
used as a food dye, induced liver adenomas
or carcinomas in most male and female
C57BL mice when fed at 020°' in the diet
(Albert, 1956, Arch. Immunol. Terap. Dosw.,
4, 189), and it was the most active of azo
472cell count does not discriminate between
classical CLL and follicular-centre cell non-
Hodgkin's lymphoma wJith a monoclonal
B-cell lymphocytosis. It is suggested that
2 ,u histological sections of either marrow- or
lymph-node biopsies are necessary to deter-
mine the correct diagnosis.
This recognition of 2 distinct histopatho-
logical sub-groups with the same clinical
syndrome may have prognostic significance.
A STUDY OF BLOOD-GROUP ISO-
ANTIGEN EXPRESSION ON NORMAL
AND MALIGNANT GASTRIC EPI-
THELIUM, USING MONOCLONAL
ANTIBODIES. P. J. FINAN*, S. H. SACKSt,
E. S. LENNOXt & N. M. BLEEHEN*, *MRC
Clinical Oncology Unit and tMRC Laboratory
ofMolecular Biology, Cambridge
It has been suggested that partial or complete
loss of blood-group isoantigen (BGI) expres-
sion accompanies malignant change in gastric
epithelium. Previous work has depended on
conventional antisera, used in both immuno-
fluorescent and specific red-cell-adherence
techniques (Davidsohn et al., 1966, Arch.
Pathol., 81, 381; Sheahan et al., 1971, Am.
J. Dig. Dis., 16, 961). The availability of
monoclonal antibodies (MeAbs) to the blood
groups A and B (Voak et al., 1980, Vox. Sang.,
39, 134; Sacks & Lennox, 1981, Vox Sang.,
40, 99) has allowed a re-investigation ofthese
findings, and an evaluation of mucosal BGI
loss as a marker of malignant change in
gastric epithelium.
Using an indirect immunoperoxidase tech-
nique on paraffin sections of normal gastric
biopsies, the expected BGI w-as present in all
11 cases. In a series of 17 gastric cancers the
BGI was lost in 6 (35%0), though present in
adjacent uninvolved mucosa. This loss was
unrelated to histological grade, secretor
status or blood subgrouping. In 6 cases, where
lymph-node metastases w%ere examined, the
BGI status was the same as in the primary
tumour.
It is concluded that McAbs to the blood
group antigens A and B, with their specificity
and homogeneity, may be usefully intro-
duced into studies on BGI expression in
malignant tissues. However, although loss
of isoantigen can be demonstrated in some
specimens of malignant gastric epithelium,
dyes tested for mutagenicity in Salmonella
typhimuriurn TA 1538 (Garner & Nutman,
1977, Mlutat. Res., 44, 9). Nevertheless it is
currently in widespread use for dyeing
maggots for use as bait by anglers, for which
purpose the hydrochloride is commonly
mixed with maggots by anglers' suppliers
before sale. This practice causes considerable
long-lasting staining ofthe hands ofshop staff
and of the very many anglers who use the
bait, often from an early age.
A Midlands dealer, who has used 14 kg of
chrysoidine HCI annually, became anxious
about its safety and informed us of 3 angling
acquaintances who had developed bladder
tumours. The early ages of presentation (each
was under 40) would suggest a possible
"occupational" origin, but none had worked
in the chemical or rubber industries.
Some other dyes, including the carcinogen
auramine, have also been used, but appar-
ently with lesser problems of contamination.
There is a clear need for epidemiological
studies to determine whether chrysoidine or
other bait dyes might be hitherto unrecog-
nized human carcinogenic hazards. Mean-
wNhile it would appear prudent to discourage
use of these suspect dyes under conditions
causing contamination.
FOLLICULAR CENTRE CELL HIST-
OLOGY IN CLASSICAL CHRONIC
LYMPHATIC LEUKAEMIA. D. I. Goz-
ZARD, A. CADAR, R. Cox, M. LIGHT & M. J.
LEYLAND, Department of Clinical Haema-
tology, East Birmingham Ho pial, Bordesley,
Birmingham B9.
Lymph-node and/or marrow histology has
been studied in 33 cases of CLL. The diag-
nostic criteria wvere those of the MRC CLL
trial, and all had a monoclonal B-cell lympho-
cytosis and mouse red-cell rosetting. The
mean presenting lymphocyte count was
111 x 109/1, with a range from 12-856 x 109/1
and 2 u plastic-embedded sections were used
both for the marrow and lymph glands.
Of the 13 cases in which lymph gland
biopsies wNere obtained, 4 had centrocytic
follicular-centre cell histology, which was
also demonstrable on the 2 tu marrow sections.
These 4 cases had presenting white-cell
counts > 100 x 109/1, and in all other respects
were classical CLL.
These data suggest that the initial white-
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this loss is unlikely to provide a reliable
marker of malignant change.
CYCLIC AMP-BINDING PROTEINS,
OESTROGEN RECEPTORS AND PRO-
GESTERONE RECEPTORS INHUMAN
BREAST CANCER. D. M. A. WATSON,
W. R. MILLER, R. A. HAWKINS, R. 0.
SENBANJO, J. TELFORD & A. P. M. FORREST,
Department of Clinical Surgery, University of
Edinburgh
Whilst human breast cancers with oestrogen
receptor (ER) and progesterone receptor
(PgR) activities are likely to be hormone
responsive, many do not respond to endocrine
therapy. Inhormone-dependent rat mammary
tumours the ratio of cyclic AMP-binding
proteins to steroid receptors may better
discriminate hormone-dependent from inde-
pendent tumours than steroid receptors alone.
The inter-relationships between cyclic
AMP-binding protein, ER and PR activities
have therefore been determined in 100
human breast cancers. Cyclic AMP binding
was detected in all tumours, ER in 70
and PR in 38. Mean cyclic AMP binding in
ER- tumours was significantly higher than
in the ER+ group. (P< 0-025 by t testing). In
tumours with both activities, there was no
significant correlation between levels of
binding (P<0a1 by Spearman rank regres-
sion analysis). Similar relationships were also
found between cyclic AMP binding and PR.
Expressing results as ratios of ER to cyclic
AMP-binding proteins, neither divided the
tumours into obvious subgroups nor dis-
criminated between PR+ and PR- tumours.
The lack of strong correlations with either
ER or PR means that it will require clinical
follow-up to determine whether cyclic AMP-
binding proteins may predict hormonal
sensitivity in human breast cancer.
BINDING OF WHEAT GERM-LECTIN
TO RAT SARCOMAS OF DIFFERING.
METASTATIC CAPACITY. N. WILMOTT,
S. A. SIMPSON & K. C. CALMAN, Department
of Oncology, University of Glasgow
The reaction of WGA with the tumour cell
surface (as expressed by amount bound,
agglutination, resistance to toxic effects) has
been reported to correlate with metastatic
potential in a number of parisophanous tum-
our cells lines (i.e. tumours derived from a
parental line). We are currently examining
a range of rat sarcomas ofindependent origin
to see whether there is any correlation be-
tween binding of WGA and metastatic
capacity. The assay used to assess binding
was based on the reaction of radiolabelled
lectin to tumour cells in suspension, and
results are expressed as a percentage of an
internal standard. Inhibition studies showed
that WGA bound to N-acetyl glucosamine
and also N-acetyl neuraminic acid. Tumour-
cell suspensions were prepared either by
detachment of cells grown as monolayers in
vitro or by mechanical disruption of a solid
tumour grown in vivo, followed by removal
of dead cells and debris by Ficoll-Paque, to
avoid the use of enzymes. It was found that
whilst in vitro cultured cells from tumours
of different metastatic capacity showed no
differences in lectin binding, differences were
apparent using cells from mechanically dis-
rupted solid tumours. It is concluded that
transplantable animal tumours of inde-
pendent origin may exhibit a correlation
between metastatic capacity and binding of
WGA, as do parisophanous tumour cell lines.
However, we have yet to assess the influence
of host-cell infiltrate in cell suspensions
derived from solid tumours.
THE LOSS OF CERTAIN WGA-BIND-
ING PROTEINS IN RELATIONSHIP
TO METASTASIS AND TO THE SITE
W-S. CHAN, A. W. JACKSON & G. A. TURNER
Department of Clinical Biochemical and
Metabolic Medicine, Royal Victoria Infirmary,
Newcastle upon Tyne NE1 4LP
Recent studies (Guy et al., 1980, Br. J.
Cancer, 42, 915; Reading et al., 1980, Proc.
Natl Acad. Sci., 77, 5943) have suggested
that membrane protein glycosylation is
important in relationship to metastasis. We
have further investigated this possibility by
determining the binding of 1251-WGA to
electrophoretically-separated proteins in Tri-
ton XIOO extracts from primary (10) and
secondary (2°) tumour cells ofa metastasizing
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hamster lymphosarcoma. It was shown that
WGA binds to a numberofproteins inextracts
from primary tumours growing in the sub-
cutaneous site. However, in extracted 20
cells that were isolated from the liver and
lymph nodes, the degree of WGA binding
was consistently reduced. Control studies
showed that the observed changes were not
due to contamination, or proteolytic digestion
of the WGA-binding proteins by host cells.
The lost WGA-binding bands reappeared if
2° tumour cells, that had previously grown
in the liver, were then grown in the s.e. site.
Later studies, on tumour transplanted into a
number of different 10 sites, indicated that
the degree of WGA-binding varied according
to the particular site investigated. These
latter findings suggest that the observed
changes are due to site-induced modulations
rather than the selection of metastatic
subpopulations.
CORRELATION OF COLLAGENASE
SECRETION WITH METASTATIC
COLONIZATION POTENTIAL IN
NATURALLY OCCURRING MURINE
MAMMARY TUMOURS. D. TARIN, B. J.
HOYT, D. J. EVANS & R. C. YDENBERG,
Departments of Histopathology, University of
Oxford, John Radcliffe Hospital, Headington,
Oxford, and Royal Postgrad. Med. School,
Hammersmith Hospital, London
In this communication we report evidence
of the secretion of a true mammalian col-
lagenase active against Type I collagen by
naturally-occurring mammary tumours of
the mouse and show that tumours capable of
heavily colonizing the lungs secrete signi-
ficantly more of this enzyme than those with
low pulmonary colonization potential or more
non-neoplastic proliferating (e.g. lactating)
mammary tissue. Plasminogen activator was
secreted in greater quantity by tumours than
by normal tissues but there was no significant
difference in the amount produced by tum-
ours with high or low pulmonary coloniza-
tion potentials.
These findings correlate well with our
earlier morphological observations of marked
connective-tissue destruction in the vicinity
of invading tumours and metastatic deposits,
and indicatethat proteasereleaseis implicated
in the mechanism of tumour spread.
METASTATIC PROPERTIES AND
CELL-SURFACE BIOCHEMISTRY OF
CLONES ISOLATED FROM AN HSV-2
TRANSFORMED HAMSTER CELL
LINE. J. R. WALKER, R. G. REES & C. W.
POTTER, Clinical Research Laboratory, Weston
Park Hospital, Sheffield and Dept Virology,
University ofSheffield
After resection of s.c. tumours derived from
the inoculation of the HSV-2-333-2-26 cell
line into Syrian golden hamsters, a small
proportion of animals developed metastatic
lesions at secondary sites. Selection of vari-
ants by s.c. re-implantation of lung foci
has produced 2 sublines, with a markedly
greater metastatic potential than the parent
line (Walker et al., 1982, Eur. J. Cancer (in
press)). In addition, numerous differences in
cell surface glycoproteins labelled by the
galactose oxidase-[3H]sodium borohydride
technique have been reported (Rees &
Walker, 1981, Br. J. Cancer, 43, 722).
The study of these cell lines has been
extended by the repeated s.c. transplanta-
tion of lung and kidney foci, to produce lines
of different organ propensity. The parent,
poorly metastatic cell line has been cloned
in vitro, to produce a range of clones of
different malignancy. Preliminary studies
have suggested that some cell-surface glyco-
protein components also differ betxveen the
cell lines. 'Thus, it has been shown that cells
of different metastatic potential exist in, and
may be selected from, the HSV-2-333-2-26
cell line. The role of the surface glycopro-
teins in this heterogeneity is under investi-
gation
QUANTITATIVE ANALYSIS OF THE
ARREST AND SUBSEQUENT FATE
OF RIF-l MOUSE SARCOMA SUB-
POPULATIONS IN THE LININGS
FOLLOWING INTRAVENOUS INJEC-
TION. J. G. REEVE & P. R. TWENTYMAN,
MRC Clinical Oncology and Radiotherapeutics
Unit, Cambridge
The RIF-1 tumour, an X-ray-induced sar-
coma of the C3H/Km mouse, consist of sub-
populations of cells which are heterogeneous
with respect to a variety ofmalignant charac-
teristics including lung-colony formation
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efficiency (LCFE). RIF-1 subpopulations of
high LCFE have been isolated from the
parent tumour by successive in vivo lung
passaging and by in vitro cloning. To investi-
gate cellular properties which affect meta-
static ability we have examined the correla-
tion between cell arrest and retention in the
lungs and the formation of pulmonary lesions
for 4 in vivo and 6 in vitro isolated RIF-1
subpopulations.
For lung arrest and retention studies
125IUdR-labelled cells were injected i.v. into
syngeneic mice. The activity remaining in
the lung 6 days post-injection was deter-
mined, and compared w%ith the number of
lung colonies visible 21 days post-injection.
Although the LCFE of in vivo isolated sub-
populations correlated well with cell reten-
tion by the lungs there was no clear correla-
tion between the LCFEs of in vitro isolated
RIF-1 clones and lung arrest and retention.
The fate post-injection of clone 16, which
is retained well by the lungs but is a poor
lung colonizer, was ascertained by using in
vitro clonogenic capacity as a measure of cell
viability in the lungs at various times post-
i.v. injection of 105 cells. Results show that
clone 16 cells arrested in the lungs are viable
for 26 days post-injection. We believe these
cells to be in a state of dormancy, and are
currently investigating the kinetic parameters
ofthese apparently dormant cells.
DIFFERENT RESULTS WITH TWO
ASSAYS OF FIBRINOLYSIS AND
THEIR CORRELATION WITH TUM-
ORIGENICITY. S. R. FAIRBAIRN, R.
ZAMMIT-PACE & J. P. ROSCOE, School of
Pathology, Middlesex Hospital Medical School,
London
We lhave studied plasminogen-dependent
fibrinolysis in cells derived at different times
after transplacental exposure to the carcino-
gen ethylnitrosourea (ENU) or buffer. The
cells were tested for fibrinolytic activity by
2 main methods: (1) lysis in a fibrin-agarose
overlay of colonies, or (2) release or radio-
activity from a layer of 3H-fibrin seeded with
whole cells. Cell lines which were tumorigenic
immediately they were derived showed
increased fibrinolytic activity in both assays
when compared with control lines. However,
some ofthese lines could lose their fibrinolytic
activity as measured by the radioactive
method, while remaining positive in the
overlay assay, tumorigenic and able to form
colonies in agar. Cell lines derived soon after
ENU exposure also developed increased
fibrinolytic activity (measured by the overlay
method) and later could grow in agar or
animals. However, latent period cultures
showed low, slightly elevated or variable
values offibrinolysis in the radioactive assay.
A comparison of the 2 assay methods sug-
gested that differences in culture conditions,
such as the time of medium change, may
cause the difference in results. Fibrinolysis
by some cells positive in the overlay assay
and not in the radioactive assay, was reduced
if the cells were incubated with fresh medium
containing serum immediately before being
overlaid. However, those cells which were
positive in both assays were not affected by
this treatment.
The difference in fibrinolytic activity of
some cell lines in the 2 assays seems at least
partly due to the difference in culture condi-
tions. The development of tumorigenicity
correlated well with increased fibrinolytic
activity measured by the overlay assay, but
less well with the radioactive assay.
QUANTITATION OF MONOCLONAL
ANTIBODY AND ANTIBODY-CONJU-
GATE BINDING TO TUMOUR CELLS
USING FLOW CYTOFLUORIMETRY.
R. A. ROBINS, M. R. PRICE & R. W. BALDWIN,
Cancer Research Campaign Laboratories, Uni-
versity of Nottingham, Nottingham NG7 2RD
Monoclonal antibody directly conjugated
with fluorescein isothiocyanate (FITC) has
been used with a flow cytofluorimeter/sorter
(Becton Dickinson FACS IV) to quantitate
accurately antibody binding to tumour cells.
Directly labelled 791T/36 monoclonal anti-
body (a mouse antibody against human
osteogenic sarcoma cell line 791T) can be
detected at a level of 100 fg per cell. Cells
labelled with antibody can be a-lalysed with-
out washing, so that the kinetics of labelled
antibody association and dissociation, and
antibody bound at equilibrium, can be
observed directly. The analysis of unlabelled
antibody preparations, and antibody con-
jugates (e.g. drug-antibody, toxin-antibody)
can also be performed rapidly and con-
veniently in competition assays; these meth-
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ods will detect changes in affinity of con-
jugated antibodies. In assays using limiting
quantities of labelled antibody, solubilized
antigen may be detected readily.
HUMAN HYBRIDOMAS FROM
PATIENTS WITH MALIGNANT DIS-
EASE. K. SIKORA, T. ALDERSON & J. ELLIS,
Ludwig Institute for Cancer Research, MRC
Centre, Hills Road, Cambridge
Monoclonal antibodies provide unique tools
to define and analyse the molecular compo-
nents of tumour cell surfaces. There are
many such antibodies of mouse or rat origin.
Here we report the production of human
monoclonal antibodies by the fusion of intra-
tumoral or regional node lymphocytes from
patients with a variety of malignant dis-
eases, in the human myeloma line, LICR/
LON/HMY2. Suspensions of lymphocytes
were obtained either by disaggregating tum-
ours or by teasing apart lymph nodes obtained
at surgery. Fusion w-as carried out using
polyethylene glycol and HAT medium used
for selection. Material was obtained from 153
patients and, after processing, hybrids
obtained in 22 of these. The total number
of separate hybrids obtained exceeded 150.
Hybridomas were analysed for DNA content
using a flomw cytometer and found to contain
DNA equal to the sum of that present in the
lymphocyte and the parent myeloma. This
DNA content was stable after 8 months of
continual culture, indicating the chromosomal
stability of this hybrid system. The
hybridoma supernatants contained human
monoclonal immunoglobulins which were
analysed using a sensitive solid-phase radio-
immunoassay. Bindingactivity to tumour-cell
surface components was detected in several
hybrid supernatants, suggesting that B cells
in the region of tumours may be involved
in host defence.
BIOLOGICAL ACTIVITY OF A MONO-
CLONAL ANTIBODY SPECIFIC FOR
A RAT SARCOMA. S. M. NORTH & C. J.
DEAN, Institute of Cancer Research, Clifton
Avenue, Sutton, Surrey SM2 5PX
A monoclonal antibody (M10/76) of IgG2
isotype, directed against a tumour associated
antigen of the chemically induced rat fibro-
sarcoma, MC24, is being used to investigate
the role of humoral immunity in metastatic
disease.
To assess the biological activity of M10/76
in vivo, affinity-purified antibody was injec-
ted i.v. into immunocompetent rats immedi-
ately before an i.v. challenge with viable
tumour cells. After 16 days the animals were
sacrificed and the number of lung colonies
estimated. Lungs from the control groups had
large numbers of tumour colonies, whereas
lungs from animals treated with specific
antibody containednovisibletumourcolonies.
Antibody M10/76 was also examined for
its effects on spontaneous metast4ses in vivo.
MC24 was grown in the hind limb of con-
genitally athymic male rats for 21 days and
then removed by amputation. Specific anti-
body was administered i.v. at a dose of50 ,ug/
rat on alternate days throughout tumour
growth, and until 75 days after amputation.
The animals were then killed and examined
for metastases. While all control animals
showed metastases either to lung or lymph
nodes, those treated with M10/76 showed
either no metastatic lesions or enhanced
metastatic disease.
We conclude that Ab M10/76 is biologic-
ally active in vivo and is capable ofinfluencing
the course of metastatic disease.
THE EFFECT OF MONOCLONAL
ANTIBODY-DIRECTED IMMUNO-
TOXINS AND IMMUNOMODULA-
TORS ON CULTURED HUMAN OSTE-
OGENIC SARCOMA CELLS. M. J.
EMBLETON*, G. R. FLANNERY*, J. PELHAM*,
G. F. ROWLANDt, & R. W. BALDWIN*,
*Cancer Research Campaign Laboratories,
University of Nottingham, and tLilly Research
Centtre Ltd, Windlesham, Surrey
A monoclonal antibody (MoAb) raised against
a human osteogenic sarcoma cell line, 791T,
was conjugated directly to various drugs and
toxins, and to lymphoblastoid interferon
(IFN, provided by Burroughs Wellcome Ltd).
Conjugates were tested for cytotoxic proper-
ties on 791T and other cell lines using radio-
isotopic assays to measure protein or DNA
synthesis.
Virtually all immunotoxin conjugates re-
tained antibody-binding activity for 791T
cells, but in most, cytotoxic activity was lost
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or diminished in comparison with the un-
conjugated agent. For example, a conjugate
of Vindesine (VDS) and MoAb was 2000-fold
less toxic than VDS alone on an LD50 basis,
when 791T cells were treated continuously
for 24 h. However, when target cells were
pre-exposed for 15 min and washed before
culture, the conjugate was selectively toxic
for 791T cells and other osteogenic sarcomas
which bind the MoAb, but not for unrelated
non-crossreactive cells.
IFN/MoAb conjugates did not directly
affect the cells, but IFN alone had only a
marginal cytostatic effect. However, IFN/
MoAb was ,highly effective in stimulating
NK cell activity against 791T and other
target cells. 791T cells, but not antigenically
unrelated cells, pre-incubated with the con-
jugate induced activation of NK cells against
51Cr-labelled third-party cells in mixed
culture.
These studies suggest that with further
development, immunotoxins may have spec-
ific anti-tumour properties, and that an
alternative approach to therapy could be
the use of indirectly acting MoAb-directed
immunomodulators.
NATURALLY CYTOTOXIC CELLS IN
THE RAT: DO THE SAME CELLS
LYSE SOLID AND LEUKAEMIC TAR-
GETS? G. R. FLANNERY, C. G. BROOKS,
J. D. GRAY & R. W. BALDWIN, Cancer Re-
search Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD
Most studies of natural cell-mediated im-
munity have used non-adherent lymphoid
target cells, and only recently has it been
recognized that cells derived from solid
tumours may also be susceptible to such
lysis. In the mouse it has been suggested that
these functions are performed by 2 distinct
effector cells. In the rat, our previous studies
showed that sarcoma cells are lysed by
effectors identical with the NK cell de-
scribed by others using lymphoid targets.
We report here that lysis of both target types
is mediated by cells indistinguishable by a
large variety ofcriteria.
A panel of solid and lymphoid targets
from several species was tested in 6h 51Cr-
release tests, using normal rat spleen cells as
effectors. Both types of killer cell (a) exhib-
ited a lag, phase prior to steady-state lysis of
some targets, (b) were absent from neonatal
animals but present from 8 weeks to 18
months of age, (e) wNere non-adherent to
nylon fibre, (d) were sensitive to anti-asialo
GM1 serum and complement, (e) were
enriched in low density fractions from dis-
continuous percoll gradients, (f) were aug-
mented 2-fold by pre-incubation at 37°C (g)
show-ed reduced activity in cross-competition
tests in which each type of target cell was
able to compete for lysis of the other.
These data, together with analysis of
surface-antigen distribution defined by var-
ious monoclonal antibodies (see Cantrell et
al., below) strongly suggest that although
NK-cell heterogeneity is found in the rat, as
in other species, the cells which lyse solid
and lymphoid targets are identical.
NATURALLY CYTOTOXIC CELLS IN
THE RAT: PHENOTYPE OF THE
CELLS MEDIATING NATURAL CYTO-
TOXICITY AND A COMPARISON
WITH CELLS MEDIATING ANTIBODY
DEPENDENT CYTOTOXICITY. D. A.
CANTRELL, R. A. ROBINS, C. G. BROOKS &
R. W. BALDWIN. Cancer Research Campaign
Laboratories, University of Nottingham, Not-
tingham NG7 2RD
The fluorescence-activated cell sorter (FACS)
was used to separate rat spleen cells into
subpopulations with and without the anti-
gens defined by W3/13, W3/25, OX6 and
OX8 monoclonal antibodies. The resultant
populations were then assayed for NK and
ADDC activity in a quantitative 6h 51Cr-
release assay. The data establish that rat
NK and ADCC effector cells are heterogene-
ous with respecttosurface-antigen expression,
and that subsets label with W3/13 and OX8
but not W3/25 and OX6 monoclonal anti-
bodies. Despite this heterogeneity, NK and
ADCC activity could not be dissociated by
W3/13 and OX8 antibodies. Also, there was
no evidence that NK-cell heterogeneity was
related to target-cell specificity, since in the
rat the data demonstrate that those NK cells
which kill solid, leukaemic and non-neoplastic
cells are identical on the basis of the surface
markers examined.
478ABSTRACTS
NATURALLY CYTOTOXIC CELLS IN
THE RAT: AUGMENTATION OF
NK ACTIVITY BY SPONTANEOUS
AND CARCINOGEN-INDUCED TUM-
OURS. G. R. FLANNERY & C. G. BROOKS,
Cancer Research Campaign Laboratories, Uni-
versity of Nottingham, Nottingham NG7 2RD
We have previously show%n that NK activity
in rats developing spontaneous solid tumours
is normal or raised, and our data suggest that
impaired NK activity is not associated with
spontaneous tumour development. HowNever,
early augmentation of NK activity, reported
by others, might provide a mechanism for
NK surveillance.
Splenic and blood NK activity was
assessed in 6h 51Cr-release tests 3 days after
inoculation of 2 x 104-5 x 105 spontaneous or
carcinogen-induced tumour cells into the
mammary pads. Stimulation of NK activity
occurred with 0/5 non-immunogenic tumours
but with 3/4 immunogenic tumours. When
injected i.p., 103-107 immunogenic and non-
immunogenic tumour cells augmented NK
activity of peritoneal exudate cells, though
this was seen in 12/31 pairs (39%O) of animals
injected with immunogenic cells but only
6/45 pairs (13%) of animals given non-
immunogenic cells. In addition, 4/4 immuno-
genic tumours produced NK activation but
only 3/6 non-immunogenic tumours did so.
Activation was generally lower in animals
receiving non-immunogenic tumour cells and
high doses of these cells sometimes depressed
responses.
These results suggest that early augmenta-
tion ofNK activity is associated with tumour
immunogenicity, and since most spontaneous
tumours are non-immunogenic, such aug-
mentation is unlikely to contribute to the
potential role of NK cells in immune surveil-
lance.
INTERFERON PRODUCTION AND NK
CELL ACTIVITY OF PERIPHERAL
BLOOD LYMPHOCYTES FROM NOR-
MAL CHILDREN AND ADULTS AND
PATIENTS WITH ACUTE LYMPHO-
BLASTIC LEUKAEMIA. A. M.DICKINSON,
S. PROCTOR, E. JACOBS, G. MOHAMMED &
G. A. ToMs, Departments of Haematology and
Virology, Royal Victoria Infirnary, Newcastle
upon Tyne
The erythroleukaemia cell line K562 lhas
been shown to stimulate normal lympho-
cytes into interferon (IFN) production. Also
NK cell activity correlated with amount of
IFN produced (Peter, et al., 1980, Eur. J.
Immunol., 10, 547). In our studies peripheral
blood lymphocytes (PBL) from normal con-
trols and children undergoing treatment for
Acute Lymphoblastic Leukaemia (ALL) were
tested simultaneously for NK activity and
IFN production against K562. NK-activitv
using 51Cr release was measured after 4h
incubation of the mictotitre plates at 37°C/
50% CO2. IFN production required replenish-
ment of the wells witlh culture medium
(RPMI 1640+10%o FCS) and incubation at
370C/500 CO2 for 24 h. Supernatants were
assayed for IFN by a dye-uptake assay in
Vero cells challenged -Nith Semliki Forest
virus. 10/13 PBL samples from normal
adults produced IFN (range 18-43 u/ml) and
simultaneously gave NK activities of 9-62
(mean 33%0). Similarly 6/9 samples from
normal children (age range 11 months to 11
years) produced IFN (range 16-43 u/ml) and
gave a range of NK activities 5-26 (mean
13%). Conversely 12 child ALL patients
(<1°h blasts in PBL) were negative for IFN
production and gave low values for NK
activity (range 0-17%//; mean 4%0). Medium
alone samples were negative. Previous studies
(Reid et al., 1977, Arch. Dis. Child., 52, 245)
showed that ALL patients were immuno-
suppressed in absolute numbers of T and B
cells. Our results have further shown that
immunosuppressive treatment also impairs
lymphocyte function in these patients.
NK AND ADCC IN HODGKIN'S DIS-
EASE, NON-HODGKIN'S LYMPHOMA
AND RENAL TRANSPLANTATION.
S. J. PROCTOR, A. M. DICKINSON, S. GEORGE
& E. JACOBS, Department of Haematology,
Royal Victoria Infirmary, Newcastle upon
Tyne
It has previously been demonstrated that in
renal-transplant populations there is a 100-
fold increase in non-Hodgkin's lymphoma in
the 2-years post-transplant period (Mitchison
& Kinlen, 1980, Prog. Immunol., 4, 645). The
present study was designed to assess the effect
of Immuran and Prednisone on cell cyto-
toxicity in an NK and ADCC assay in trans-
plant patients and patients with Hodgkin's
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disease and non-Hodgkin's lymphoma.
Target cell for the NK assay was K562
erythroleukaemia cell line. Chang liver cells
were used as targets in the ADCC assay. The
cytotoxicity testing was performed on the
separated PBL and overnight cultures from
affected lymph nodes in a small group of
patients with Hodgkin's disease and non-
Hodgkin's lymphoma. The result indicate a
gross suppression of NK and ADCC activity
in transplant patients (mean NK 120o, mean
ADCC 8% Cr release in 4h assay) in com-
parison Awith normals (mean NK normal
40 o, mean ADCC normal 38 o). NK and
ADCC activity was normal in peripheral
blood in Hodgkin's patients and those
patients withnon-Hodgkin's lymphoma show-
ing complete response to treatment. In a
group of 10 high-grade NHL patients
(patients dying less than one year from
diagnosis) NK and ADCC activity was also
significantly reduced (mean NK 220;, mean
ADCC 15%). In suspensions from lymph
nodes, low activitv was seen in 2 patients
with Hodgkin's disease demonstrating
atypical clinical and cytological features. The
possibility exists that the removal of
cytotoxic T population or NK populations by
immunosuppressive drugs may allow the
outgrowth of neoplastic B cells and suggests
that the cellular immunosurveillance system
has a role in prevention of B-cell tumours.
FUNCTIONAL CHARACTERISTICS
OF NATURAL CYTOTOXICITY MEDI-
ATED BY HUMAN TONSILLAR LYM-
PHOCYTES. I. KIMBER & M. MOORE.
Departmnent of Immunology, Paterson Labora-
tories, Manchester 20
The possibility that cytotoxicity mediated
by natural killer (NK) cells represents the
in vitro expression of a non-adaptive mechan-
ism of host resistance to malignancy has
generated considerable interest.
Although the capacity of human peri-
pheral and splenic lymphocytes to effect
substantial lysis is now well documented,
cytotoxicity mediated by cells isolated from
other secondary lymphoid tissues is less well
characterized, having been found in some
studies but not in others.
To further clarify the somewhat elusive,
phenomenon of extra-vascular natural cyto-
toxicitv we have examined the functional
characteristics of lysis mediated by lympho-
cytes isolated from human palatine tonsils.
We report that lysis of the NK-suseeptible
cell line K562 by tonsil lymphocytes although
weak compared with autochthonous vascular
lymphocytes, is invariably manifest at high
effector:target ratios. Like peripheral NK
cells, tonsillar cytotoxic lymphocytes have A
low buoyant density which allows their
partial enrichment from non-cytotoxic cells
by centrifugation on discontinuous Percoll
gradients. However, examination ofcytotoxic
fractions indicates that, unlike vascular
cytotoxicity, effector function is not asso-
ciated with the presence of lymphocytes of
characteristic large granular morphology.
Furthermore, a functional distinction from
classical NK cells is apparent since, although
tonsillar cytotoxicity is significantly en-
hanced following exposure to supernatants
from polyclonally-activated allogeneic tonsils,
pretreatment, with IFN-cx, at doses shown to
maximally potentiate peripheral cytotoxicity,
fails to influence reactivity.
These data provide preliminary evidence
for the existence of, at least limited, hetero-
geneity among human natural killer cells.
GENERATION OF SUPPRESSOR
CELLS FOR NK CELL ACTIVITY IN
CANCER PATIENTS BY SURGERY.
A. UCHIDA, M. COLOT, & M. MICKSCHE,
Institute for Cancer Research, University of
Vienna, Austria
As surgery often increases incidence of meta-
stases, it is important to know the effects of
surgery on NK activity and its regulatory
mechanism in cancer patients. NK activity
against K562 cells determined in a 4h 51Cr
release assay of untreated patients was com-
parable to that of normal controls. After
surgery blood NK activity significantly fell,
while the number of large granular lympho-
cytes (LGL) did not. When postoperative
lymphocytes were depleted of monocytes and
cultured for 24 h, they showed an increase in
NK activity. However, the mere addition of
blood monocytes to cytotoxicity assays did
not inhibit NK activity. 24 h preculture of
NK cells and postoperative monocytes sup-
pressed NK activity. The monocytes also
suppressed the enhancement of NK activity
by interferon. These results suggest that
480ABSTRACTS
postoperative monocytes inhibit the main-
tenance and development, but not effector
phase, of NK cells. After contact with sup-
pressor monocytes, NK cells changed their
form from an irregular motile one to a round
resting one and lost their active motility,
which could be one mechanism of NK sup-
pression, since the motility of NK cells is an
important step of NK-mediated cytolysis.
This w%vas confirmed by using a new agarose
inicrodroplet assay in Awbich NK cells migra-
ted from an agarose droplet toward target
cells in medium and killed them. OK-432, a
streptococcal preparation, reduced the sup-
pressor activity of monocytes both in vivo
and in, vitro. This suggest that blood mono-
cytes play an important role in the regulation
of NK activity in cancer patients after
surgery, and its modulation by OK-432 may
produce a subsequent benefit to the host.
AUGMENTATION OF AUTOLOGOUS
LYMPHOCYTOTOXICITY (ALC) BY
OK-432-A STREPTOCOCCAL PRE-
PARATION. M. MICKSCHE & A. UCHIDA,
Instttute for Cancer Research, UTniversity of
Vienna, Austria
OK-432, a streptococcal preparation, has
been already shown by us to enhance NK
activity after in, vivo and in vitro application.
In an ongoing clinical trial, patients with
malignant pleural effusions (breast and lung
cancer) are treated by intrapleural applica-
tion of OK-432. Pleural-effusion fluid is
collected immediately before injection and
lymphocytes and tumour cells are separated
by discontinuous gradient centrifugation
(Uchida, 1981, Cancer Immunol. Immuno-
ther., 11, 131). Lymphocytotoxicitv is deter-
mined in a 4h 51Cr-release assay, using auto-
logous effusion derived tumour cells as
targets. Patients with no ALC before therapy
were founid to express high cytotoxicity soon
after the first wreek of treatment.
In vitro studies have demonstrated that
24h pretreatment of lymphocytes with OK-
432 led to an increase or induction of ALC,
whereas interferon (Hu-IFN o) failed to
modify this reactivitv.
Induction of ALC by OK-432 therapy
might be one mechanism responsible for
therapeutic response (i.e. disappearance of
pleural effusion) after intrapleural applica-
tion ofOK-432.
INDUCED CYTOTOXIC ACTIVITY IN
HODGKIN'S AND NON-HODGKIN'S
LYMPHOMA. D. B. JONES, K. HIGGINSON
& D. H. WRIGHT, University Department of
Pathology, General Hospital, Southampton
S09 4QY
The data presented represent a preliminary
study of NK activity inducible in mono-
nuclear cells prepared from tissue biopsies of
Hodgkin's disease (HD) and non-Hodgkin's
lymphoma (NHL).
Mononculear cell preparations from 15 HD
spleens showed a significant increase in
native NK activity over cells from 20 con-
trol spleens. NK activity was low or absent
in 7 spleen-cell preparations from patients
with NHL. This low activity could not be
explained by dilution of effector cells by
tumour, or by the absence of T cells.
The induction ofcytotoxicity by co-culture
with mitomycin C-treated lymphoblastoid
cells and polyclonal-lymphocyte activators
which induce NK like effectors via the
induction of interferon synthesis (Potter &
Moore, 1981, Clin. Exp. Immunol., 44, 332)
gave comparable results. Cells from HD
spleen were easily inducible to high levels of
activity against K562 target cells. NHL
tissue cells gave levels ofinduced cytotoxicity
which fell below those observed with normal
spleen cells. The induction results suggest
that qualitative or quantitative differences
exist between the spleen-cell populations in
HD and NHL, which account for the differ-
ing response to polyclonal T-cell activation.
Individual HD spleens also produce sig-
nificant killing over 5 days in control culture
with non-mitogenic human AB serum. This
spontaneous activation in culture is related
to the level of T cell activation in normal
uninvolved HD spleen, and may reflect the
production of soluble potentiators of NK
activity.
LYMPHOCYTE SUBSETS INFIL-
TRATING HUMAN MAMMARY CAR-
CINOMAS. 0. FREMIN, J. ASHLEY, M.
BROWN & S. WILLIAMSON, Department of
ClinicalSurgery, University ofEdinburgh
Lymphocytes infiltrating human mammary
carcinomas have been well documented histo-
logically, but their precise role in vivo and
possible anti-tumour activity has not been
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defined. Lymphocytes w%ere isolated from
primary human mammary tumours using
mechanical and enzymatic preparative tech-
niques and cell passage down a Sephadex
G-10 column. Rosetting techniques wrere
used to characterize both T and B lympho-
cyte subsets within the tumours. The pattern
detected was different, in certain respects,
from that found in the blood, and suggested
a selective subset migration into the tumour.
This wvas confirmed by in vitro cytotoxicity
assays revealing an absence of K cells and a
paucity of NK cells. The study also estab-
lished the hyporeactive state of mitogen
assays ofthetumour-infiltrating lymphocytes,
in contrast to the normal activity of blood
lymphocytes.
QUANTITATION OF HUMAN TUM-
OUR-REACTIVE LYMPHOCYTES IN
BLOOD AND TUMOUR BY LIMITING-
FREQUENCY ANALYSIS. B. M. VOSE,
Department of Immunology, Paterson Labor-
atories, Christie Hospital and Holt Radium
Institute, Manchester M20 9BX
Antigen-activated T cells can be maintained
in conditioned media containing interleukin-2
(IL-2). Limiting-dilution techniques depend-
ent upon IL-2 allow the quantitation of
tumour-reactive lymphocytes at different
sites by enumeration of cells stimulated in
mixed lymphocyte-tumour cultures (MLTC).
Blood lymphocytes (PBL) and those iso-
lated from 8 enzymatically dispersed lung
and breast tumours (TIL) were plated under
limiting-dilution conditions with irradiated
autologous tumour, blood mononuclear cells
as feeders and IL-2, and incubated for 7-9
days. Microcultures were assayed for pro-
liferation by uptake of [3H]dT and cytotoxi-
city against autologous and allogeneic tumour
and K562. Tumour-associated lymphocytes
showed significantly higher frequencies of (1)
spontaneously IL-2-reactive cells (1/900 and
1/4750) and (2) proliferative (1/200 and
1/1200) and cytotoxic tumour-reactive pre-
cursors, than blood lymphocytes, but lower
frequencies of NK (1/2500 and 1/1600)
precursors. 4-8-fold concentrations of tum-
our-reactive cells were regularly found in
TIL. Phenotypic analysis revealed that
although proportions of T cells in PBL and
TIL were similar (60-850%) TIL showed a
marked increase in the number of OKT8+
(cytotoxic/suppressor) cells (5000 of total T)
compared with the periphery (15-27%).
There was a corresponding fall in OKT4
(helper) cells, though early data suggest that
TIL were more efficient producers of IL-2
in MLTC than PBL. Taken together these
data support the conclusion that there is
significant homing of reactive T cells to the
tumour site in human neoplasia.
HUMAN TUMOUR-REACTIVE CUL-
TURED T-CELL LINES: ANTIGENS
ON LUNG AND BREAST TUMOURS
DETECTED IN THE PRIMED LYM-
PHOCYTE TEST. B. M. VOSE & G. D.
BONNARD, Christie Hospital, Manchester 1M120
9BX and National Cancer Institute, Bethesda,
MD 20205, U.S.A.
Co-cultivation of cancer-patients' lympho-
cytes and autologous tumour cells (MLTC)
leads to (1) production of interleukin-2
(IL-2), (2) induction of blasts and their
proliferation and (3) the generation of
specific cytotoxic effectors. Blasts generated
in MLTC from 18 cases were isolated by
flotation on discoiitinuous Percoll gradients
and cultured in lectin-free conditioned media
from mitogen-stimulated lymphocytes. In all
cases growth was rapid so that redilution to
3 x 105 cells/ml and addition of fresh condi-
tioned media was necessary every 3-4 days.
Cultured T-cell lines (CTC) were used as
responders in primed lymphocyte tests after
10 days in vitro. Decreasing numbers of CTC
(104-1-25 x 103/well) were dispensed into
microtest plates and restimulated with
5 x 104 irradiated cells or conditioned media
in 0 2 ml microcultures. Proliferation was
assessed by uptake of [3H]dT over the last
6 h of a 48h test. Restimulation of MLTC-
blast CTC was obtained in all cases with
autologous tumour cells, but not with auto-
logous monocytes, tumour-associated macro-
phages or lymphocytes. Tests are in progress
with normal lung cells. Similar levels of
restimulation were induced by allogeneic
tumours ofthe same site and histology as the
autologous. Tumours from different sites or
histologies, allogeneic monocytes and lympho-
cytes, did not induce a significant increase of
[3H]-dT uptake. This suggests that human
tumours ofcommon site and histology express
cross-reactive specificities, the nature of
which has yet to be identified. Cloned T
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cells from MLTC blasts are presently under
investigation to facilitate further analysis.
CYTOXICITY OF HUMAN BRONCHO-
ALVEOLAR MACROPHAGES AND
PERIPHERAL-BLOOD MONOCYTES
FOR CULTURED HUMANLUNG TUM-
OUR CELLS. S. SWINBURNE & P. COLE,
Host Defence Unit, Department of Medicine,
Cardiothoracic Institute, Brompton Hospital,
Fulham Road, London SW3 6HP
As part of the potential host anti-tumour
response, mononuclear phagocytes may enter
a bronchial tumour from at least 2 sources,
blood and bronchus. Human bronchoalveolar
macrophages (BAM) were purified from
bronchial lavage fluid obtained from patients
undergoing diagnostic fibreoptic broncho-
scopy. Human peripheral blood monocytes
(PBM) were purified from the blood ofnormal
volunteers. The cytotoxic activities of the
BAM and PBM for a cultured human lung
tumour cell line, A549, were then tested using
a modification of the 75Se-methionine uptake
assay devised by Brooks et al. (1978) J.
Immunol. Meth., 21, 111.
The cytotoxicity of BAM increased in a
dose-dependent manner, approaching 100%
at an effector cell target cell ratio of 20:1.
The dose-response nature of the cytotoxicity
was similar, whether the BAM were obtained
from the lungs of patients with mild bron-
chialinflammation, chronicbronchitis, crypto-
genic fibrosing alveolitis, allergic alveolitis or
bronchial carcinoma. BAM were cytostatic at
lower E:T ratios but cytolytic at higher
ratios. In contrast, PBM cytotoxicity plat-
eaued at an E:T ratio of 3:1 and was only
cytostatic.
The results of kinetic studies of BAM and
PBM cytotoxicity and the abilitv of BAM,
but not PBM, to be cytotoxic for 2 additional
human lung cell lines, E14 and MS853, sug-
gest that there are qualitative differences in
cytotoxicity between PBM and BAM.
MONOCYTE-LYMPHOCYTE INTER-
ACTION IN HODGKIN'S DISEASE.
I. H. MANIFOLD, M. D. WHITHAM, L. BRUCE
& B. W. HANCOCK, University Department of
Medicine, Royal Hallanishire Hospital, Shef-
field
In Hodgkin's disease, it is thought that
lymphocyte transformation (LT) is inhibited
in vitro by prostaglandin-secreting monocyte
suppressor cells. Previous studies have de-
pleted monocytes from monocyte-lymphocyte
cell suspensions. by methods said to be
traumatic and prolonged. (Alonso et al.,
1978, J. Immunol. Meth., 22, 361). We have
selectively depleted monocytes using the more
recent method of one 15min passage through
Sephadex GIO columns in 11 untreated
Hodgkin's patients and 11 age/sex-matched
controls. This produced no significant change
in mean percentage T cells, a small decrease
in B cells (12-2-10.5% in patients; 10.2-9-7%
in controls), but greatly reduced monocytes
(18-6 to 1-3%o in patients; 11-8%o to 1-3%o in
controls. LT was measured before and after
monocyte depletion. LT was grossly reduced
in patients from controls but monocyte
depletion caused a marked LT enhancement
to sub-optimal concentration of PHA in
patients in autologous serum (3-79 mean
ct/minx 10-3 vs 7-67, P<0-001) indicating
the dominant effect of monocyte suppressors.
Enhancement was masked by indomethacin,
present in pre- and post-column passage, and
indomethacin added to cultures with un-
depleted monocytes, mimicked the effect of
monocyte depletion, indicating that prosta-
glandin mediates the suppression. This pat-
tern was not seen in controls nor in AB serum,
nor with PWM and Con-A as mitogens.
Rather in some of these series monocyte
depletion significantly reduced LT, suggesting
that monocyte helper cells were predominant.
Further in some of these series, a subpopula-
tion of suppressor monocytes appeared to be
present with the helper cells, since indometh-
acin still caused LT enhancement. Thus
monocytes have an important but complex
role in modulating LT in Hodgkin's disease,
and Sephadex column passage is a useful
technique in its analysis.
DISTINCT SUPPRESSOR-CELL POP-
ULATIONS IN SPLEENS OF TUM-
OUR-BEARING MICE. S. HOWIE & W. H.
MCBRIDE, Department ofBacteriology, Univer-
sity of Edinburgh EH8 9AG
Spleens of tumour-bearing mice contain
tumour-specific T helper cells which will
collaborate with hapten primed B cells to
induce specific antibody in vitro. Helper
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activity disappears when the tumour is large.
This loss of helper activity coincides with the
appearance of 2 distinct types of suppressor
cells (a) nylon-wool-non-adherent T cells
which are tumour specific and (b) nylon-wool-
adherent non-T cells which are not specific in
their action.
INDUCTION OF CELL-MEDIATED
CYTOTOXICITY TO A HUMAN LEUK-
AEMIA: DIFFERENCES BETWEEN
THE RESPONSE OF A PATIENT AND
HLA-MATCHED SIBS. G. M. TAYLOR,
Department of Medical Genetics, St Mary's
Hospital, Manchester M13 OJH
Cell-mediated cytotoxicity (CMC) was in-
duced in mixed lymphocyte cultures to a
human acute leukaemia. We have studied the
capacity of different HLA-mismatched lym-
phocytes to stimulate CMC to autologous
leukaemia (aut L) cells in lymphocytes from a
patient and his HLA-identical sibs. The
results showed differences in the response to
different allogeneic cells, and between the
patient and sib's response to the aut L. The
patient generated CMC to aut I, in response to
allogeneic stimuli, which was synergistically
amplified by aut L, but did not respond to aut
L alone. The sib responded to aut L and to
allogeneic cells but did not respond syner-
gistically to a mixture ofthe two. Stimulation
ofsib lymphocytes with HLA mismatched sib
cells gave CMC to aut L irrespective of the
HLA-type of the stimulator. Parallel tests on
targets sensitive to NK-lysis, suggest that the
leukaemia was sensitive to NK-CMC. No
evidence was found in CMC assays on sib
targets that leukaemia cells expressed in-
appropriate HLA antigens, though a number
ofnon-HLA-directed reactions were found.
ENHANCEMENT OF TRANSPLANTA-
TION IMMUNITY TO A SPON-
TANEOUS MURINE TUMOUR. A.
VYAKARNAM, P. J. LACHMANN & K. SIKORA,
Ludwig Institutefor Cancer Research, Mechan-
is8ms in Tumour Immunity Unit, MRC Centre,
Hills Road, Camnbridge
Previous work from our laboratories has
shown that immunization with tumour cells
coupled to tuberculin (PPD) can enhance the
in vivo transplantation immunity to some
chemically induced murine tumours in the
syngeneic host. PPD is strongly recognized by
T cells, and it was suggested that the coupling
ofPPD on to tumour cells may provide T-cell
help in the induction of the anti-tumour
response. Spontaneously arising murine car-
cinomas which may well provide more
realistic models for human cancer are claimed
to be non-immunogenic in conventional
rejection assays. We have examined the
antigenicity of a spontaneous murine car-
cinoma using PPD as an immunogenic carrier
determinant. It was observed that multiple
immunizations of PPD-coupled tumour cells
did potentiate a significant anti-tumour
response. Moreover such immunizations re-
tarded the growth of tumours in previously
un-immunized animals. Such enhancement
may well have clinical application.
HETEROGENEITY OF CIRCULATING
IMMUNE COMPLEXES IN LUNG
CANCER AND OTHER CHRONIC PUL-
MONARY DISEASES. K. M. COOPER &
M. MOORE, Paterson Labs., Christie Hospital
and Holt Radium Inst., Manchester
Circulating immune complex (IC) levels in
sera from 58 healthy controls and a total of
212 patients with various chronic lung
diseases, including 74 witlh bronchial carcin-
oma were measured using 3 assays: 2
complement-dependent assavs (Clq fluid
phase and Raji) and a complement-indepen-
dent assay (L1210). The 3 assays generally
revealed similar patterns of reactivity when
control and pathological groups were com-
pared by the L1210 assay invariably demon-
strated the lowest incidence ofpositive values
in each group. The most significant elevations
in IC levels were in bronchiectasis (chronic
bronchial suppuration) and bronchial car-
cinoma. However, within these 2 groups,
correlations between IC assays performed on
individual sera were poor. Significant but
weak correlations (P< 0-01) were only seen for
Clq vs Raji in bronchiectasis and Clq vs L1210
in bronchial carcinoma. Complement-binding
ICs were present to a similar extent in both
conditions. However, non-complement bind-
ing ICs were found to be commoner in
bronchiectasis. Although interfering factors
may contribute to the disparity between the
assays, the interpretation favoured is that the
lack of correlation is primarily a reflection of
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the intrinsic heterogeneity of immune com-
plexes formed under similar and dissimilar
pathological conditions.
A COMPARISON OF METHODS FOR
IMMUNIZING PIG MESENTERIC
LYMPH NODES AGAINST HUMAN
TISSUE. D. M. MORRIS, D. HEINEMANN &
M. 0. SYMES, Departments of Obstetrics &
Gynaecology andSurgery, University ofBristol,
Bristol
The use of immune pig mesenteric lymph-
node cells to treat tumours in mice (Pritchard-
Thomas & Symes, 1978a, b, Cancer Immunol
Immunother, 4, 129, 135) and man (Symes et
al., 1978, Urology, 12, 398) has been reported.
In order to study the optimal route and time
of immunization, fragments of human skin
were implanted into pockets in the mesentery
or directly on to the surface ofthe mesenteric
node. Alternatively, human leucocytes were
injected into Peyers Patches. Three, 5, 7 or 14
days after immunization the reactivity ofthe
lymph-node cells were compared, using a 75Se-
release assay against human PBL as targets.
Nodes immunized for 7 or 14 days showed no
cytotoxicity. However, after 3 or 5 days
immunization co-culture of effector and
target cells produced negative cytotoxicity, in
that 75Se release was less than that from
target cells cultured alone (00 cytotoxic - 14
to +200,/ at an E/T ratio of 40:1). This
phenomenon was more marked using LNC
cells, from nodes in contact with human skin.
It suggested there was recognition of the
target by the effector LNC, which did not
proceed to target cell lysis. Recognition was
confirmed by increased uptake of [3H]dT by
LNC, showing negative cytotoxicity. Mesen-
teric lymph nodes immunized for 3 days
showed hyperplasia of the thymus-dependent
cortex, not seen after 7 days immunization.
PIG LYMPH-NODE-CELLS IN THE
TREATMENT OF THE OVARY. G. M.
TURNER, D. MORRIS, V. BARLEY, E. RHYs
DAVIS & M. 0. SYMES, Departments of
Obstetrics and Gynaecology, Radiotherapy,
Radiodiagnosis and Surgery, University of
Bristol
Pig mesenteric lymph-node cells have been
used to treat patients with T3 or T4 carcinoma
of the ovary who have previously received
standard treatment (i.e. surgery, +chemo-
therapy ± radiotherapy).
The Phase 1 study (Turner & Symes, 1979,
Br. J. Cancer, 40, 823) now involves 6 patients
in whom patient tumour or skin immune pig
cells were used. Two patients are alive 7 1 and
14 years later. One patient who died 2 months
after treatment showNed complete disappear-
ance of previously existing multiple i.p.
tumours. Two patients had objective evidence
of tumour remission (in one there was no
recurrence ofpreviously persistent ascites and
in the other a return to normal activity and
weight). However, both patients eventually
died from progressive disease. One further
patient died within 2 weeks of treatment and
sho-wed haemorrhagic tumour necrosis at
autopsy.
In the Phase 2 study similar patients w-ere
allocated at random to receive non-immuine or
immune pig cells. To date there are respec-
tively 6 and 9 patients in the 2 arms of this
study. All the patients have died and the
survival times in days from treatment have
been for non-immune cells, 9, 13, 34, 73, 91
and 116; and for immune cells 14, 25, 36, 47,
59, 62, 84, 98 and 150. One patient treated
with non-immune cells has shown evidence of
partial disease remission. Of the patients
receiving immune cells one had a partial
remission.
A RANDOMIZED TRIAL COMPARING
VINDESINE VDS WITH VINDESINE
PLUS CIS-PLATINUM (DDP) IN
INOPERABLE NON-SMALL CELL
LUNG CANCER (NSCLC). J. A.
ELLIOTT*, S. AHMEDZAIt, R. D. STEVENSONt,
A. J. DORWARD & K. C. CALMANt, *Western
Infirmary; tRoyal Infirmary, IDepartment of
Clinical Oncology University of Glasgow
Between January 1981 and January 1982, 59
patients with previously untreated inoperable
NSCLC were randomly allocated to treatment
with VDS (n =29) or VDS +DDP(n =30). As
a single agent VDS was given in a dose of
3-4 mg/M2 weekly x 8 and 4 mg/M2 2 wk
thereafter in responding patients. In combina-
tion VDS was given in a dose of 30 mg/M2
weekly x 8 and 3 mg/m2q 2 wk thereafter in
responders) together writh 100 mg/Mi2 DDP
with mannitol-induced diuresis at 0, 4 and
8 wks, then q 6 wks thereafter in responders.
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40 patients are fully evaluable. There was
one partial tumour response in 23 patients
given VDS alone (40o). Of 17 evaluable
patients receiving VDS+DDP 9 (5300)
showed a partial response.
Myelosuppression was mild in both groups,
but significantly greater with the combina-
tion. Significant neurotoxicity, principally
paraesthesiae and sensory impairment, was
manifested by most of patients; severe
neuropathy was seen with equal frequency in
both groups (70). Urinary creatinine clear-
ance fell in nearly all patients receiving DDP,
which prevented further DDP in 2 patients.
Our preliminary results confirm that
VDS +DDP is an active combination in
NSCLC and suggest its superiority over VDS
as a single agent. The study is on-going.
Survival data are not yet available.
INTERMITTENT HIGH-DOSE CY-
CLOPHOSPHAMIDE WITH AND
WITHOUT PREDNISOLONE IN
METASTATIC LUNG CANCER. N.
THATCHER, J. WAGSTAFF, H. ANDERSON, M.
PALMER & D. CROWTHER, Depts. Medical
Onolocy and Medical Statistics, Christie Hos-
pital, Wilmslow Road, Manchester M20 9BX
57 patients with metastatic lung carcinoma
were treated with either high-dose cyclo-
phosphamide (CY) alone or with a combina-
tion of high-dose CY and Prednisolone
(100 mg/Mi2 o.dailyx 2). The CY was given
i.v. on 3 occasions at 1 5 g/m2, 2-5 g/m2 and
3-5 g/m2 with 3 week intervals between
courses.
The overall response rate was 5700o
(1800 CR) median survival 24 weeks (range
6-130) for CY alone and 240% (30% CR)
median 14 weeks (1-94) for Cy+Pred.
Patients with small-cell carcinoma given CY
alone had a 69% response rate (19% CR)
median survival 7 months and with non-
small-cell-pathology 42% (16% CR) median
survival 16 weeks. Performance scores and
survival were better for responding patients.
Addition ofPrednisolone did not improve the
therapeutic efficacy of high-dose CY, nor
ameliorate toxicity. No marked or unexpec-
ted toxicity was observed with the high-dose
CY. Blood counts had returned to normal by
3 weeks in the great majority of patients.
A short course of high-dose CY was not
associated with unacceptable side-effects, and
the therapeutic results obtained were superior
to those described by CY at conventional
dosage. High-dose CY is of value to patients
with metastatic lung cancer, and the incor-
poration of the regimen into chemothera-
peutic combinations could be advantageous.
FACTORS INFLUENCING RESPONSE
TO CHEMOTHERAPY IN SMALL-
CELL ANAPLASTIC LUNG CANCER.
A. GREGOR, J. CARMICHAEL, G. K. CROMPTON,
I. W. B. GRANT & J. F. SMYTH, Departments
of Clinical Oncology and Medicine, Western
General Hospital, Edinburgh
73 previously untreated patients with histo-
logically proven small-cell carcinoma of the
bronchus were treated with methotrexate
(MTX) (200 mg/M2 i.v. over 24 h) and
cyclophosphamide (CY) (1 g/m2 i.v. q 3/52)
with CCNU (100 mg/M2 p.o. q 6/52). Mean
age was 59-4 years (range 28-75). 330% of
patients were females. With conventional
staging, 4700 had extensive disease. 690% of
patients had performance status (PS)M1.
Assessment of response, including repeat
bronchoscopy, was carried out at 12/52.
Objective response rate was 5700, with 23%
complete response (CR). Of 24 females, 7000
responded and 3000 achieved CR, despite
700o having extensive disease. In comparison,
only 5000 of males responded (20% CR rate),
350% having extensive disease. 650% of
patients with PS, none responded, with 340%
PS 0+1 patients achieving CR. 200% of
extensive-disease patients achieved CR. Only
1/11 patients with liver metasases, and none
of the 7 patients with marrow involvement,
achieved CR. 3/5 patients with inappropriate
ADH secretion responded (1 CR) but both
patients with inappropriate ACTH secretion
were non-responders. Sex and performance
status were the principal factors influencing
response to chemotherapy.
PILOT STUDY OF COMBINATION
CHEMOTHERAPY WITH LATE DOSE
INTENSIFICATION AND AUTOLOG-
OUS MARROW RESCUE IN SMALL
CELL BRONCHIAL CARCINOMA. S.
BANHAM, A. BURNETT, R. STEVENSON, D.
CUNNINGHAM, S. KAYE, S. AHMEDZAI, M.
SOUKOP, Glasgow Royal Infirmary and Gart-
navel General Hospital, Departments of Res-
piratory Medicine, Haematology and Oncology
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The long-term survival in small-cell broncho-
genic carcinoma remains poor despite good
initial responses to combination chemo-
therapy. A prospective pilot study of the role
of late dose intensification, in selected
patients, with Cyclophosphamide 12g i.v. and
autologous-marrow rescue, following 5
courses of combination chemotherapy with
Cyclophosphamide (1 g/m2), Adriamycin
(40 mg/M2), Vincristine (2 mg) and Predniso-
lone (CHOP) was commenced in Glasgow in
January 1981. 44 patients have been admit-
ted to the study, 40 being evaluable at
present. 14 patients have received high-dose
Cyclophosphamide therapy (HDCT) includ-
ing both patients with limited and extensive
disease and with responses to induction
chemotherapy varying from a complete
response to disease progression on treatment.
All patients, receiving HDCT who had
residual tumour following induction chemo-
therapy, subsequently had a further reduc-
tion in tumour size on HDCT. Several
patients with limited disease and a poor
response to induction regime of CHOP
subsequently had good responses to HDCT,
with only minimal residual tumour being
detected. HDCT was well tolerated even by
unwell patients with major weight loss and
progressive disease. One patient died on Day
10 post HDCT and post-mortem suggested an
acute cardiomyopathy. Aspirated marrow
was stored at 4°C and reinfused at about 36 h
from the commencement of HDCT. Subse-
quent marrow recovery occurred in all
patients between 9 and 17 days post therapy.
We consider HDCT a useful addition to the
treatment of small-cell bronchial carcinoma,
but its proper integration in the treatment
requires further investigation.
THE RESPONSE OF HUMAN LUNG-
TUMOUR XENOGRAFTS TO HIGH-
DOSE MELPHALAN. E. WIST* & J. L.
MILLARt, *The Norwegian Radium Hospital,
Montebello, Oslo, Norway and tInstitute of
Cancer Research, Sutton, Surrey
The response of human tumour xenografts to
cytotoxic treatment has correlated well with
the response in the patients from whom the
tumours were derived (Shorthouse et al., 1980,
Br. J. Surg., 6, 715). It was hoped that by
studying the melphalan uptake in different
33
lung tumour xenografts, a relationship could
be established with their response to treat-
ment with melphalan. No such relationship
was found.
Indeed, the more chemosensitive oat-cell
xenografts took up less drug than the more
chemoresistant large-cell and adenocarcinoma
xenografts. The response of these oat-cell
tumours, as measured byin situgrowth delay,
was, as expected, consistently greater than
that ofthe more chemoresistant tumours.
During these investigations, the residual
red-cell volume, plasma volume, extracellular
volume and vascular permeability of these
xenografts was measured atdifferent stages of
their growth. One striking finding of these
studies was how rapidly the uptake of
melphalan, per g tissue, declined with
increasing tumour size. Tumours were meas-
ured from 041-2 g and over this weight range
uptake ofmelphalan per g oftissue declined a
decade. The implications of this in the
adjuvant use of chemotherapy will be
discussed.
PROGNOSTIC VALUE OF CYCLIC
AMP-BINDING PROTEIN IN HUMAN
BREAST CANCER. R. 0. SENBANJO,
W. R. MILLER, J. TELFORD, D. M. A. WATSON
& A. P. M. FORREST, Department of Clinical
Surgery, University ofEdinburgh
Cyclic AMP and its binding proteins are
involved in regulating the growth of mam-
mary tumours in experimental animals (Cho-
chung, 1978, Cancer Res., 38, 4071; Cho-
chung et al., 1978, J. Biochem., 86, 51. In the
present study, we have investigated the
relationship between cyclic AMP-binding
proteins in human breast cancers and clinical
parameters including prognosis. The binding
proteins were measured in the cytosols from
75 human breast cancers. All tumours
contained measurable amounts of binding
proteins, levels varying from 0-81 to 15-05
pmol/mg cytosol protein (mean=5.34). No
relationship was found between level of
activity and menopausal status ofthe patient,
clinical stage of the disease and presence or
absence of nodal involvement. Poorly differ-
entiated tumours have significantly higher
binding activity than better differentiated
tumours (P<0Q01).
A group of 10 patients who at primary
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treatment had no evidence of metastatic
disease, but have developed recurrence within
36 months have been compared with a similar
group of 11 with a minimum of 24 months
follow-up and were disease-free. Levels of
cyclic AMP-binding proteins were signifi-
cantly higher in tumours from women having
early recurrence than in those disease-free
(P<0 005 by Wilcoxon rank test). The range
indisease-free patients was 1-57-7 21 pmol/mg
cytosol protein; whereas in 9 of 10 tumours
that subsequently recurred early it was
7-75-13-02. It is concluded that although
levels of cyclic AMP binding protein are not
associated with the clinical parameters de-
scribed, it may be of independent prognostic
significance.
A COMPUTER PROGRAMME TO
ASSIST THE PREOPERATIVE DIAG-
NOSIS OF AXILLARY-LYMPH-NODE
METASTASES IN BREAST CANCER.
R. J. C. STEELE, J. D. MCGREGOR, 0. EREMIN
& A. P. M. FORREST, Departments of Clinical
Surgery and Pathology, University of
Edinburgh
Clinical examination is known to be inaccur-
ate in the diagnosis of axillary lymph-node
metastases in breast cancer (Wallace &
Champion, 1972, Lancet, i, 217). An attempt
has therefore been made to improve this by
combining several factors known to be
associated with nodal tumour spread.
In 100 patients with breast cancer, nodal
metastases were found to be significantly
associated with tumour size, tumour border,
histological grade and duration of symptoms.
These parameters, along with clinical find-
ings, were thenused to create a data base from
which the probability of nodal involvement
by tumour could be derived. The calculation
was carried out by a basic language computer
programme, which used Bayesian probability
theory. This programme was then tested on a
total of 159 patients and achieved an overall
accuracy rate of 84%, compared with 65%
from clinical examination alone.
Such computer-assisted diagnosis may be
useful in the preoperative assessment of
breast-cancer patients, and may have impli-
cations for the selection of therapy.
REACTIVITY OF MONOCLONAL
ANTIBODIES AGAINST HUMAN
LUNG CANCER CELL LINES. D. T.
BROWN & M. MOORE, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester 20
A panel of monoclonal antibodies was
produced by fusion of sensitized murine
spleen cells with the NS-1 myeloma, against
several human lung carcinoma cells, includ-
ing the E14 and BEN lines (squamous-cell
carcinoma). Most of the monoclonal probes,
tested by radioimmunoassay, recognized
species-specific antigens or lung differentia-
tion antigens. However several of the anti-
bodies showed reactivity against target
antigens with a more restricted distribution.
Antibodies designated 7B3 5, 7B5-4 and
7B17 7 were reactive with a variety ofhuman
carcinoma cell lines derived from several
different tissues, but were negative against
several normal lung lines. Two monoclonal
antibodies (7B24-4, 7BC9-1) recognized a
target antigen found only on the immunizing
cell line (BEN) and in the case of 7BC9-1 at a
much lower density on one colorectal car-
cinoma cell line (W1DR). These antibodies
should prove useful for the definitive charac-
terization of putative human tumour-asso-
ciated antigens in lung and other cancers.
MONOCLONAL ANTIBODY ISOTOPE
SCANNING IN THE DETECTION OF
METASTATIC CARCINOMA. H. M.
SMEDLEY,, K. SIKORA, E. LENNOX & P.
WRAIGHT, Ludwig Institute for Cancer Re-
search, MRC Centre, MRC Laboratory of
Molecular Biology, Department of Nuclear
Medicine, Addenbrooke's Hospital, Hlills
Road, Cambridge
We present our initial results together with
representative scans obtained from patients
with metastatic cancer following the injection
of radioisotope-labelled monoclonal anti-
bodies. Rat monoclonal antibodies were
prepared by immunizing rats with- lhuman
colorectal carcinoma cell membranes and
fusing splenic lymphocytes with a rat mye-
loma, Y3 Ag 123. Hybridoma supernatants
were screened by binding assays on colorectal
carcinoma cell lines. One hybridoma super-
natant contained a monoclonal antibody with
high binding activity and was grown in large
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quantities in serum-free medium. After
ammonium and sulphate precipitation the
antibody was purified by ion-exchange chro-
matography. A modified version of the
chloramine-T method was used for iodination
with 1311. Binding assays to cell lines and in
v?ivo experiments on xenograft-bearing
immune-deprived mice revealed that this
coupling method leaves the biological activ-
ity and specificity ofthe monoclonal antibody
substantially unaltered. This preparation has
been injected into patients with metastatic,
colorectal and breast tumours without un-
toward side-effects. Gamma-camera scans
have been obtained at 6, 24 and 48 h and
following estimates of the blood pool using
conventional imaging reagents, computerized
subtraction scans were obtained showing
areas of localized high uptake corresponding
well with areas of known disease. No clinical
complications of this technique have been en-
countered, and one patient has been scanned
on 2 separate occasions without apparent
problems. This work is currently being
expanded to use other monoclonal antibodies
with patients with different types of
malignancy.
THE DETECTION OF BLOOD-
GROUP ISOANTIGEN ON SUPER-
FICIAL BLADDER TUMOURS USING
MONOCLONAL ANTIBODIES AND
ITS VALUE IN PREDICTING SUBSE-
QUENT INVASIVE RECURRENCE.
P. J. FINAN*, E. S. LENNOXt, & N. M.
BLEEHEN*, *MRC Clinical Oncology Unit and
tMCR Laboratory of Molecular Biology,
Cambridge
It has been claimed that loss of normally
occurring blood-group isoantigen (BGI) on
malignant transitional epithelium is a reliable
predictor of subsequent invasive recurrence
(Limas & Lange, 1979, Cancer, 44, 2099).
Previous workers have used the specific red-
cell-adherence test together with conven-
tional antisera. However, problems have been
encountered both with the technique and
reproducibility of results. We have therefore
investigated a more direct method for
demonstrating the presence ofBGI on normal
and malignant transitional epithelium.
Using an indirect immunoperoxidase tech-
nique and monoclonal antibodies to the blood
groups A and B (Voak et al., 1980 Vox. Sang.,
39, 134; Sacks & Lennox, 1981, Vox. Sang.,
40, 99) BGI was detected on paraffin sections
of normal urothelium from 14 patients. On
initial biopsies from 39 patients with super-
ficial bladder tumours, followed for 5 years or
until muscle invasion occurred, BGI was
detected in 31 (790%). The rate of invasive
recurrence in the isoantigen-group was signi-
ficantly higher than in the isoantigen- group
(P=0 04, Fisher's exact test).
Using these specific reagents, blood-group
isoantigen may be readily detected on
paraffin-embedded material. Furthermoreloss
of isoantigen expression would appear to
identify a group of patients at higher risk of
developing an invasive recurrence, who
should be subjected to closer follow-up.
CIRCULATING LYMPHOCYTES IN
BLADDER-CANCER PATIENTS
TREATED WITH MEGAVOLTAGE X-
RAY THERAPY. L. L. ALEXANDER*, W.
DUNCANt, C. M. STEEL*, & J. N. WEBBt,
*MRC Clinical and Population Cytogenetics
Unit, tUniversity ofEdinburgh and Radiation
Oncology Unit, Western General Hospital and
.Dept ofPathology, W.G.H., Edinburgh
30 patients with transitional-cell carcinoma of
bladder have been studied by serial counts of
circulating lymphocytes, and ofT cells before,
during and at intervals (up to 3 years) after
radiotherapy.
Total lymphocyte counts fell, reaching a
nadir (less than 5000 of pretreatment levels)
one month after the end of treatment.
Recovery of lymphocyte numbers was very
gradual and did not approach pretreatment
levels for about 2 years. The proportion of T
cells remained within normal limits through-
out. Nine patients died oftheir disease within
18 months of entering the study. In this
group, pretreatment lymphocyte counts were
higher and post-treatment counts lower than
in the remaining patients. This correlation
between patterns of change in circulating
lymphocytes and survival was independent of
either stage grade ofthe original tumours.
Lymphocytes from every blood sample
have been stored in liquid N2. With the
availability of monoclonal antibodies, these
are now being examined to establish the
behaviour of T-cell subsets in this group of
patients.
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A POPULATION-BASED STUDY OF
FAMILIAL ASPECTS IN SOFT-
TISSUE SARCOMAS OF CHILDHOOD.
J. M. BIRCH & A. L. HARTLEY, University of
Manchester, Department of Epidemiology and
Social Research, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX
A familial syndrome involving soft-tissue
sarcomas (STS) in children and early-onset
breast cancer in their mothers has been
described. At present neither the proportion
of familial childhood STS nor the risk to the
mothers can be estimated. The present study,
based on the Manchester Children's Tumour
Registry (MCTR), seeks to do this, and to
identify features which distinguish familial
from non-familial cases.
Between 1954 and 1981, 154 cases of STS
were included in the MCTR. The ratio ofboys
to girls was 1-4:1. The median age at onset
was 4 years among the largest group, the
rhabdomyosarcomas.
A search to the MCTR records ofthese 154
cases revealed: (a) 5 sib-pairs involving a STS
compared with 5 sib-pairs with other tum-
ours, among -2800 cases in the MCTR as a
whole; (b) 2 mothers with early-onset of
breast cancer, including the mother of one of
the sib-pairs; and (c) 14 other cases with close
relatives who had early onset breast, child-
hood or other cancers. In addition 9 ofthe 154
cases had congenital abnormalities and 5 had
1 or more first degree relatives with congenital
abnormalities. There were 4 cases who were
one of a pair of twins and 5 cases who had
twins amongst their close relatives. This
represents an increased frequency of both
congenital malformations and twinning.
More detailed investigations of children
with STS and their families are under way to
characterize the familial cases further. The
work has important implications for genetic
counselling.
MARROW INVOLVEMENT IN ADULT
SOFT TISSUE SARCOMAS. V. BRAM-
WELL, M. B. LITTLEY, J. CHANG, & D.
CROWTHER, Depts ofMedical Oncology, Haemn-
atology, Christie Hospital, Manchester and
Stepping Hill Hospital, Stockport
As marrow involvement is common in
disseminated childhood rhabdomyosarcoma,
and implies a poor prognosis, we wished to
assess the incidence and significance of
marrow infiltration in adult soft tissue sar-
coma. There was invasion of the marrow by
tumour in 4/74 cases, all from the group of 56
patients who had other evidence ofmetastatic
disease, giving an overall incidence of 700.
Angiosarcomas of the breast are extremely
aggressive, and long-term survivors are rare.
Our only patient with this diagnosis had
marrow invasion demonstrated by trephine
biopsy, and rapidly succumbed, despite
intensive chemotherapy. About 120% tumour
giant cells were found in the marrow aspirate
from a patient who had a solitary pulmonary
metastasis from a pleomorphic rhabdomyo-
sarcoma of the right biceps muscle. A third
case had widespread metastases from a poorly
differentiated sarcoma of uncertain histo-
genesis. Marrow aspirate and trephine demon-
strated almost complete replacement of
normal marrow by undifferentiated tumour
cells. A single case of well differentiated
myxoid liposarcoma also metastasized to the
marrow. This tumour disseminated widely,
yet the metastases retained the low mitotic
rate and myxoid appearances ofthe primary.
Although 270 ofthe total material comprised
leiomyosarcomas, none metastasized to mar-
row. Durations of survival from the time of
documented marrow involvement were 4, 5,
20, 19 + months, and did not differ signifi-
cantly from those of the whole group with
metastatic disease (median 11 months).
Although it was not possible to determine
whether response to chemotherapy was
influenced by marrow involvement, haemato-
logical toxicity seemed excessive.
LECTIN BINDING TO THE PERI-
PHERAL BLOOD MONONUCLEAR
CELLS OF PATIENTS WITH
LYMPHOMA-CORRELATION WITH
CLINICAL STAGE AND OTHER SUR-
FACE MARKERS. G. BLACKLEDGE, J.
GALLAGHER, A. MORRIS & I). CROWTHER,
CRC Dept of Medical Oncology, Christie
Hospital, Manchester M20 9BX
The binding of various lectins to the surface
membranes ofdifferent cell types has been re-
ported previously and using Con A, LCA and
WGA, characteristic binding patterns have
been obtained for acute myelogenous, acute
lymphoblastic and chronic lymphocytic leuk-
aemia. The peripheral blood mononuclear
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cells of patients with lymphoma have been
studied by flow cytometry using the method
previously described (Blackledge et al., 1980,
Flow Cytometry, 4, 222). It has been found
that there are particular patterns of lectin
binding to PBL cells in different pathological
types oflymphoma. Those lymphomas with a
poorly differentiated cell type (Rappaport)
regardless of whether nodularity exists in the
tumour, have a repeatable pattern. Tumours
with the so-called histiocytic type of cell also
have a reproducible pattern oflectin binding,
with a population of cells having an increased
lectin binding. Cells from patients with
DWDL lymphoma resembled those found in
CLL. These results suggest that regardless of
morphological evidence of blood involvement
by lymphoma, there are definite changes in
the peripheral blood mononuclear cells, which
may indicate abnormal cells in the peripheral
blood or some other influence on the binding
of lectins to normal PBL.
TREOSULFAN CHEMOTHERAPY IN
ADVANCED OVARIAN CANCER: A
LONG-TERM EVALUATION IN PRE-
VIOUSLY UNTREATED DISEASE.
W. F. WHITE & J. E. MASDING, Regional
Centre for Radiotherapy and Oncology,
Guildford, Surrey
Previously presented data (White, 1982,
Curr. Chemother. and Immunother., in press)
indicated that treosulfan chemotherapy
administered in an intermittent regimen was
superior to a continuous regimen, in terms of
improved survival and reduced toxicity. This
communication reports on progress ofpatients
with ovarian cancer on intermittent treo-
sulfan, and includes a number of patients
enrolled since the previous evaluation.
From November 1977 to December 1980
inclusive, a total of56 patients with advanced
(FIGO Stages III/IV) non-radically operable,
ovarian cancer ofepithelialoriginwere treated
with treosulfan, in a regimen which usually
comprised 1 g daily for 28 days followed by 28
days off treatment. Patients aged 75 or over
were started at 750 mg/day. All patients had
residual disease after operative procedures,
and significant surgical reduction of tumour
masses was carried out in only 20 cases.
Of 47 fully evaluable patients, there were
18 complete responders (CR:38%) 14 partial
responders (PR:30o). and 15 non-responders
(NR:32%). Median survival of CRs is at
present > 19 months, ofPRs 11-5 months and
NRs 9 months. Of the CRs, 6 are continuing
in remission, 3 are alive with recurrent disease
and 9 have died. Two PRs are in complete
remission at 12 and 40 months, due to radical
"'2nd-look" laparotomy. Dose-limiting toxic-
ity was haematological: 35 (74%O) of patients
required dose modification due to leucopenia
and/or thrombocytopenia. The commonest
side-effect was a generalized skin pigmenta-
tion which occurred in 12 (26%) patients.
Treosulfan is a well-tolerated treatment for
advanced ovarian cancer, and produced a
higher remission rate than those generally
reported for other types ofalkylating agent.
TOTAL ABDOMINAL AND PELVIC
IRRADIATION FOLLOWING TREAT-
MENT WITH CIS-DICHLORODI-
AMININE PLATINUM II (CDDP) AND
SECOND-LOOK LAPAROTOMY IN
PATIENTS WITH ADVANCED OVAR-
IAN CARCINOMA: A PHASE I STUDY.
K. K. CHAN, T. A. LATIEF, G. A. NEWS-
HOLME, T. J. PRIESTMAN, C. E. NEWMAN,
R. A. HURLOW, J. FIELDING, D. LUESLEY &
A. HOWELL, Departments, Medicine and
Obstetrics & Gynaecology, Queen Elizabeth
Hospital, Birmingham
It has been shown that total abdominal and
pelvic irradiation (TAR) improves survival in
patients with microscopic residual disease
after surgery for ovarian carcinoma (Dembo,
et al., 1979, Am J. Obstet Gynaecol, 134, 793).
The aim of this study was to reduce bulky
disease with CDDP x 5 courses and cyto-
reductive surgery, and to treat patients with
no macroscopic residual disease with TAR.
Eleven patients were treated according to
this protocol between 1979 and 1981. CDDP
100 mg/M2 was given at 3-weekly inter-
vals x 5 followed by second-look laparotomy.
Only patients with a surgical complete
remission or who could be converted to no
macroscopic residual disease were entered.
TAR was given by the strip technique
(Dembo et al., 1979, J. Radiol Oncol. Biol.
Phys., 5, 1933). Two patients failed to
complete TAR, because ofdisease progression
during treatment. Nine completed treat-
ment; toxicity included diarrhoea (3) vomit-
ing (2) nausea (2) abdominal colic (1) and
parasthesiae (3). Treatment was delayed
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because of marrowi- suppression in 3 patients
(1 leukopenia, 2 thrombocytopenia). One
patient required transfusion 8 weeks after
TAR began. Mean creatinine clearances
before CDDP, before surgery and after TAR
were 66-7, 77-3 and 72-7 ml/min; no early
renal toxicity was seen. Five patients are alive
and well at 36, 24, 19, 17 and 8 months, one
alive with disease and 3 died with progressive
disease. It is possible to give TAR after CDDP
with minimal toxicity.
ASSESSMENT OF RENAL FUNCTION
DURING HIGH-DOSE CIS-PLATIN
THERAPY IN PATIENTS WITH
OVARIAN CARCINOMA. P. K. BAUMAH,
A. HOWELL, H. WHITBY E. S. HARPUR & A.
GESCHER, Depts. of Clinical Chemistry and
Medicine, Queen Elizabeth Medical Centre,
University ofBirmingham, Dept. ofPharmacy,
University ofAston, Birmingham
Renal function was assessed in 22 previously
untreated patients with Stage III/IV ovarian
cancer treated with CDDP (100 mg/M2) at 3-
weekly intervals x 5. Hydration consisted of
3 1 saline on Day 1 and 5 1 saline and 11100%
mannitol with i.v. bolus CDDP on Day 2. Day
1 urine was collected for creatinine clearance
and early-morning urine on Day 1 for B2
microglobulin (B2M) excretion and osmolality
(n=22). The brush-border enzyme alanine
aminopeptidase (AAP) and the lysosomal
enzyme N-acetyle-B-glucasaminidase (NAG)
w-ere estimated on concentrated urine speci-
mens taken - 34 h before and 38 and 62 h
after CDDP bolus for 2 consecutive courses
(n=7).
Mean creatinine clearances (ml/min) before
the first and fifth courses of treatment were
75 8 + 25 6 (s.d.) and 76-8 + 26-0. There was no
change in mean urine osmolality and the
mean B2M excretion fell from 143 to
86 mg/mmol creatinine. Pre-CDDP urinary
NAG was raised in 5/7 and AAP in 4/7
patients. There was a tendency for pre-
CDDP, AAP but not NAG excretion to rise
with consecutive treatments (P=0 025). Both
NAG and AAP excretion increased at 38 h
post CDDP and tended to fall by 62 h. In
view of the absence of changes in conven-
tional indices ofdeteriorating renal function it
is not clear w%Ahat significance may be
attributed to the increased excretion of AAP
and NAG in urine.
THE ANTI-EMETIC POTENTIAL
OF ORAL LEVONANTRADOL IN
PATIENTS RECEIVING CANCER
CHEMOTHERAPY. J. F. B. STUART*t, J.
WELSH*, G. SANGSTER*, M. SCULLION*, H.
CASH:, S. B. KAYE*, K. C. CALMAN*,
*Pharmacy Department, University of Strath-
clyde, tDepartment of Oncology, University of
Glasgow, tClinical Projects Manager, Pfizer
Ltd, Kent.
Levonantradol a new anti-emetic -which has
no activity on the dopaminergic system, has
shown to be effective in controlling nausea
and vomiting caused by cis-platin chemo-
therapy. A dose-ranging study was made,
using 0-25mg capsules of levonantradol in
patients who had suffered from severe nausea
and vomiting following different chemothera-
peutic regimes despite adequate doses of
conventional anti-emetics. Various doses of
levonantradol were explored ranging from
0-25 mg 4-hourly to 1 mg of drug 4-hourly in
24 h after chemotherapy. 20 patients were
studied who were receiving drugs such as cis-
platin and cyclophosphamide, -which are
known to cause severe nausea and vomiting.
The 20 patients were divided into 4 groups of
5. Five patients in Group 1 were given
0 25 mg oflevonantradol and the remaining 3
groups of 5 received 0 5 mg, 0 75 mg and 1 mg
respectively. Treatment with the drug was
started 1 h before chemotherapy. The results
obtained from the 4 different dose levels were
as follows: only one patient in the 2 groups
with 0 25mg and 0 5mg dose obtained >5000
relief from nausea and vomiting. In the
0-75mg and lmg group 7/10 patients obtained
a >5000 relief from nausea and vomiting, as
compared with previous anti-emetic therapy.
Toxicity due to the anti-emetic was mild but
did show a dose relationship. As a result of
these findings further studies at the 0-75mg
and lmg doses are planned, and alteration of
dose schedules will be explored.
EVALUATION OF NABILONE AS AN
ANTI-EMETIC. M. A. CORNBLEET, D. A.
HAMILTON, P. CHRISTIAN & J. F. SMYTH,
Department of Clinical Oncology, Western
General Hospital, Edinburgh
Of the major side-effects of cytotoxic chemo-
therapy, nausea and vomiting remain among
the most distressing. Conventional anti-
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emetics are of only limited benefit and some
patients find it impossible to continue
treatment. Although the anti-emetic proper-
ties of marijuana are well established, its
psychoactive properties make it unlikely to be
widely acceptable. Nabilone is a synthetic
cannabinoid in which a dimethylheptyl side-
chain prevents conversion iiito A9 tetrahydro-
cannabinol, the psychoactive metabolite of
marijuana. In a pilot study, nabilone has been
assessed as an anti-emetic in 18 patients
receiving cytotoxic chemothlerapy. Twelve
were treated with platinum-containing com-
binations, 4 received methotrexate and
cyclophosphamide and 2 received adriamycin-
containing combinations. All had previously
experienced chemotherapy-associated nausea
or vomiting. Nabilone was prescribed as 2mg
capsules 6-hourly commencing 12 h before
treatment, and then 2 mg bd for the duration
of chemotherapy. Ten patients reported
significant psychotropic effects of whom 6
recorded dysphoria and 4 euphoria. Five were
sufficiently distressed to refuse a further trial
of nabilone. Postural hypotension was
observed in 1 patient, but no other side-effects
were detected. 230/ of patients experienced
minimal or no nausea or vomiting but 770°
still experienced moderate or severe symp-
toms. The high incidence (550/) of significant
psychotropic side-effects make nabilone un-
likely to be ofroutine value as an anti-emetic,
particularly in out-patient practice. However
a significant proportion of patients (390/)
found chemotherapy more tolerable -when
treated with nabilone in this way.
METOCLOPRAMIDE: DOSE-RELA-
TED EFFECT ON THE EMESIS OF
CHEMOTHERAPY. R. Cox, C. E. NEW-
MAN & M. J. LEYLAND, East Birmingham
Hospital and Newfoundland Cancer Treatment
and Research Foundation
The nausea and vomiting induced by chemo-
therapy is a major problem.
A randomized placebo-controlled trial of
metoclopramide (M) was conducted in
patients receiving chemotherapy for small-
cell carcinoma of the lung. 10 mg of M or
placebo was given i.v. or orally 4-hourly
during treatment. The i.v. route was used for
nauseated or vomiting patients. No vomiting
occurred in 28/59 courses with M, compared
with 10/59 with placebo. The difference is
highly significant (X2= 12X17, 1 df, P <0-001).
In a further 39 courses in which M or placebo
was given less than 4-hourly, no difference
was noted.
It was thought that the anti-emetic effect
of M could be dose-related. Groups of 5
patients undergoing chemotherapy were
given 1-4 mg/kg/day of M i.v. in 6 divided
doses. A further group of 9 patients have
received 5 mg/kg/day. Only one episode of
vomiting occurred and only one patient felt
nauseated of these 9. Of 8 patients capable of
eating all but 1 ate something of every meal
whilst receiving M. One patient had moderate
extra-pyramidal side-effects.
These preliminary data suggest that pre-
vious studies of metoclopramide have used it
in inadequate doses, and that at high doses
i.v. it is an effective anti-emetic.
ASSESSMENT OF NUTRITIONAL
SUPPLEMENTATION AND PLASMA-
PHERESIS IN CANCER PATIENTS.
G. E. RAINES, J. M. TROTTER, J. C. WILLOX,
G. MACAULEY & K. C. CALMAN, Department
of Clinical Oncology, Gartnavel General Hos-
pital, Glasgow
The effectiveness of enteral hyperalimenta-
tion and plasma exchange were investigated
in cancer patients, examining in particular,
albumin and urea metabolism, with the aim of
improving their condition and determining
wi-hich patients were likely to respond to
nutritional support.
The distribution and rate of excretion or
synthesis of the appropriate radioactive
products, following i.v. injection of 131L-
human serum albumin, sodium 125lodide and
sodium 14Carbonate, was monitored to deter-
mine albumin catabolism, synthesis and
transcapillary escape rate and urea synthesis
rate and half-life.
Of the patients studied to date with
nutritional support, all had normal or high
albumin synthetic, catabolic and transcapil-
lary escape rates, in contradistinction to the
previously reported low synthesis rates
(Waldmann, et al., 1963, J. Clin. Invest., 42,
171) and to the normal adaptation to protein-
energy malnutrition. Most patients had
normal urea-synthesis rates and half-lives,
although 2 patients had low rates, despite
their hypercatabolic state and nutritional
support, and one patient studied before and
493during feeding showed a rise in urea-synthesis
rate.
The benefits ofplasma exchange were more
obscure, though short-term clinical improve-
ments were noted (Shaw et al., 1980, Br. Med.
J., 281, 1459). The changes in biochemical
parameters and metabolism effected by the
tumour were not ameliorated for greater than
12-24 h, except for a slight though statistic-
ally insignificant fall in urea-synthesis rate
and a rise in transcapillary-escape rate. From
these preliminary data it was concluded that
a patient with net albumin synthesis was
more likely to respond to nutritional supple-
mentation and show an improved prognosis,
than with a net catabolism.
COMBINATION CHEMOTHERAPY IN
ADVANCED GASTRIC CANCER. D.
CUNNINGHAM, D. C. CARTER, C. S. MCARDLE
& M. SOUKOP, Department ofMedical Oncology
and University Department of Surgery, Royal
Infirmary, Glasgow
The median survival of patients with
advanced gastric cancer is 4 months. Recent
reports of combination chemotherapy have
been encouraging. We thus undertook a
prospective Phase II study of 28 consecutive
patients with inoperable or meastatic gastric
cancer treated with intravenous 5-Fluoroura-
cil, Adriamycin and Mitomycin-C (F.A.M).
Seventeen patients (61%) failed to respond
(median survival 2-5 months). In 11 patients
(390o) a partial response was obtained, their
median survival being 9 months; 9 are still
alive. They included 2 patients whose cancer
became resectable after cytotoxic therapy
and a further patient with dysphagia in whom
the need for intubation was avoided. Apart
from alopecia, the treatment was well
tolerated. Before therapy, performance status
was similar in both groups; all responders
subsequently showed an improvement in
performance status.
This study suggests FAM prolongs survival
and may permit secondary resection in
patients initially considered to be inoperable.
ORAL CANCER EPIDEMIOLOGY IN
SCOTLAND. P. BOYLE*T, C. SCULLYt &
C. R. GILLISt, *IARC, Lyon; tUniversity
Department of Oral Medicine and Pathology,
Glasgow and I West ofScotland Cancer Surveil-
lance Unit, Glasgow
The epidemiology of oral cancer in Scotland
appears not to have been studied, and it is
now 10 years since the last published major
study in England and Wales (Binnie et al.,
1972, OPCS Studies on Medical and Popula-
tion Subjects No. 23, HMSO). We have
therefore examined mortality from oral
cancer in Scotland since 1911 and incidence
since 1963. The all-ages age-standardized
mortality rates for oral cancer fell during the
67 years as did the rates for those subsites for
which data were available-lip, tongue and
rest of mouth. Similar declines in mortality
were observed in both sexes, these mirroring
the falls in incidence. Falls in mortality and
incidence were observed in all age groups. A
strong birth-cohort effect was found for all
subsites, with each cohort born in 10-year
periods subsequent to that centred on the
year 1878 experiencing declining levels of
mortality from oral cancer. In view of the
strength and consistency ofthe demonstrated
association between oral cancer and the use of
tobacco, this decline is surprising, and
suggests the presence of other aetiological
factors of more importance in the Scottish
environment.
PROGNOSTIC FACTORS IN HODG-
KIN'S DISEASE. G. VAUGHAN HUDSON &
A. M. JELLIFFE, The British National Lymph-
oma Investigation
During the last 12 years many patients with
Hodgkin's Disease have been referred to the
B.N.L.I. It has become apparent that various
pretreatment factors, including clinical stage,
symptoms, age, histology, ESR, lymphocyte
count, haemoglobin, and albumin, can be
related to the tempo ofthe disease and thus to
the prognosis of the individual case and need
for more vigorous treatment.
Factors associated with a poor prognosis
appear to be advanced clinical stage, "B"
symptoms (weight loss, fever, night sweats),
older age group (over 45), poor histology
(including recently recognized Grade II
nodular sclerosis), high ESR, and low peri-
pheral-blood values for lymphocytes, haemo-
globin and albumin.
The provisional results of a detailed
analysis of 1600 cases are presented with
reference to is possible implications for
staging and management.
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IMPLICATIONS OF GOMPERTZIAN
GROWTH OF TUMOURS FOR RATE
OF DECLINE OF CLONOGENIC CELL
NUMBER DURING SINGLE-AGENT
CHEMOTHEARPY. T. E. WHELDON*, R.
BELLt & G. F. BRUNTONX, *MRC Cyclotron
Unit, tDepartment of Medical Physics, Ham-
mersmith Hospital, London W12 and IDept of
Clinical Physics and Bio-engineering, Glasgow
04 9LF
Gompertzian growth of tumours may be due
to a decreasing growth fraction, an increasing
cell-loss factor, or both. When Gompertzian
retardation is primarily due to a changing
growth fraction, cycle-specific chemotherapy
is increasingly efficient in killing clonogenic
tumour cells, more of these cells being called
into cycle as the tumour regresses and the
growth fraction expands. However, when
retardation is largely due to a changing loss
factor, there is no increase in the vulnerability
of clonogenic cells during regression, but, as
the net specific growth rate increases, regres-
sing tumours may display "kinetic resist-
ance", the rate ofregrowth increasing until it
balances the rate of cell kill. Kinetic
resistance may also be displayed by tumours
conforming to Gompertz growth kinetics (of
either type) when treatment is with a non-
cycle-specific drug. This may provide a
mechanism for the failure of long-term
chemotherapy to achieve cure, in some cases
where short-term chemotherapy using the
same agent is seen to cause tumour regression.
STRUCTURE-ACTIVITY STUDIES
WITH THE HOMOLOGOUS SERIES
OF CROSSLINKING DIMETHANE-
SULPHONIC ACID ESTERS. P.
BEDFORD & B. W. Fox, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester M20 9BX
The ability of members of the homologous
series of dimethanesulphonic acid esters
(n = 1-9) to crosslink the DNA ofcells derived
from the transplantable rodent Yoshida
Lymphosarcoma, was assayed by the tech-
nique of alkaline elution described elsewhere
(Bedford & Fox, 1982, Chem. Biol. Interact.,
38, 119). A peak of interstrand crosslinking
occurred after treatment of the cells with
hexane dimethanesulphonate (n=6) which
decreased with shorter, or longer alkylating
chain lengths. The peak of crosslinking
activity by the 6-carbon chain member was
paralleled by its optimal cytotoxicity towards
the Yoshida cells in culture. Ethylene
dimethanesulphonate (n =2) produced no
detectable interstrand crosslinks, which was
reflected in a lack of in vitro cytotoxicity and
in vivo antitumour activity. A possible
relationship between DNA-DNA interstrand
crosslinking ability and cytotoxicity through-
out the series was obtained, which was
partially but not wholly reflected in the
antitumour effectiveness of members of the
series. Preliminary data suggest however that
the action onhaemopoietic and spermatogenic
systems may not correlate with DNA-DNA
interstrand crosslinking in the same way.
ASPECTS OF ANALYSIS, FORMULA-
TION AND PHARMACOKINETICS OF
1,3,5 - TRILGLYCIDYL - S - TRIAZINE-
TRIONE (ocTGT) AFTER I.V. ADMIN-
ISTRATION. M. N. AzMIN*t, J. F. B.
STUART*t, A. SETANOIANS*, R. G. G.
BLACKIE*, D. WHITEHILL*, J. WELSH*,
*Department of Oncology, University of
Glasgow and tDepartment of Pharmaceutics,
Strathclyde University
The search for new cytotoxic agents led to the
discovery of oxTGT, a tri-epoxide derivative
shown to have antineoplastic activity in
several murine tumours including the cyclo-
phosphamide-resistant P388 murine tumour
lines. Recent Phase I clinical trials have
suggested that oxTGT may be useful in
treatment of human malignancies. Since this
drug is intended for parenteral administra-
tion, the final dosage form must be sterile and
have an acceptable level of purity and
stability. The poor aqueous solubility and
stability of aTGT are the added problems
which have to be taken into account during
the preparation ofthe injectable formulation.
About 10-13 mg cxTGT dissolved in every ml
of water. otTGT in water is broken down to 3
degradation products, and the process is
accelerated by an increase in temperature.
Breakdown of dry uTGT was also evident
after exposure to y-irradiation. Since heat and
y-irradiation could not be used, filtration is
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the only viable method for sterilization
though about 20%/ of the drug may be lost in
the process. The sterile filtrate was freeze-
dried to the final form, which is stable for at
least 2 months when stored at 4°C. The
aqueous solubility of aTGT was doubled or
trebled by the addition of non-ionic surfact-
ants. Apart from reducing the bulkiness of
aTGT solution to 1/2 or 1/3 prior to filtration
and freeze-drying, the surface-active agent
added was also found to reduce the rate of
aTGT degradation. Of the i.v. infusion fluids
studied, only 5/' dextrose solution was found
to be suitable as a vehicle for ocTGT. 09%O
sodium chloride injection on the other hand
enhanced oxTGT breakdown.
DEFICIENCY OF 3-HYDROXYBUTY-
RATE UTILIZATION IN TUMOURS.
M. J. TISDALE & R. A. BRENNAN, C.R.C.
Experimental Chemotherapy Group, Depart-
ment of Pharmacy, University of Aston,
Birmingham B4 7ET
Ketone bodies (3-hydroxybutyrate, acetoace-
tate and acetone) are an important metabolic
fuel for peripheral tissues during starvation.
Utilization of3-hydroxybutyrate requires the
presence of a 3-oxoacid CoA transferase,
whereby the CoA moiety of succinyl CoA is
transferred to the oxoacid thereby providing
a precursor for the formation of acetyl CoA.
This enzyme is present in variable amounts in
all normal tissues except liver, but is virtually
absent from a range of murine and human
tumours, which are unable to utilize 3-
hydroxybutyrate in vitro. In contrast with
the loss of 3-oxoacid CoA transferase, the
activity of3-hydroxybutyrate dehydrogenase
is comparable in tumour and normal tissue.
This suggests that such tumours may be
unable to maintain their ATP levels under
conditions in which ketone bodies are the
predominant energy source. Such a situation
could be achieved in vivo by feeding patients a
low carbohydrate diet supplemented with
high levels of 3-hydroxybutyrate, together
with an inhibitor of gluconeogenesis from
lactate. In view of the ability of 3-hydroxy-
butyrate to feedback-inhibit breakdown of
muscle and adipose tissue, such a treatment
wvould also be expected to alleviate the
w%vasting syndrome sometimes associated with
advanced cancer.
THE SITE OF ACTION OF AMINO-
GLUTETHIMIDE (AG) IN ADVANCED
BREAST CANCER. A. L. HARRIS*, M.
DOWSETTt, S. JEFFCOATEt, I. E. SMITH*,
*Royal Marsden Hospital, Fulham Road,
London and tEndocrinology Department,
Chelsea Hospital For Women, London
AG is an effective drug in advanced postmeno-
pausal breast cancer. It inhibits the conver-
sion ofcholesterol to androgens in the adrenal
glands (desmolase) and also the conversion
of androgens to oestrogens peripherally in
adipose tissue and breast carcinoma (aromat-
ase). It is combined with replacement doses of
hydrocortisone.
Short Synacthen tests (250 jig Synacthen
i.m.) were performed on 10 post-menopausal
women with advanced breast cancer who had
received AG (250 mg 4 x day) plus hydrocorti-
sone (20 mg 2 x day) for at least 3 months.
There was no significant rise in cortisol,
oestrone or dehydroepiandrosterone sulphate.
However, 170H progesterone (170HP), A4
androstenedione, (A4A) and dehydroepian-
drosterone rose markedly. 170HP rose by up
to 53-fold, and A4A up to 10-8-fold. This
pattern of response to ACTH suggests that
there is little inhibition of desmolase by AG,
but that inhibition of aromatase is more
important, and even a marked rise in
precursors does not override aromatase
inhibition. Since conventional dose AG is
given to inhibit desmolase we used low
dose AG without hydrocortisone to inhibit
aromatase, which in vitro is more sensitive
than desmolase. Twelve postmenopausal
patients were given AG (125 mg 2 x day) for 1
week and in all patients oestrone fell
(50x19% of baseline). AG was more than
doubled each week until 500 mg 2xday.
Oestrone at the highest dose of AG was
54 + 28% of baseline. The addition of 20 mg
hydrocortisone 2 x day did not further sup-
press oestrone (55+250% of baseline). This
suggests that adrenal suppression by hydro-
cortisone does not contribute to the effect of
AG, and that low-dose AG alone should be
assessed for therapeutic effect.
INCREASED ANTITUMOUR ACTIV-
ITY OF PLATINUM DRUGS IN COM-
BINATION WITH PREDNISOLONE.
P. M. GODDARD, C. R. SHEPHERD & K. R.
HARRAP, Dept Biochem. Pharmacol., Inst.
CancerRes., Sutton, Surrey
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In experimental tumour systems. predniso-
lone potentiates the antitumour activity of
some alkylating agents by reducing host
toxicity and increasing tumour-cell kill, par-
ticularly against alkylating-agent-resistant
tumours. The clinical efficacy of alkylating
agents is also increased by their use in
combination with prednisolone. The modes
of action of alkylating agents and platinum
drugs are very similar: both cross-link DNA
and interact with nuclear proteins. Alkyl-
ating-agent-resistant Walker and Yoshida
tumours are cross-resistant to platinum
compounds, and we now report increased
antitumour activity ofplatinum/prednisolone
combinations. Using both s.c. and i.p. routes,
prednisolone, 4 h after either cisplatin (cis-
dichloro diammine platinum (II)) or CHIP
(cis-dichloro, trans-dihydroxy bis-isopropyl-
amine platinum IV), resulted in a doubling of
the therapeutic index against the alkylating-
agent-sensitive Walker tumour carried in
Wistar rats. Prednisolone alone is not active
against this tumour. The host toxicity of the
combination was identical to that of the
platinum drug alone, but the ED90 was
halved. An increased cell kill ofthe alkylating-
agent-resistant tumour was also obtained
using platinum/prednisolone combinations.
These data suggest that therapeutic benefit
may be obtained from the use ofprednisolone
in combination with platinum drugs in the
clinic even for non-steroid responsive
tumours.
MODIFIERS OF DRUG METABOL-
ISM: THEIR EFFECTS ON THE RE-
SPONSE OF TUMOUR AND NORMAL
TISSUES TO CYTOTOXIC AGENTS.
P. WORKMAN & P. TWENTYMAN, MRC
Clinical Oncology and Radiotherapeutics Unit,
Cambridge
We have investigated the effects of the
hepatic microsomal enzyme-inducer pheno-
barbitone and the inhibitor SKF 525A (pro-
adifen HCI) on the response of the RIF-1 and
KHT solid tumours to cytotoxic agents in
mice. Effects on peripheral white-blood cells
and LD50 were also determined. SKF 525A
enhanced tumour response to chlorambucil
and CCNU but not melphalan. Normal-tissue
responses indicated a therapeutic gain wNith
CCNU but not chlorambucil. Phenobarbi-
tone reduced botlh tumour and normal-tissue
responses to CCNU and chlorambucil, but the
effects on therapeutic ratio were complex.
Studies are in progress with cyclophos-
phamide.
The effects of SKF 525A on cytotoxic drug
response are very similar to those with the
nitroimidazole misonidazole, which is under
investigation as a chemosensitizer for clinical
use. For a range of misonidazole analogues,
structure-activity relationships for chemo-
sensitization were closely similar to those for
enhancement of pentobarbitone sleep-time,
used to assay inhibition ofdrug metabolism.
We conclude: (1) response to cytotoxic
drugs can be altered by modifiers of drug
metabolism, and this can result in changes in
therapeutic ratio; (2) inhibition of drug
metabolism appears to represent a major
component of the in vivo chemosensitization
mechanism.
CHEMOTHERAPY OF A NEW WELL
DIFFERENTIATED TRANSPLANT-
ABLE MOUSE ADENOCARCINOMA
OF THE COLON (MAC 30/T). J. A.
DOUBLE & M. C. BIBBY, Clinical Oncology
Unit. University of Bradford, Bradford BD7
iDP
The MAC series (Double et al., 1975, J. Natl
Cancer Inst., 54, 271) has been used in a
variety of chemotherapy studies. MAC 30/T
was regrown from MAC 30 (Cowen et al., 1980,
J. Natl Cancer Inst., 64, 675) after storage in
liquid N2. The tumour is a well-differentiated
mucoid adenocarcinoma which has remained
histologically unaltered in a subcutaneous
serial passage in NMRI mice for 31 months.
The epithelium ofthe tubules contains goblet
cells with periodic acid-Schiff and Alcian Blue
positive contents.
The anti-tumour activity of a series of
standard agents against this line has been
determined. Antitumour activity was mea-
sured by growth delay from semi-log plots of
relative tumour volumes calculated from
serial calliper measurements. The growrth of
control tumours has remained consistent
throughout the course of these experiments,
with a mean volume doubling time of 3-4
days. Like other tumour lines within this
series responses are only seen close to
maximum tolerated dose. Results to date
indicate that the best responses are seen with
the alkylating agents Methyl CCNU and
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Cyclophosphamide, where tumour-volume-
doubling can be delayed by as much as 16
days. The antimetabolite 5FU at MTD
however, produced a delay ofless than 3 days.
A tumour exhibiting these response charac-
teristics with different agents would seem a
useful model for further studies, particularly
in the area of combination chemotherapy.
COMBINATION CHIP-X-RAYTREAT-
MENT OF THE C3H MOUSE MAM-
MARY ADENOCARCINOMA, M. PEN-
HALIGON, M. LAVERICK & A. H. W. NIAS,
Richard Dimbleby Department of Cancer
Research, St. Thomas's Hospital Medical
School, London SE1 7EH
CHIP (cis-dichlorobis(isopropylamine)trans-
dihydroxy platinum (IV)) has previously been
shown to enhance the radiation response of
hypoxic C3H mouse mammary adenocar-
cinoma cells in vitro. The enhancement ratio
was 2-1 using 60 ,ug/ml 1 h before X-rays
(Laverick & Nias, 1981 Br. J. Radiol., 54,
529). In vivo combination studies were made
using the C3H mouse mammary adenocar-
cinoma since it has a high hypoxic fraction
and is radioresistant (TCD37 68-8 Gy in air,
Tozer, 1981, Br. J. Radiol., in press). We use
SPF-derived C3H mice in which the LD50 of
CHIP is 65 mg/kg. Unanaesthetized mice were
given the maximum tolerated single dose of
CHIP, 40 mg/kg, i.p. either 30 min, 1 or 3 h
before a single dose of50, 70 or 90 Gy.
When the experiment was repeated, one
group of animals received 40 mg/kg of the
protective agent WR 2721 30 min before
CHIP in order to raise its MTD to 90 mg/kg.
Tumours were then treated with X-rays
(70 Gy) 1 h later. Tumour response was
assessed by both regrowth delay aild cure
(TCD37 by 80 days).
ENHANCEMENT OF RESPONSE OF A
LYMPHOBLASTIC TUMOUR BY
COMBINATION OF THE CYCLE
SPECIFIC DRUGS CISPLATIN AND
TREOSULFAN. A. W. PREECE & M.
WELLS-WILSON, Radiotherapy Centre, Bristol
BS2 8ED)
Clinical interest in the treatment of solid
tumours, particularly ovarian cancers, with
combinations of active agents has led to the
investigation of these agents in animal
tumour lines. The L2C lymphoblastic tumour
in strain 2 guinea-pigs has been proposed as a
useful model for testing chemotherapeutic
regimens (Murphy, 1978 in Immunological
Parameters of Host-Tumour Relationships, 5,
20). Chemotherapy is administered when
lymphoblastoid cells appear in the blood
(about 8 days after implantation).
Varying doses of treosulfan, cyclophos-
phamide, cisplatin and prednisolone were
administered. Prednisolone had no effect on
tumour growth, either alone or in combina-
tion with cyclophosphamide or treosulfan.
Moderate doses of treosulfan or cyclophos-
phamide produced temporary remissions, but
cisplatin was less effective. Combinations of
cisplatin and treosulfan produced longer
remissions than either agent alone, with no
evidence of increased toxicity, which might
have been predicted by drug classification.
These studies may indicate potentially
useful chemotherapeutic combinations for
clinical adoption.
PHASE II TRIAL OF 5-FLUOROUR-
ACIL IN DIFFUSE MALIGNANT
MESOTHELIOMA. V. J. HARVEY, M. L.
SLEVIN,B. A. J. PONDER & P. F. M. WRIGLEY,
ICRF Dept of Medical Oncology, Hackney and
St Bartholomew's Hospitals, London
Malignant mesothelioma is a rare tumour.
Although predominantly a localized tumour,
long-term survival following surgery or
radiotherapy is uncommon. Assessment ofthe
value of chemotherapy has been limited. FU
has been reported to be active in mesothel-
ioma in a total of 3/8 patients in 3 different
studies. Our experience with l patient who
had a dramatic response to FU led us to
conduct a Phase II trial of this agent.
Adriamycin is currently the most active agent
tested with 16/36 patients responding. We
have therefore treated patients who relapse oI
progress on FU with adramycin in a second
Phase II study. Since 1978 we have treated 18
consecutive patients with a confirmed diag-
nosis ofdiffuse malignant mesothelioma ofthe
pleura or peritoneum with FU as a single
agent (550 mg/M2 daily x 5 q 28 days). Seven-
teen patients had pleural mesothelioma, and 1
patient had peritoneal mesothelioma. There
were 12 males with a median age of 56 years
and 6 females with a median age of 41 years.
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No responses were seen in the 18 patients
receiving FU and the only patient responding
to adriamycin (1/8) was the patient who had
responded initially to FU. The median
survival was 5-2 months and the longest
survival amongst the non-responders was 15
months. The 1 responder is alive and has
recently relapsed at 54 years. We conclude
that FU has only minimal activity in diffuse
malignant mesothelioma. Our experience with
adriamycin is not yet sufficient to make
definite conclusions, but to date little activity
as a second-line agent has been demonstrated.
A COMPARISON BETWEEN A
SINGLE-AGENT SHORT-COURSE
CHEMOTHERAPEUTIC REGIMEN
AND A QUADRUPLE PROLONGED-
COURSE REGIMEN, FOR SMALL
CELL BRONCHOGENIC CARCINOMA
OF LIMITED EXTENT. K. B. CARROLL,
H. MOUSSALLI & N. THATCHER, Regional
Cardiothoracic Unit, Wythenshawe Hospital,
Manchester
68 patients with inoperable but "limited"
stage small-cell carcinoma of the bronchus
were treated with 2 different chemothera-
peutic regimens. 34 patients received metho-
trexate, cyclopliosphamide, procarbazine and
vinieristine in standard dose over a 2-year
schedule. 34 patients received cyclophospha-
mide alone over a period of 3 months. The
groups were evenly balanced with respect to
clinical details which are, fully described.
The toxicity was acceptable.
The median actuarial survival for the whole
group was 11 months, the 1-year, 2-year and
4-year survival being 48°/, 30%o and 1.500
respectively. There was no statistically signifi-
cant difference in survival between those
classified as responders and those as non-
responders, nor between the groups treated
with the 2 different regimens. There was a
high local-recurrence rate.
METASTATIC MEDIASTINAL TERA-
TOMA. D. PARKER, E. S. NEWLANDS,
G. J. S. RUSTIN, R. H. J. BEGENT & K. D.
BAGSHAWE, Department of Medical Oncology,
Charing Cross Hospital, Fulham Palace Road,
London W6 8RF
Malignant mediastinal teratoma has been
regarded as inevitably incurable. By contrast,
4/7 patients referred to our unit have survived
for between 12 and 123 months in remission
after a combination of chemotherapy and
surgery. The 3 factors preventing success in
the 3 patients who died were: failure of
previous therapy before referral; severe
respiratory embarrassment due to breakdown
of extensive disease on starting therapy, and
drug resistance in a patient with a yolk sac
element in the teratoma.
Our experience suggests that successful
treatment depends upon (1) the use of drug
combinations including cis-platin at an early
stage (Newlands et al., 1980, Br. J. Cancer, 42,
378), (2) moderation of initial drug dose if
there is very extensive disease, (3) the use of
tumour markers to calculate the optimal time
for thoracotomy after chemotherapy.
HYPOVITAMINOSIS C IN LUNG CAN-
CER. H. M. ANTHONY & C. J. SCHORAH,
University Departments of Immunology and
ChemicalPathology, Leeds General Infirmary
In a study involving 158 samples from 139
lung cancer patients, 64% had plasma
vitamin C values below 0-3 mg% and 25%
had buffy-coat levels below 10 jtg/108 cells,
the thresholds for incipient 'clinical scurvy.
Vitamin C levels were diet-dependent and
could be increased by oral supplementation.
Compared with control values established in
this laboratory, levels were low both in
tumour-bearing patients and in those clinic-
ally free ofdisease after resection, particularly
in the first 6 months.
The expected tendency for buffy-coat
vitamin C to correlate with the proportion of
lymphocytes in peripheral blood was only
apparent in ' unreactive" patients. Patients
with relative lymphocytosis (>25%) tended
to show an inverse relationship, significant in
the group clinically free ofdisease, in many of
whom subelinical recurrence is likely. A link
between lower mononuclear-cell vitamin C
higher lymphocyte counts and resectability
was noted in 14 samples taken on diagnosis, in
which the former was measured directly.
The vitamin C content of 13 surgical
specimens of primary lung tumours was
assayed: tumours had higher vitamin C
content (mean 67-7 + 33-4 mg/g tissue) than
normal lung (35 5 + 12-4 mg/g tissue).
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The data cannot be explained solely by
preferential accumuilation of vitamin C in
tumour tissue in patients with inadequate
vitamin C intake: it appears that vitamin C
utilization in repair after major surgery and in
resistance to lung cancer also contributes.
4' EPI-DOXORUBICIN IN LEUK-
AEMIA AND LYMPHOMA (A PRE-
LIMINARY CLINICAL TRIAL). S.
ERIDANI, A. KUBIE & F. LUNGU, Department
ofHaematology, St Thomas' Hospital, London
4' Epi-Doxorubicin (EDX) is a stereoisomer
of doxorubicin with a different configuration
in the sugar moiety. After early results in
solid tumours (Bonfante et al., 1979, Cancer
Treat. Rep., 63, 915) we have started a clinical
trial in leukaemia and non-Hodgkin's lym-
phoma, substituting EDX for daunorubicin
and doxorubicin in combination regimes.
Thirteen patients so far have been treated:
6 cases of previously untreated acute leuk-
aemia at presentation (4 myeloblastic, 1
monoblastic, 1 lymphoblastic), 1 case of
undifferentiated acute leukaemia in full
relapse after 2 years' remission, 1 case of
multiple myeloma also in relapse, 5 cases of
non-Hodgkin's lymphoma either in incom-
plete remission or relapse, all treated pre-
viously. The age range was 18-64, with a
prevalence of the over-50's. Patients were
unselected; in particular no exclusion was
made on the basis of short life expectancy. In
the acute leukaemia group at presentation
there was a variable response: 3 complete and
1 partial remission, and 1 failure. An
additional failure was seen in the patient
with full-blown relapse. All 5 patients with
lymphoma achieved complete remission, and
in the case ofmultiple myeloma, a favourable
response. The highest dose, of EDX was
620 mg, (1 case) including 180 mg doxo-
rubicin given previously. Side effects were
limited: occasional nausea, hair loss in 1 case,
depression in a few cases. No signs of eardiae
impairment were found either on clinical or
laboratory evidence.
If confirmed, these results could indicate
that EDX has similar activity to other
antracyclines, but with less cardiac and
general effects
I.V. TREOSULFAN IN ADVANCED
OVARIAN CANCER: A MULTI-
CENTRE PILOT STUDY. U. ABDULLA*,
H. H. MAKANJI*, C. Coxt, T. K. ALSAIDI-t,
WV. F. WHITES& J. E. MASDINGt, *Department
of 0 & G, Royal Liverpool Hospital, tDepart-
ment of 0 & G, Walsgrave Hospital, Coventry
and IRadiotherapy Centre, St Luke's Hospital,
Guildford
A formulation of treosulfan for i.v. use has
recently been made available for investiga-
tion. From December 1979 to September
1981, 22 patients with inoperable, histologic-
ally confirmed, ovarian cancer have been
treated with this preparation as first-line
chemotherapy at 3 centres.
The usual dose regimen wN-as 5-15 g either
by bolus i.v. injection or i.v. infusion,
repeated at 2-3-weekly intervals depending
on blood counts; a marked variation in
individual tolerance to treosulfan was found.
Of 18 fully evaluable patients at March 1982,
there were 14 responses (78) of a minimum
duration 3 months (range 4-28 + months), 8
of which were complete (CR), mainly judged
on clinical evaluation. "Second-look" opera-
tions were not routine, but were carried out in
4 instances: 1 CR was confirmed, and 2 PRs
underwent radical surgery, though both
relapsed, at 2 and 9 months following
operation.
Dose-limiting toxicity was leucopenia (leu-
cocytes <2500/mm3 in 500o) and thrombo-
cytopenia (thrombocytes < 100,000/mm3 in
4500). Single instances of vomiting were
observed in 2 patients, and some hair loss in 1
patient.
Iv. treosulfan is an effective treatment for
ovarian cancer, enabling a response to be
obtained in a high proportion ofpatients. The
formulation is suited to combination with
active agents in this disease in view of
moderate toxicity when carefully monitored,
and excellent patient acceptability.
IMPORTANCE OF CYTOPLASM/CELL
MEMBRANE DAMAGE INDUCED BY
ADRIAMYCIN. J. M. WALLING & M. J.
ORD, Department of Biology, University of
Southampton, Hants. S09 3TU
Adriamycin has been shown to have a variety
of cellular effects besides intercalation into
DNA, including an inhibition of mitochon-
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drial enzymes (Iwamoto et al., 1974 Biochem.
Biophys, Res. Commun., 58, 633) and an
interaction with membrane phospholipids
including cardiolipin (Goormagtigh et al.,
1980, Biochim Biophys Acta, 597, 1). In the
present study Adr was found to have a
biphasic pattern of toxicity towards A.
proteus and CHO cells. Cells were either killed
very rapidly as a result of complete loss of
membrane integrity and consequent organelle
destruction, or more slowly over a period of
up to 8 days following removal of the
treatment solution as assayed by single-cell
cloning.
EM studies on amoebae show%Ned aberrant
mitochondrial profiles with a reduction in the
number of internally located cristae and a
widening of the peripherally located cristae.
Very aberrant mitochondria were eventually
sequestered in autophagoeytic vacuoles.
The typical anthracycline-induced nucleolar
fragmentation was often seen in later stages
of pathogenesis. However, this was never
observed without concomitant cytoplasmic
damage. The results of an initial series of
nuclear transfers between treated and control
amoebae suggest that treated cytoplasms
have a far poorer ability to survive than
treated nuclei.
Taken together the results with both
amoebae and CHO cells suggest that damage
to the cytoplasm/cell membrane may con-
tribute considerably to Adr-induced cell
death.
EFFECT OF ADRIAMYCIN ON MEM-
BRANE POTENTIAL OF HUMAN
ERYTHROCYTES. S. B. CHAHWALA, J. A.
HICKMAN & R. G. GRUNDY, C.R.C. Experi-
mental Chemotherapy Group, Department of
Pharmacy, University of Aston, Birmingham
B4 7ET
The antitumour activity of adriamycin (Adr)
is generally considered to be related to its
ability to intercalate DNA, though other
targets have been proposed, particularly the
cell membrane (Tritton et al., 1976, Biochem.
Biophys. Res. Commun, 84, 802). Dasdia et al.
have reported that 10-7M Adr altered ion flux
in HeLa cells and they suggested that these
changes may be relevant to cytotoxicity,
presumably since changes in alkali metal and
calcium ion fluxes are associated with control
of cell growth (Pharmacol. Res. Commun.,
1979, 11).
We have studied the effects of Adr on the
membrane potential (TI) (a refiection of
complex changes in ion flux) ofhuman RBCs,
a cell type used previously as a model for the
study of Adr interaction with membranes
(Mikkelsen et al., 1977, J. Molec. Med. 2, 33).
Measurements of 'I were obtained by follow-
ing the accumulation of the lipophilic cation
triphenyl methylphosphonium bromide
(TPMP+) into fresh RBCs. Resting 0 was
9-98 + 1-09 mV (nr=4) wliich agrees ANith that
obtained by other methods. Adr (10-7M) had
no effect on T after 1 h. Adr (10-4MI) for 1 h
induced a hyperpolarization with Al'M of
25 + 2 mV (n=3). The lack of effect of 10-7M
Adr on T of RBCs may be explained by
supposing that 10-7M Adr has little effect on
the Cl- Donnan equilibrium, which predomin-
antly governs RBC T (Ouabain, an inhibitor
of Na+K+ATPase (10-4M), similarly had no
effect). The effects of 10-4M Adr may bave
been induced via gross morphological changes
observed by us and Mikkelsen et al., resulting
in the disturbances of the CL- equilibrium.
THE USEFULNESS OF HUMAN PRO-
STATE TUMOUR-CELL LINES IN
THE STUDY OF CHEMOSENSI-
TIVITIES. S. A. METCALFE, J. R. W.
MASTERS & B. T. HILL, Institute of Urology
and Imperial Cancer Research Fund Labor-
atories, London
We are using cell lines derived from human
prostate carcinoma to evaluate in vitro
methods for predicting response oftumours to
anticancer agents. Logarithmically grow-ing
cells were exposed to drugs for 24 h and their
viability assessed by measuring growth rates
and clonogenicity in agarose. On the basis of
growth rates, PC3mA2 and DU145 cells
showed a greater sensitivity to a range of
drugs than PC3 cells, possibly reflecting the
longer population-doubling time of the PC3
line. WVhen cloned in agarose (0-17o%) the
CFEs were -15, 4 and 0-20/ for PC3mA2,
DU145 and PC3 respectively, so only
PC3mA2 and DU145 cells have been used to
study chemosensitivity based on colony-
forming ability. Using this assay, PC3mA2
cells were more sensitive than DU145 cells to
several drugs, including cis-platinum ICRF-
159, dibromodulcitol and methotrexate;
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though some drugs (e.g. FU), had a similar
effect on both lines. Survival data with
DU145 cells for these drugs were similar to
those described using a human neuroblastoma
line, CHP100 (Hill & Whelan, 1981, Pediatr.
Res., 15, 1117) and a human colon carcinoma
line, LoVo (Drewinko et al., 1981, Cancer Res.,
41, 2328, treated for 24 or 1 h respectively.
Certain antitumour drugs thus appear more
effective in killing PC3mA2 prostate carcin-
oma cells. Preliminary studies are underway
to assess the response of human prostate
tumour biopsy material from individual
patients to chemotherapy, using the human
stem" cell assays.
IN VIVO CONCENTRATION AND
TIME INTER-RELATIONSHIPS FOR
ANTI-CANCER DRUG CYTOTOXI-
CITY TO HUMAN OVARIAN CAR-
CINOMA CELLS. H. T. RUPNIAK & B. T.
HILL, Laboratory of Cellular Chemotherapy,
Imperial Cancer Research Fund, London
WC2A 3PX
We have studied the drug sensitivity of
cryopreserved tumour cells obtained from the
ascitic fluid of a patient with ovarian
carcinoma who had relapsed following treat-
ment with chlorambucil. Tumour-cell sur-
vival of drug treatment in vitro was assessed
by measurement of colony-forming ability
using the Courtenay assay (Courtenay et al.,
1978 Br. J. Cancer, 38, 77). The anticancer
drugs cis-platinum (cis-Pt) and adriamycin
(Adr) generated exponential survival curves,
wherein increasing time ofexposure increased
degrees of cell kill. For cis-Pt, the doses
required to reduce tumour cell survival to
10% (DIo) after 1, 6, 18 h and continuous
exposure were 14-6, 3.3, 0 7 and 0-18 ,ug/ml
respectively. The D1o values for treatment
with Adr for 1, 6, 18 h and continuously were
1 1, 0-38, 0-19 and 0 03 jug/ml respectively. In
contrast, treatment with hydroxyurea (HU)
in concentrations up to 1 mg/ml for either 1 or
6 h elicited no detectable cell kill. However,
when HU was incorporated into the agar
cloning system, producing continuous drug
exposure, an exponential survival curve
resulted with a Dmo value of 28 ,g/ml.
Exposure to methotrexate in concentrations
up to 10 jug/ml for 1 h also resulted in no
detectable cell kill, though this may be partly
attributable to protection/rescue by dT
present in the Ham's F12 medium used for
these studies. The patterns of response to
drug treatment are in essential agreement
with most studies in tumour cell lines but
appear inconsistent with some of the data
derived from the alternative Hamburger &
Salmon assay (Hamburger et al., 1978, Cancer
Res., 38, 3438).
THE ACTION OF 6-MERCAPTO-
PURINE (MP) NUCLEOTIDE "PRO-
DRUGS" ON MP-RESISTANT CELLS.
D. M. TIDD, H. P. J. JOHNSTON & I. GIBSON,
University of East Anglia, Norwich, Norfolk
NR4 7TJ
Purine and pyrimidine antimetabolite-resist-
ant cells with reduced drug nucleotide-
forming capacity may be inhibited by so-
called "prodrugs" of the analogue nucleoside
5'-monophosphate. It has been suggested that
this is due to intracellular uptake of intact
prodrug molecules and their subsequent
hydrolysis to the free nucleotide. We report
that bis-(6-mercaptopurine-9-f3-D-ribofurano-
side)-5',5"'-monophosphate (bis-(MPR)P) and
its butyryl derivative, bis-(03'-dibutyryl-6-
mercaptopurine-9-f/-D-ribofuranoside)-5',5"'-
monophosphate (bis-(dibutyrylMPR)P) in-
hibited growth of thiopurine-resistant
L1210/MPR cells in culture with EC50 values
of580 ,uM and 42 juM respectively, whilst 1mM
MP riboside (MPR) had no effect. Bis- (dibu-
tyryl-MPR)P was less readily broken down to
MPR by serum enzymes than bis-(MPR)P,
and cells did not contribute to its extra-
cellular degradation. The breakdown product,
MPR, was responsible for the delayed cyto-
toxicity of the pro-drugs on MP-sensitive
L121/0 cells. Bis-(MPR)P elicited a delayed
cytotoxicity in L1210/MPR cultures, in keep-
ing with is proposed action as a prodrug of
MPR 5'- monophosphate, whilst bis-(dibu-
tyrylMPR) Pinduced acute growth inhibition
and no delayed cytotoxicity in the resistant
subline. However, MPR wasincorporated into
L121/O) DNA as 6-thioguanine deoxyribo-
nucleotide, whilst bis-(MPR)P was not incor-
porated into L1210/MPR DNA. These results
suggest that the action of the prodrugs may
not represent true circumvention of MP-
resistance.
502N-Methylformamide (NMF) is active against
certain murine and human xenograft tumours
in mice and is currently undergoing Phase 1
trials in man. There is evidence that is
activitydepends upon metabolic activation in
vivo (Gescher et al., 1982, Br. J. Cancer, 45,
843). N-Hydroxymethylformamide (HMF),
which appears to be formed during oxidative
metabolism ofNMF in vivo (Ross et al., 1982,
Br. J. Cancer, 44, 278), is a possible candidate
for the active species. HMF (30 mM) gave
approximately a 4 log cell kill of TLX5 lym-
phoma cells incubated for2 h at 37°C whereas
500mM NMF was non-toxic. HMF (2.5 mM)
inhibited the incorporation of radiolabelled
formate, leucine, uridine and thymidine into
cellular macromolecules of TLX5 cells under
these incubation conditions. The inhibition of
uridine incorporation into TLX5 cells was
abolished by preincubation of the cells with
2-5mM semicarbazide. This suggests that the
inhibition is caused by formaldehyde, a
known cytotoxic agent, which is a decomposi-
tion product of HMF and found in small
amounts (<300) in aqueous solutions of
HMF. Similar results were obtained using
human ovarian carcinoma cells in vitro. HMF
had no significant antitumouractivity against
murine tumours which are sensitive to NMF
(M5076 sarcoma, TLX5 lymphoma) nor did it
reduce hepatic glutathione, as did NMF. It is
concluded that the formation ofHMF may be
a deactivation pathway of NMF metabolism,
unlike the formation of an N-hydroxymethyl
compound from another N-methyl-containing
drug, hexamethylmelamine, in which case the
N-hydroxymethyl compound appears to play
a role in cytotoxicity (Rutty & Connors, 1977,
Biochem. Pharmacol., 26, 2385).
CHARACTERIZATION OF CHEMO-
RESISTANCE OF HUMAN MALIG-
NANT MELANOMA TO DAUNORUBI-
CIN, METHOTREXATE, VINDESINE
AND DTIC. J. M. GAAUKROGER*, N. G. L.
HARDINGt, L. WILSON* & R. M. MACKIE*,
*Depts. of Dermatology and tPathological
Biochemistry, tUniversity of Glasgow
Following in vitro culture ofmelanoma cells in
continuous contact with chemotherapeutic
agents used for the treatment of melanoma
and other malignant diseases, we have
produced cell lines (murine and human)
resistant to daunorubicin (10-7M), metho-
CHROMOSOME DAMAGE IN LEWIS
LUNG (LL) TUMOUR LINES WITH A
SPECTRUM OF SENSITIVITIES TO
MeCCNU. J. H. PEACOCK, G. CASEY, T. J.
MCMILLAN & T. C. STEPHENS, Institute of
Cancer Research, Sutton, Surrey
In the course of a study to explore the
development ofresistance to the chemothera-
peutic drug methyl CCNU (MeCCNU) in wild-
type LL we have derived several tumour lines
varying widely in sensitivity to this drug.
These lines could have arisen either by
selection of cells surviving treatment or by
genetic or epigenetic changes induced by the
treatment. Initially, we have studied the
chromosomal content ofsome ofthese lines to
look for specific genetic differences.
Five lines, wild-type LL, a line designated
R4/1 (resistant to MeCCNU) and 3 closely
related lines RIO (MeCCNU sensitive), RIO/i
(resistant) and R1O/4 (sensitive) were karyo-
typed. The modal chromosome number varied
slightly between the lines (- 70); however the
most striking difference was the presence of
only 2 metacentric marker chromosomes in
both the resistant lines compared to 3 in the
other lines.
We have also studied MeCCNU-induced
DNA damage in wild type LL and R4/1, using
the occurrence of sister chromatid exchange
(SCE) and micronucleus formation as end-
points. The relationship between SCE occur-
rence and drug dose was similar for both lines;
however micronucleus formation at a given
dose was substantially less in R4/1, consistent
with its resistance to the drug.
The micronucleus assay is a measure of
chromosome fragmentation and loss, and
suggests that MeCCNU is capable ofinducing
chromosomal changes leading to altered cell
karyotypes. Studies are continuing to further
elucidate the mechanism of appearance of
these genetically distinct lines, and also to
investigate the specificity of chromosomal
markers in resistant tumour lines.
CYTOTOXICITY AND ANTITUMOUR
ACTIVITY OF N-HYDROXYMETHYL-
FORMAMIDE, A PUTATIVE META-
BOLITE OF N-METHYLFORMAMIDE.
P. G. COOKSEY, E. N. GATE, A. GEScHER,
J. A. HICKMAN, S. P. LANGDON & A. E.
WILSON*, C.R.C. Experimental Cancer Chemo-
therapy Group, University of Aston, Birming-
ham B4 7ET and *Withington Hospital,
Manchester M20 8LR
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trexate (10-6M), DTIC (10-3M) and vindesine
(5 x 10-7M). The drug concentrations lethal to
the wild type cells are respectively 10-10M,
10-1Oi, 10-5M and 10-10M.
We have developed in vivo 2 murine cell
lines resistant to 10-3M DTIC, and we are
currently developing vindesine resistant lines
in vivo. Analysis ofthe genetic content of the
DTIC resistant cell lines has not revealed any
change in the base sequence of the cellular
DNA and we are therefore studying amino-
acid incorporation into cellular protein.
Vindesine is currently favoured for the
treatment of malignant melanoma, and
although we have been able to obtain the
radiolabelled drug, it unfortunately appears
to be subject to radiolysis. We have, however,
commenced a study on the metabolism of
vindesine by melanoma patients receiving
this drug as a single agent. In vitro melanoma
cells do not appear to metabolize this agent to
any significant extent.
Studies with a tumour stem cell assay have
just started with some success. Preliminary
trials on continuous cell lines including a
resistant human melanoma line, resulted in
cell division and growth of clones visible to
the naked eye after 3 weeks.
FORMATION AND RETENTION OF
METHOTREXATE POLYGLUTA-
MATES BY A HUMAN BREAST-
CANCER CELL LINE IN THE
PRESENCE AND ABSENCE OF
INSULIN. D. G. KENNEDY*, R. CLARKE*,
H. W. VAN DEN BERGt, & R. F. MURPHY*,
*Dept Biochemistry and tDept Therapeutics
and Pharmacology, The Queen's University of
Belfast
The rate and extent ofthe formation ofMTX
poly-y-glutamates has been studied in a
human breast-cancercell linle (MDA.MB .436).
Cells were exposed to medium containing
10-7M radiolabelled MTX for various times.
Cell extracts were subjected togelfiltration on
Bio-Gel P2 and radioactivity in each fraction
determined. This has allowed quantitation of
the relative amounts of MTX and its
polyglutamate derivatives. It has been pro-
posed that MTX polyglutamates may act as
storage forms of the drug which could result
in prolonged cytotoxicity. This possibility
was investigated by determining the ability of
the cell line to retain MTX and its
polyglutamate derivatives for periods ofup to
48 h after removal of MTX from the
incubation medium. Ourresults show that the
lower-mol. wt polyglutamates (<4 extra glu-
tamic acid residues) rapidly efflux from the
cell, while the higher-mol. wt species (>4
glutamic acid residues) are extensively re-
tained, an efflux half-life of -30h. It has
been shown that insulin may potentiate the
cytotoxicity ofMTX to breast-cancer cells in
vitro. Our results indicate that in the
MDA.MB.436 cell line total intracellular drug
at steady state is unaffected by insulin
(10-6M). However insulin does increase by
2600 in the contribution of the higher
molecular weight polyglutamates to total
intracellular drug. Our data therefore suggest
that the ability of insulin to potentiate the
cytotoxic effects of MTX may be related to
the hormone's ability to modulate the
synthesis ofMTX polyglutamates.
ISOLATION AND CHARACTERIZA-
TION OF A SUBLINE OF CHO CELLS
WITH INDUCED RESISTANCE TO
ICRF 159. S. J. KENWRICK & A. M.
CREIGHTON, Cellular Pharmacology Labora-
tory, Imperial Cancer Research Fund, London
WC2A 3PX
A subline ofCHO cells has been derived, with
induced resistance to the antitumour drug
ICRF 159. This subline (CHO/159-1) has a
consistent resistance index of 300 relative
to the parent line in colony-forming assays,
and has the same diploid chromosome number
and growth rate. Since the presence of the
detergent Tween 80 does not restore any
sensitivity, it seems unlikely that the resist-
ance is due to a membrane alteration affecting
the uptake of the drug. No cross resistance
has been demonstrated to a variety of
cytotoxic drugs including alkylating agents
and antimetabolites. A 2-fold increase in
resistance has been observed to the anthra-
cycline antibiotics, adriamycin and dauno-
mycin similar to that found earlier with 1 out
of 3 BHK lines with induced resistance to
ICRF 159 (White & Creighton, 1976, Br. J.
Cancer. 34, 323). Although complete cross-
resistance is shown to ICRF 202 (a more
potent homologue ofICRF 159) CHO/159-1 is
not significantly resistant to the Chinese drug
AT-1727 (the bis-N-morpholinomethyl deriv-
ative ofICRF 154). The latter result is a little
surprising since the morphological effects of
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AT-1727 on cells closely resemble those
produced by ICRF 159. Relevant markers
have been introduced into both the parent
and the drug-resistant sub-line and inter-
specific hybrids with mouse L/TK- cells have
been shown to express a codominant resistant
phenotype. Analysis of the DNA content by
flow cytometry and of the chromosome
number and type confirmed the hybrid
nature of these cells. The codominant nature
of the resistance makes it feasible to attempt
its transfer into L/TK- cells with chromosome
or DNA preparations.
FLOW-CYTOFLUORIMETRIC DE-
TERMINATION OF INTRACELLULAR
LEVELS OF DAUNORUBICIN IN P388
CELL LINES SHOWING DIFFEREN-
TIAL SENSITIVITY TO THE DRUG.
A. T. McGOWN, T. H. WARD & B. W. Fox,
Experimental Chemotherapy, Paterson Labora-
tories, Christie Hospital and Holt Radium
Insthtute, Manchester M20 9BX
Resistance to the anthracycline antibiotics
daunorubicin has been attributed to a net
decrease in drug accumulation. The technique
of flow-cytometry coupled wAith the intrinsic
fluorescence of these agents allows the rapid
examination of large, statistically valid,
numbers ofindividual cells for drug content.
P388 mouse lymphoma cell lines slhowing
differential sensitivity to daunorubicin have
been developed. The resistant cell line can be
seen to show a lower drug accumulation than
the wild-type by both flow-cytometry and by
extraction ofdrug from the cells. The effect of
pH, temperature, drug concentration, and
metabolic inhibitors on drug uptake have
been investigated.
FLOW-CYTOFLUORIMETRIC STUD-
IES WITH A FLUORESCENT DERIVA-
TIVE OF METHOTREXATE ON
SENSITIVE AND RESISTANT CELL
LINES. D. G. POPPITT, A. T. MCGOWN, &
B. W. Fox, Paterson Laboratories, Christie
Hospital and Holt Radium Institute, Man-
chester M20 9BX
L1210 mouse leukaemia cell lines showing
differential sensitivity to the antimetabolite
MTX, have been studied using techniques of
cell culture and flow cytofluorimetry. A
fluorescent derivative of MTX has been
prepared and comparative studies of enzyme
inhibition and cell survival with MTX sug-
gest similar modes of action. The resistant
cell line has been shown previously to owe
its resistance to an increased production of
the enzyme, dihydrofolate reductase. Flow
cytofluorimetric studies after treatment with
fluorescent methotrexate can detect cells
with increased dihydrofolate reductase. Fur-
thermore, in a mixed cell population, it is
possible using a Fluorescent Activated Cell
Sorter (FACS), to recognize and separate the
the 2 subpopulations.
BIOCHEMICAL DISTURBANCES OB-
SERVED IN VITRO AND IN VIVO
FOLLOWING INHIBITION OF THY-
MIDYLATE SYNTHETASE BY C 3717.
A. L. JACKMAN, G. A. TAYLOR, A. H.
CALVERT, D. R. NEWELL & K. R. HARRAP.
Dept. Biochem. Pharmacol., Inst., Cancer Res.,
Sutton, Surrey
CB 3717 isaquinazoline-based folate analogue
which is a potent inhibitor of thymidylate
synthetase (TS) (Jones et al., 1981, Eur. J.
Cancer, 17, 11. Inhibition of the de novo
synthesis ofthymidylate may be achieved by
pyrimidine analogues (e.g. 5-fluorouracil)
whose active metabolite, 5-fluorodeoxyuridyl-
ate, inhbiits TS, or indirectly by folate
analogues (e.g. MTX),. which inhibit dihydro-
folate reductase. Both have additional loci
of action: The former is incorporated into
RNA and the latter inhibits de novo purine
synthesis. There is strong evidence that in
cultured cells the inhibition of TS is the sole
cytotoxic locus of CB 3717. We also have
evidence to suggest that the antitumour
properties ofthe drug tn vivo are also attribut-
able to this same locus. Firstly, CB 3717 is
not metabolized to a compound that might
act at a different locus. Secondly, plasma
levels of deoxyuridine in mice, following
treatment with CB 3717, rise to a peak at 4 h.
This observation correlates with the large
increase in intracellular deoxyuridylate ob-
served in vitro. Finally the antitumour
activity of CB 3717 against the L1210
tumour is prevented by co-administration of
thyinidine. CB 3717 is currently undergoing
clinical evaluation which w,ill allow the thera-
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peutic value of the specific inhibition of TS
to be evaluated in man for the first time.
ALGINATE: A NEW REVERSIBLE
GELLING MEDIUM FOR INVESTI-
GATING CELL TRANSFORMATION.
J. P. RoSCOE & A. M. OWSIANKA, School of
Pathology, Middlesex Hospital Medical School,
London
Previous investigations of the malignant
transformation of rat brain cells by ethyl-
nitrosourea (ENU) have shown that tumor-
igenic cells form colonies in agar. Further-
more, pre-neoplastic cells which do not form
colonies nevertheless survive, but in an
essentially non-dividing state, for much
longer (up to 10 weeks) than control cells
(Roscoe & Winslow, 1981, Br. J. Cancer, 41,
992). Investigation of this phenomenon has
been hampered by the technical difficulties
of long term maintenance and recovery of
cells suspended in methocel or agar. We have
developed alginate as an alternative sus-
pending medium from which viable cells can
be recovered by disrupting the cation
dependent linkages with a chelating agent.
A base layer of 0.6% agar is allowed to set
and the appropriate concentration of CaCl
solution placed on top. Cells suspended in
1% sodium alginate (Manucol FH, Alginate
Industries Ltd, London) are immediately
overlaid, forming a gel as the Ca ions
react with the alginate. Cells can be released
by addition ofEDTA and collected by centri-
fugation. The results using this medium
show that (1) tumorigenic and non-tumori-
genic cells can be distinguished by colony-
forming ability in alginate (2) the difference
in viability of pre-neoplastic and control
cells in agar can be reproduced, with the
advantage that the recovery over several
weeks can be quantitated. The method is
therefore useful as a test for transformation
and for investigating anchorage dependence
and similar phenomena.
HETEROGENEITY INTHERESPONSE
OF LEWIS LUNG TUMOURS (LL) TO
MeCCNU. T. C. STEPHENS, K. ADAMS &
J. H. PEACOCK, Institute of Cancer Research,
Sutton, Surrey
Using an excision cell-survival assay, we
have demonstrated that most cells in wild-
type LL tumours are exquisitely sensitive to
the chemotherapeutic drug MeCCNU (sur-
vival curve D10=1-8 mg/kg). Cell-survival
data predict that 02 g tumours should be
cured by a single dose of 15 mg/kg (about 1/3
LD1o), but in practice only about 30%o cures
can be achieved at 40 mg/kg. Model calcula-
tions show that this discrepancy can be
explained if the tumours contain a sub-
population ( _ 10-6) of cells which are ca
5-10 x 10-6 more resistant to5the drug, and
the existence of a biphasic growth delay
curve supports the model. However, the
model also predicts that all tumours regrow-
ing after high MeCCNU doses should be
resistant to the drug, but this was not found.
Of 4 tumour lines which regrew after 40 mg/
kg, only 1 was more resistant than wild-type
LL, using both cell survival and regrowth
delay endpoints. In a repeat experiment,
using regrowth delay only, 2 lines were
resistant, 4 were of similar sensitivity to
wild-type LL and 2 were more sensitive. For
comparison, 6 clonal lines, derived from
previously untreated wild-type LL, showed
the same sensitivity to MeCCNU as the
wild-type tumour. Therefore, a more com-
plex model, possibly involving sanctuary
sites in which inherently sensitive cells are
protected from drug exposure, or perhaps
drug-induced fluctuations in the sensitivity
of cells to MeCCNU, is necessary. It may be
relevant that MeCCNU has a substantial
mutagenic effect in mammalian cells, and we
have shown that it can induce chromosome
fragmentation (these Abstracts). Experi-
ments involving fractionated MeCCNU treat-
ments are underway, in order to characterize
more precisely the mechanisms underlying
resistance to this chemotherapeutic agent.
MODIFICATIONS OF CLONOGENIC
ASSAY PROCEDURES RESULTING
IN ENHANCED PLATING EFFICIEN-
CIES FOR HUMAN TUMOUR-CELL
LINES. R. D. H. WHELAN & B. T. HILL,
Laboratory of Cellular Chemotherapy, Imperial
Cancer Research Fund, London WC2A 3PX
In an attempt to enhance the colony-forming
efficiency (CFE) of certain established human
tumour-cell lines, we have compared the
published assay methods of Chu & Fischer
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(1968, Biochem. Pharmacol., 17, 753),
Courtenay & Mills (1978, Br. J. Cancer, 38,
77) and Hamburger & Salmon (1977, Science,
197, 461) and made certain modifications.
The lines tested included 2 derived from
colon, COLO 205 and LoVo, 2 from prostate,
DU145 and PC3mA2 and 2 neuroblastomas,
CHP100 and LAN-1.
Using the first soft-agar procedure, a
reduction of the agar or agarose concentra-
tion from 0.300/, to 0 1800 increased the CFE
(2-15-fold with all the lines, except the
LoVo cells). The Courtenay assay proved
most valuable, improving for example, the
CFE of COLO 205 cells from 20% to 40o
and PC3mA2 cells from 1.500 to 370 in
0-300 agar. CFE may be further increased
(up to 2-fold) by a reduction of the agar
concentration. The quality of colonies pro-
duced was also superior and they could be
scored in 6-12 days instead of 2-4 weeks.
The Hamburger & Salmon assay failed to
support reproducible colony growth. The
addition of EGF did not enhance the CFE in
any of these cell lines. However, the sub-
stitution of Ham's F12 medium, 10% foetal
calf serum and RBC from August rats
recommended by Courtenay, resulted in
satisfactory CFEs, comparable to those
obtained with the Courtenay assay. Use of
the low 02 gassing mixture had minimal
effects.
Drug sensitivities of the cell lines tested
were not altered by enhancing CFE by these
modifications. We recommend wider use of
the Courtenay procedure, together with
reduced agar/agarose concentrations.
DEMONSTRATION OF PATCHES OF
DIFFERING GENOTYPE IN TISSUE
SECTIONS OF GENETICALLY MOS-
AIC MICE. B. A. J. PONDER*, M. WILKIN-
SON*, D. ROBERTSON*, P. E. MONAGHANt &
M. WOODS. *Institute of Cancer Research;
tLudwig Institutefor Cancer Research, Clifton
Avenue, Sutton, Surrey; and tMRC Labora-
tory Animal Centre, Carshalton, Surrey
Genetically mosaic mice are made by aggre-
gation of early embryos of mice of different
inbred strains. The aggregated embryos are
transferred to the uterus of a pseudopregnant
foster mother and develop in the normal way.
The tissues of the resulting chimeras are a
mosaic of patches of cells derived from each
of the 2 embryos. These mice are potentially
useful for studies of cell lineages in develop-
ment, of organogenesis, tissue organization,
and of the cellular populations involved in
pre-neoplastic and early neoplastic lesions.
A major limitation on their use has been the
lack of a general method to distinguish the
cells of the 2 component genotypes in tissue
sections.
We describe the successful development of
such a method using immunohistochemical
techniques with (i) monoclonal antibodies to
H2 antigens in H2a<-+H2b chimeras and (ii) a
newly discovered polymorphism for binding
of Dolichos biflorus lectin to gut epithelium
and vascular endothelium of different mouse
strains. Preliminary results from analysis of
11 chimeras suggest that (i) patches in the
epithelium examined are mostly rather large
(of the order of several hundred cells), but
that patches in vascular endothelium are
probably smaller and (ii) the epithelium ofan
intestinal crypt is always composed entirely
of cells of one genotype, suggesting origin
from a single precursor cell.
GROWTH OF HUMAN TUMOUR CELL
COLONIES FROM XENOGRAFTS
USING 3 SOFT-AGAR TECHNIQUES.
R. RANJINI RAO, Dept Radiotherapy Re-
search, Institute of Cancer Research, Sutton,
Surrey
Three methods are currently in use for in
vitro clonogenicity assay of human tumour
cells: Method A (Courtenay, 1976, Br. J.
Cancer, 34, 39); Method B (Hamburger &
Salmon, 1977, Science, 197, 461) and Method
C (Courtenay & Mills, 1978, Br. J. Cancer,
37, 261). The plating efficiency of tumour
cells from human melanoma biopsies and
from xenografts was much higher with
Method C than Method B (Tveit et al., 1981,
Br. J. Cancer, 44, 530).
The objective of the present study was to
compare the clonogenicity of human tumour
cells from xenografts of 5 different tumours
using the same 3 methods. The techniques for
preparing single cell suspensions and for
plating the cells in the agar cultures were as
reported for these methods, except that con-
ditioned media and 2-mercaptoethanol were
omitted from Method B. The 5 human xeno-
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grafts used were HX117 (melanoma), HX70
(adenocarcinoma-lung), HX113 (adeno-
carcinoma-ovary), HX69 and HX123
(small-cell carcinoma). Colonies of more than
50 cells were counted, usually after 14-21
days of incubation. PE of 4-37% were
obtained with HX117, HX70 and HX123 in
Method C, and of 2-17% with Method A.
No colonies were detected with Method B,
though some clumps were noted. HX113
did not form colonies in soft agar with any
ofthe 3 methods. A few colonies (PE 0-0070)
wNiere obtained from HX69 cells using Method
C after 6 week incubation.
These results suggest that Methods A
anid C which incorporate rat (August) red
blood cells and hypoxic gas phase (500 C02/
5% 02/90% N2) yield much higher PEs than
Method B, not only with human melanoma
xenografts but with other types of human
tumour xenografts as well.
THE USE OF VINCRISTINE TO MEA-
SURE THE CELL PRODUCTION RATE
IN A MOUSE C3H MAMMARY CAR-
CINOMA FOLLOWING IRRADIATION.
B. JONES & R. S. CAMPLEJOHN, Richard
Dimbleby Department of Cancer Research, St
Thomas' Hospital Medical School, London
SEI 7EH
The stathmokinetic method has proved use-
ful in the investigation of cell populations
which have fluctuations in their cell kinetics
(e.g. Wright et al., 1980, p. 102 in Cell Pro-
liferation in the Gastro Intestinal Tract). In
the current study, the stathmokinetic effect
of Vincristine was used to determine cell
production rates in a transplantable mouse
C3H mammary carcinomas after irradiation
(20 Gy). Remarkable constant values of cell
production were found during a 7-day period
in which there was no growth.
The apparent discrepancy of a constant
flow of cells into mitosis in the absence of
tumour growth, must be explained by an
increase in cell loss following irradiation.
Histological methods were used to monitor
the time course of such changes. A 7-fold
increase in the percentage of pyknotic cells
was observed by Day 2 following irradiation
and normal values were again attained by
Day 7. These changes may reflect the pro-
cesses of reoxygenation and repopulation
known to influence the results offractionated
radiotherapy.
QUANTITATION OF THERMOTOL-
ERANCE CAPACITY OF AN EXPERI-
MENTAL RAT TUMOUR. T. E.
WHELDON, E. C. HINGSTON & J. L. LEDDA,
M.R.C. Cyclotron Unit, Hammersmith Hos-
pital, London W12
The ability of tumours subjected to hyper-
thermia in vivo to acquire heat resistance
(thermotolerance) was investigated using the
rat fibrosarcoma SSBla, serially trans-
planted in Wistar/CFHB rats in the dorsal
site. Hyperthermia treatment was by water-
bath heating of tumours, previously clamped
to occlude blood flow, at 43-5°C for various
times. Both single treatments (heating times
10-60 min) and split treatment (initial time
30 min, interval 24 or 48 h, variable second
heating time 10-90 min) were given and
tumour response assessed as growth delay.
Single treatments yielded a linear dose-
response curve, whilst split treatments (at
both 24 and 48 h intervals) yielded less
uniform, though approximately linear, dose-
response curves of considerably shallower
slope. Comparison of the slopes of these
dose-response curves gave a "Thermotoler-
ance ratio" (TTR) of 4 09 at 24 h and 3-45
at 48 h, indicating a large capacity for
thermotolerance. Monte Carlo simulation
studies suggest that the distribution of
tumour sensitivities to a second treatment is
much broader than to a first treatment.
Thermotolerance is capable of providing
substantial but variable protection of tum-
ours against subsequent hyperthermia, and is
influenced by factors other than those which
determine response to a first heat treatment.
RELATIONSHIPS BETWEEN RADIA-
TION CELL-SURVIVAL-CURVE PAR-
AMETERS. J. KIRK & G. F. BRUNTON,
Glasgow Radiobiology Group, Glasgow Insti-
tute of Radiotherapeutics and Oncology, Bel-
videre Hospital, London Road, Glasgow G31
4PG and West of Scotland Health Boards,
Department of Clinical Physics and Bio-
Engineering, Glasgow G4 9LF
Assessment of cellular radiation damage is
based on loss of reproductive integrity,
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quantified by the fraction of surviving
clonogenic cells and depicted by cell-survival
curves. Recent studies challenge the estab-
lished view, held for more than 30 years, that
the parameters of the expressions used to
describe radiation cell-survival curves are
independent and characteristic of a cell line.
Investigations using CHO derived cell lines
indicate on the contrary, that cell-survival
parameters are related and that, within that
constraint, cell lines can display different
survival characteristics under different condi-
tions and after trauma. That parametric
relationship is not an artefact of formulation
or data fitting, and has been identified for
various melanoma cell lines in animal and
man; in vitro and in vivo.
Further evidence (Sparrow et al., 1967,
Radiat. Res., 32, 915) supports the view that
a simple relation exists between these cell
survival curve parameters and chromosome
volume or DNA content, strongly suggesting
that radiation damage and repair may be
linked through the chromosome volume.
Clinically, the implications of these rela-
tionships may be of considerable significance;
offering the possibility ofrapid assessment of
cellular radiation characteristics for certain
tumour classes from assays of the DNA
content of cells taken from patients during
biopsy, and offering the prospect for im-
proved treatment of such radio-resistant
tumours as melanoma.
IDENTIFICATION OF 2 DIVIDING
CELL POPULATIONS IN THE RAT
JEJUNUM WHICH RESPOND DIF-
FERENTLY TO X-RAYS. P. G. BARNES
& N. A. WRIGHT, IHistopathology Department,
Royal Postgraduate Medical School, London
W12 OHS
A method has been devised for the investiga-
tion of any heterogeneity of cellular response
to cytotoxic agents that may arise with
respect to differentiation and position in the
cell cycle.
From studies over a time course after
exposure to a wide range of doses of X-rays,
it has been found that:
1. The population of cells in the last transit
cell cycle (a) undergoes death via liquefaction
necrosis, (b) is the population from which
survivors give rise to clonal repopulation
after expsoure to high doses.
2. The population of cells in previous transit
cell cycles (a) produces a large number of
autophagosomes that contain nuclear mater-
ial within 2 h of irradiation, (b) is unusually
sensitive to a rapid, interphase cell death.
The biological origin of these differences is a
matter of speculation. Identification of the
point at which the differentiating progeny of
the functional stem cells are no longer poten-
tial stem cells has previously been a matter
ofconjecture. These studies provide definitive
evidence that cells lose their "stemness" at
the last transit division. Two implications of
this result are that in this renewal system
(a) functional organization appears to differ
from that in the haemopoietic system, where
multipotential "stemness" is promptly lost
on differentiation, (b) arguably, all dividing
epithelial cells in tumours (of the intestine)
may be clonogenic, as is the case in normal
tissue.
THE VALUE OF LACTATE DEHYDRO-
GENASE AS A NON-SPECIFIC TUM-
OUR MARKER IN SEMINOMA OF
THE TESTIS. A. G. ROBERTSON & G.
READ, Department of Radiotherapy, Christie
Hospital, Manchester
Serum ot-foetoprotein and ,B-HCG have been
found to be excellent tumour markers in
malignant teratoma of the testis, but are of
little value in seminoma. Serum lactate
dehydrogenase (LDH) has been found to be
a non-specific tumour marker. Serum LDH
levels were measured in 38 patients with
seminoma of the testis treated between
December 1980 and December 1981 at the
Christie Hospital, Manchester. No patients
with minimal or no para-aortic disease had
raised levels of the marker. Ten out of 11
patients with more advanced disease had
high levels. Serum levels were measured
during treatment with radiotherapy and
chemotherapy. Of the 10 patients with high
levels, 7 returned to normal before the
completion of treatment. Subsequent evalua-
tion with computer assisted tomography
confirmed complete resolution of the disease.
One patient's level fell, but not to normal,
and at his first follow-up visit was found to
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have further metastatic disease. One patient
with iising levels died of uncontrolled dis-
ease and the third had residual disease. In
1 patient, on follow-up, levels rose before
clinical recurrence became apparent. It is
suggested that LDH levels may aid assess-
ment of the extent of disease in seminoma
and its response to treatment.
THE TECHNIQUE AND POTENTIAL
APPLICATION OF PROGESTERONE
RECEPTOR MEASUREMENT BY
ISOELECTRIC FOCUSING. R. HARLAND,
E. HAYWARD, D. M. BARNES, A. HOWELL,
L. G. SKINNER & R. A. SELLWOOD, Depart-
ment of Surgery, Withington Hospital and
Clinical Research Laboratories, Christie Hos-
pital, Manchester
Recently the induction of progesterone
receptor (PR) synthesis in human breast
cancer by tamoxifen has been described
(Namer, et al., 1980, Cancer Res., 40, 1750)
and it has been suggested that this may give
a specific prediction of hormone response.
However, metastases may be inaccessible or
too small for assay by standard techniques
(Scatchard analysis). This reduces the value
of any test which relies of PR measurement
at the time of treatment.
A method has been developed which
allows the use of small samples including
needle biopsies, for PR estimation. After
incubation of cytosol (minimum total volume
70 u1A) with 3H-R5020 (a synthetic progesta-
gen), hormone-labelled receptor was separa-
ted by iso-electric focusing (IEF). PR
measured by IEF, though an underestimate,
correlates with Scatchard analysis (rho=
0-89) with a specificity of 9400 and a lower
limit of sensitivity of 30 fmol/ml cytosol.
This method has allowed us to measure
PR before and after starting tamoxifen in
14 patients, of whom 4 showed induction of
PR. Progression of disease by 3 and 6 months
respectively was seen in 0/4 and 0/3 patients
in whom PR was induced, compared with
6/10 (NS) and 7/7 (P=0-0167) patients in
whom no induction occurred. PR assay by
IEF increases the availability of PR data
in metastatic disease and may allow an early
indication ofhormone response.
BACKSCATTERED ELECTRON IMAG-
ING BY SEM OF NORMAL AND NEO-
PLASTIC URINARY BLADDER. G. P.
SMITH & A. E. WILLIAMS, Teaching and
Research Centre, University of Edinburgh,
Western General Hospital, Edinburgh
The study of urinary bladder cancer by
scanning electron microscopy (SEM) has
concentrated on the changes in luminal sur-
face structure and organization during neo-
plasia (Hodges, 1979, in Biomedical Research
Applications of Scanning Electron Micro-
scopy Vol 1, p. 307). However, SEM back-
scattered electron imaging (BSE) of tissues
stained with heavy elements such as silver,
allows visualization of subsurface structures
(Becker & Sorgard, 1979, SEM/II, 825).
This method was used to examine normal and
carcinogen treated rat bladders, and biopsies
from patients under investigation for bladder
cancer. Results show a predominance of
binucleate superficial cells in the bladders of
normal rats, and an organizational relation-
ship between the superficial layer of cells
and the underlying intermediary cell nuclei
suggestive of the proliferative unit organiza-
tion seen in epidermis (Potten, 1974, Cell
Tissue Kinet, 7, 77). In rat bladders treated
with methylnitrosurea, changes were ob-
served in intracellular organization before
urothelial changes could be observed histo-
logically or by SEM examination of surface
topology; superficial cells became predomin-
antly uninuclear, and the relationship be-
tween superficial and intermediary cells was
lost. Areas where these changes have occurred
can be readily seen at low magnification.
Preliminary observations of human biopsy
material suggest that similar organizational
and neoplastic changes occur. The results
suggest that the use of BSE imaging may
provide a useful tool in the early diagnosis
ofbladder cancer.
PROPERTIES OF DIHYDROFOLATE
REDUCTASE FROM HUMAN TUM-
OURS. J. A. BLAIR, A. E. PHEASANT, A. M.
SALEH, A. SAHOTA, S. B. WHITBURN, G. D.
OATES & R. N. ALLAN, Department of
Chemistry, University ofAston inBirmingham,
Birmingham B4 7ET and The General
Hospital, Steelhouse Lane, Birmingham 4
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Dihydrofolate reductase (DHFR) plays an
important role in cell proliferation. Its
inhiibition arrests the cell cycle at the G1-S
transition. 10-Formylfolate and 10-formyl-
folatetetraglutamate are formed by oxidation
of the tetrahydro forms found in mammalian
cells. Bovine liver DHFR does not reduce 10-
formylfolate and is inhibited by 10-formyl-
folate and 10-formylfolatetetraglutamate
(K, =2 x 10-8M and 1 3 x 10-8M respectively).
Lactobacillus casei DHFR reduces 10-formyl-
folate slowvly and is weakly inhibited by it.
In normal man 10-formylfolate is not reduced
and inhibits the5reduction of folic acid by
DHFR. DHFR from some human intestinal
and breast tumours slowly reduces 10-formyl-
folate and is wveakly inhibited by it. Thus
DHFR from these tumours is similar to the
L. casei enzyme, and different from the nor-
mal mammalian enzyme. 13C NMR studies
suggest that the reduced binding of10-formyl-
folate to the L. casei DHFR is caused by lack
of a nucleophilic group on the enzyme. It is
suggested that an important event in some
malignant transformations 5is the synthesis
via a mutated gene of a DHFR which no
longer fully responds to a normal cell
proliferation control mechanism.
CORRELATION OF SIALYLTRANS-
FERASE AND SIALIC ACID AND
THEIR COMPARISON WITH 6
OTHER BIOCHEMICAL MARKERS
FOR MONITORING THE EXTENT
OF DISEASE IN PATIENTS WITH
BREAST CANCER. B. J. MCDERMOTT*,
C. C. QUINN*, B. M. LEAMYt, L. JEFFREY:
& R. F. MURPHY*. *Dept Biochemistry,
Queen's University Belfast; tBon Secours
Hospital, Cork and tBelvoir Park Hospital.
Belfast
For up to 24 mnonths post-mastectomy the
following serum markers were measured in
86 patients: carcinoembryonic antigen (CEA),
C-reactive protein (CRP), a-acid glycoprotein
(AGP), erythrocyte sedimentation rate (ESR),
1-glutamyl transferase (GGT), alkaline phos-
phatase (AP), sialyl transferase (ST): sialic
acid (SA) was determined retrospectively.
Prior to therapy, there was a higher incidence
of raised marker measurements in the sera
of patients wA-ithl metastatic cancer than in
35
those who were apparently disease-free,
except for ST. Only CEA and ST concentra-
tions were raised in a significantly greater
iumber of patients wN-ith minimal disease
(lymph-node involvement or recurrence) than
in the tumour-free group (CEA, P <001:
ST, PS0005). In those with minimal dis-
ease, 5/6 raised values were attributed to the
lymph-node+ group. A patient defined as
tumour-free had the higher ST value. Lymph-
node involvement was detected clinically 6
months later. Alterations in tumour burden
were reflected in 5000 of the changes in ST
concentrations by comparison with a correla-
tion of >75% for CEA, CRP and GGT
measurements. ST values were raised up to
8 months before clinical detection of advan-
cing disease in 9/17 patients. In 7 cases, ST
concentrations reached a peak and then
declined; notably in the evolution of meta-
stases, values returned to normal before
progression was overt. ST results have been
substantiated by SA estimations in both
vertical and horizontal studies. These mark-
ers appear to be particularly sensitive to
distant spread of disease at an early stage.
THE SURFACE PROTEINS OF HU-
MAN ASTROCYTOMAS IN CULTURE.
G. V. SHERBET*, M. WILDRIDGE* & R. M.
KALBAGt, *Cancer Research Unit, Royal
Victoria Infirmary and tDepartment of Neuro-
logical Surgery, Newcastle General Hospital,
Newcastle upon Tyne
Cell cultures were initiated from human
astrocytomas. Surface proteins of subcon-
fluent cultures were labelled by lactoperoxi-
dase-catalysedradio-iodination, andseparated
by electrophoresis on 6.0% cylindrical poly-
acrylamidegels. Normalglial andastrocytoma
cells were found to have a common surface-
protein pattern, but there were significant
quantitative changes in the expression of
certain protein components of the astro-
cytomas, as compared with normal glial
cells. A component of mol. wt -225K which
appears, by criteria of electrophoretic be-
lhaviour and immunological reactivity with
mono-specific anti-fibronectin antibodies, to
be fibronectin, was reduced by between
15 and 70%o in 6/8 astrocytomas. However,
receptors for fibronectin could be detected
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on the surface of the cells. Anotlher comnpo-
nent(s) of average mol. w%vt of 148K appeared
to be amplified by a factor of 16-3-5 in all
astocrytomas. Surface components of mol. wt
<75K also incorporated more radioiodine
than did the corresponding external proteins
of normal glial cells. It is suggested that
some of these changes, especially in the 225K
and 148K external proteins, may be associa-
ted wNith the malignant state.
AN E.M. STUDY OF ALKALINE PHOS-
PHATASE IN A TRANSPLANTABLE
OSTEOGENIC SARCOMA OF THE
RAT. P. M. INGLETON, P. V. GAITENS,
L. A. COULTON* & R. G. G. RUSSELL*.
Departments of Zoology and *Human Meta-
bolism and Clinical Biochemistry, The lni-
versity, Sheffield S1O 2TN
Studies of a transplantable osteogenic sar-
coma of the rat have shown that it lays
down ground substance which can mineralize
(Ingleton et al., 1977, Lab. Anim. Sci., 27,
748); that areas, designated A-D, can be
distinguished within the tumour mass on the
basis ofmitotic activity, hormone responsive-
ness and degree ofnecrosis and mineralizationi
(Underwood et al., 1979, Eur. J. Cancer, 15,
1151); and that it is rich in bone-like alkaline
phosphatase (AP) (Ingleton et al., 1979,
Eur. J. Cancer, 15, 685). This report details
ultrastructural investigations, using Gomori's
technique, into the site of AP activity in the
tumour, during growth after implantation.
After only 15 days growth no distinct areas
could be discerned in the tumnour noduile, but
AP activity was seen in cells throughout,
particularly in Golgi membranes, as discrete
punctate areas on plasma membranes and as
tiny spots on matrix vesicle membranes.
Active cells of areas A-D from tumours
growing for 22-35 days had menmbrane-
associated AP activity, even w%hen dividing.
Area C contained a high proportion of
necrotic tissue and no AP activity could be
detected in the cell debris. Organized collagen
developed intercellularly during tumour
growth and AP activity was detected in
discrete bodies associated with collagen.
Crystalline calcium spicules also developed,
apparently from AP-containing bodies,
whether on cell membranes or collagen
bundles. notably in area D afte- 35 days
growth. The close association of AP activity
with tumour cells during early stages of
tumour growth. and later appearance inter-
cellularly and in venules, correlates, witlh
previous in vico observations that serum AP
concentrations only rise significantly after
the tumour has been growA-ing for at least
11 days.
ISOFERRITIN STUDIES USING THE
LEUCOCYTE-ADHERENCE INHIBI-
TION ASSAY IN PATIENTS WITH
MALIGNANT LYMPHOMA. L. BRUCE.
A. GRAIL & B. W. HANCOCK, Department oJ
Medicine, Royal HIallamsIhire Hospital, Shef-
field
We have shown (Hancock et al., 1979, Br. J.
Haernatol., 43, 223) that ferritin from
Hodgkin's disease involved spleen differs in
its immunological reactions from ferritin
from normal spleen.
l,AI assays (Browne et al., 1980, Tumour
Diafgnos., 5, 266) were performed oIn 17
patients Awith malignant lymphoma and 14
controls, comprising 5 patients with non-
lymphomatous disease and 9 normald individ-
uals. Ferritin was purified from autopsy
spleens and resolved into a series of iso-
ferritins of discrete pl by preparative iso-
electric focusing. Normal spleen ferritin,
lymphoma spleen ferritin and constituent
acidic and basic isoferritins were tested in
LAI assavs.
A non-adherence index (NAI) was calcu-
lated for acidic and basic isoferritins in eachi
patient and control. In the lymphoma group
a NAI of 3941 was obtained with the acidic
isoferritins, compared to a NAI of -80 in
the control group (P<0-01). With the basic
isoferritins, the lymphoma group gave a
NAI of 17-5 and the control group -1 2
(P<0 2).
Analytical isoelectric focusing of lyin-
phoma-spleen ferritins revealed no extra
acidic isoferritins in comparison w-ith normal-
spleen ferritin. but there w-ere differences in
basic components. The LAI results suggest a
possible difference in the antigenicity of
isoferritins associated with mealignant lvm-
phoma.
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INHIBITORY EFFECT OF THE
LANDSCHUTZ ASCITES CARCINOMA
ON GRANULOMATOUS INFLAM-
MATORY RESPONSE INDUCED BY
CORYNEBACTERIUM PARVUM L. C.
MCINTOSH, R. G. P. PUGH-HUMPHREYS*,
R. A. FRASER. A. W. THOMISON & J. I.
MILTON, Departments of Pathology and *Zoo-
logy, University of Aberdeen, Aberdeen AB9
2ZD, Scotland
I.p. or i.v. administration of Corynebacteriumn
parvum (CP) within MF1 mice resulted in a
generalized inflammatory response, associa-
ted with marked hepatosplenomegaly and
accompanied by a pronounced granulomatous
response in the liver. Injection of the Land-
schiitz ascites carcinoma (LAC) 24 h after
the microorganism substantially reduced the
intensity of the inflammatory response. and
decreased both the frequency and size of the
hepatic granulomas, as revealed by mor-
phometric analysis of histological sections.
The difference in cellular composition of
the granulomas between the experimental
groups, as revealed by light microscopy, was
f'urtlier emphasized and characterized by
ultrastructural studies. These revealed the
predominance of macrophages within the
granulomas in tumour-bearing mice, in con-
trast to the predominance of epithelioid cells
in those lesions which developed in mice
given CP alone.
Our experimental findings showr that the
inhibitory effect of the growing LAC on
granuloma formation in response to CP
cannot be ascribed to (a) sequestration of
tlhe microorganism within the growing tum-
our, nor (b) the action of a non-specific
inflammatory stimulus nor (c) diversion and
sequestration of mononuclear phagocytes in
the growring tumour. The observed inhibition
of liver granuloma formation is consistent
with an effect mediated by a soluble, heat-
stable tumour-associated factor(s).
BLOOD GROUPS IN LUNG CANCER
PATIENTS AND THE EFFECTS OF
IMMUNOTHERAPY. H. M. ANTHONY,
University Department of Jmmunology, Leeds
General Infirmary
In a trial started in 1975, lung cancer patients
treated with Levamisole on an intermittent
schedule starting before operation showed
significantly greater post-operative mortality
(Anthony et al.. 1979, Thorax, 34,), par-
ticularly if they were Blood Group 0 or
Rh(D) -ve. The trial patients have now been
followed for at least 4 years, and deaths in
persons of these blood groups were also
significantly increased from 7 weeks after
operation onwards if they received
Levamisole.
The trial patients showed rather higher
A/O and D+/D- relative incidences if they
wvere node- than if they were node+. This
has been confirmed in 2 other series of lung-
cancer patients, though the difference within
each series did not reach significance. Pre-
liminary results suggest higher A/O and
D+/D- relative incidences in a series
selected for longer survival, but no effect of
blood group on survival of trial patients
treated wi-ith placebo has been observed.
An interaction of blood group with the
response to immunotherapy has also been
described in AML by Harris et al. (2nd
Meeting on the Immunotherapy of Cancer,
N.I.H., in press), in which patients who were
Blood Group A and/ or Rh(D)+ve survived
longer if treated with immunotherapy. It
seems that the interaction of genotype with
the response to immunotherapy may be a
more generalized effect, linked to differences
in the mechanisms of resistance to tumour
spread, though our data suggest that the
mechanisms involved may not be identical
in respect of ABO and Rh Groups.
IN VITRO LYMPHOCYTE RESPON-
SES AND PLASMA COPPER LEVELS
IN PATIENTS WITH MALIGNANT
LYMPHOMA. M. D. WHITHAM & B. W.
HANCOCK, Department of Medicine, Royal
Hallamshire Hospital, Sheffield
In this study, in vitro lymphocyte response
to PHA, T-cell population and plasma
copper levels have been assessed in 70
patients with malignant lymphoma, as all
of these indices have been shown to deviate
from normal in these patients and elevated
plasma copper has been associated with
depressed in vitro lymphocyte responses
(Hancock et ral., 1980. Tumor Diagnosis, 3,
140).
39 patients with Hodgkin's disease (HD)
and 31 with non-Hodgkin's lymphoma (NHL)
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have been tested together wi-ith groups of
age/sex-matched controls. Taken as groups,
significant differences were seen from control
responses in HD for PHA response in auto-
logous plasma (P<0001) and AB serum
(P<0 005), T-cell population (P<0-025) and
plasma copper (P<005). In the NHL
group significant differences were seen in
PHA response in autologous plasma (P <
0.001) but not in AB serum, in T-cell popula-
tion (P<0.005) but not in plasma copper.
Taking individual responses, in HD gener-
ally the number of abnormal values increase
with disease stage for PHA response and
plasma copper but not T-cells. In NHL the
relationship between stage and abnormal
values is not as clear; only plasma copper
levels show any association. No association
was found in either group between high
plasma copper and depressed lymphocyte
responses.
We have observed abnormal PHA respon-
ses and T-cell counts in both HD and NHL
and abnormal copper levels in HD, and are
continuing the study to see whether these
responses correlate with response to treat-
ment.
INCIDENCE AND TYPE OF TUM-
OURS INDUCED BY ORAL DMBA
IN NK-DEFICIENT C57B1 BG/BG
MICE, +/BG LITTERMATES AND H-2
CONGENIC STRAINS OF B10 OF
VARYING NK ACTIVITY. A. J. COCHRAN,
S. ARGOVt, K. KXRREt, G. 0. KLEIN* &
G. KLEIN*, *Pathology andSurgery, University
of California, Los Angeles and tDepartment
of Tumor Biology, Karolinska Institutet,
Stockholm
To study the effect of the beige mutation on
chemical carcinogenesis, 64 C57BL bg/bg
mice and 83 + /bg littermate controls received
5 weekly intragastric doses of DMBA. We
examined the incidence and histological
types of tumours that developed. By 165
days after first DMBA contact 180/ of +/bg,
and 31% of bg/bg mice developed tumours.
Beige mice had a higher incidence of epithel-
ial and non-epithelial tumuors in cutaneous
or subcutaneous sites. The incidence of
lymphomas was similar in the groups but
they appeared earlier in the beige. After
500 days, 33 + /bg and 27 bg/bg mice were
still alive, 60/83 + /bg animals (72%) and
47/64 bg/bg (740%) having developed tumours.
The beige group showed a higher incidence
of non-thymic lymphomas, but the incidence
of thiymic lymphomas, cutaneous epithelial
tumours and bile-duct adenomas was similar
in the 2 groups.
In a continuing study of NK, intact Bi1
(27), B1OA (25), B10.BR (39), BIOG (48)
mice and developed more frequently in
BIOS congenic animals (30), squamous car-
cinomas have developed more frequently in
BiOS animals (B1OS 8/30-27%) than in the
rest (11/139-8%, P<0.05). At present it
looks as though both thymic and extra-
thymic lymphomas may also be of increased
frequency in the BiOS, NK-deficient animals.
The role of DMBA as a suppressor of NK
activity has been confirmed.
IN VIVO AND IN VITRO CHARAC-
TERIZATION OF A TRANSPLANT-
ABLE, SPONTANEOUS MURINE
ASTROCYTOMA. G. J. PILKINGTON*,
J. L. DARLINGt, P. L. LANTOS* & D. G. T.
THOMASt, *Department of Neuropathology,
Institute of Psychiatry and tGough Cooper
Department of Neurological Surgery, Institute
ofNeurology, London
Spontaneous brain tumours of mice are rare,
but Fraser (1971, J. Pathol., 103, 266) found
gliomas in 1.5% of mice from the inbred VM
strain. Homogenates oftumour-bearing brain
when injected intracerebrally into syngeneic
mice produced anaplastic astrocytomas. The
present paper describes the fine structure and
immunohistochemistry of these transplanted
tumours.
Three cell lines derived from VM tumours
(Serano et al., 1980, Acta Neuropathol., 51,
53) have also been maintained in vitro and
examined by fluorescence and electron micro-
scopy in order to establish the glial nature
of the cells. Immunofluorescence studies
using the astrocyte specific markers (glial
fibrillary acidic protein and glutamine syn-
thetase) and large extracellular transforma-
tion-sensitive protein were carried out.
TEM of cell pellets reveals different ratios
of microtubules to 10 nm filaments in the 3
cell lines; this indicates the degree of cellular
differentiation. The effects of dbcAMP on the
surface activity and organelle distribution
have also been assessed. Multicellular spher-
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oids have been induced and examined by
scanning and transmission EM in order to
elucidate the extent of adhesion between
cells.
Tumours are now being induced in VM
mice by intracerebral injection of cells frorn
the line with the most obvious astrocytic
features.
LIPID CLEARANCE IN A COLONIC
TUMOUR MODEL IN RATS. R. WINDLE
& P. R. F. BELL, Department of Surgery,
University of Leicester, Royal Infirmary,
Leicester
AMarked derangement of fat inetabolism
occurs in cancer. Body fat is lost and serum
triglyceride (TG) levels may be elevated
(Dilman et al., 1981, Br. J. Cancer, 43, 637).
Although adipose tissue lipolysis is increased
in experimental cancer (Kralovic et al., 1977,
Eur. J. Cancer, 13, 1071) an alternative
explanation may be that there is a reduction
in turnover of circulating TG. This may be
measured by the clearance of an exogenous
lipid emulsion load (Rossner et al., 1974,
Eur. J. Clin. Invest., 4, 109).
In order to test this hypothesis lipid clear-
ance has been measured wA-ith TG levels
during the induction of a, colorectal cancer
model in rats. Tumnours were induced by 15
weekly injections of 15 mg/kg dimethyl-
hydrazine (DMH). Serum TG and the rate
of clearance of i.v. lipid emulsion (0.5 ml/kg
of 2000 intralipid) were measured before
DMH and 8 weeks thereafter in 6 groups of
12 fasted rats. Groups of age-matched rats
not given DMH acted as controls.
Tumours appeared at 32 Aweeks in the
DMH groups. TG levels were reduced by
18 o at 16 and 24 weeks and then became
raised by 3300 over pretreatment levels at
48 mweeks, by which time the animals had
lost 15-20V/ of their body wNeight. Lipid
clearance was 'significantly increased at 16
and 24 wNeeks and then reduced by half at
48 wreeks. Administration of hepaiin at 48
weeks increased lipid clearance and reduced
TG levels. There was no change with time in
TG levels or in lipid clearance rate in the
control groups. In conclusion, TG levels are
related to the rate of lipid turnover. Thie
early increase of clearance may have been
caused by DM11. A large tumour load was
associated with raised TG levels and a
reduction in turnover.
THE EFFECT OF A SUB-CUTANEOUS
GROWING TUMOUR ON THE ACT-
IVITY OF HOST TISSUE MITO-
CHONDRIA. J. CUMMINGS & K. C.
CALMAN, Department of Oncology, University
IofGlasgoiv
Mitochondrial fractions wvere prepared from
the liver, kidney and skeletal muscle of rats
1. 6, 12, 18 and 26 days after an s.e. injection
of either a suspension of Walker carcino-
sarcoma cells (105) or sterile saline, and im-
mediately assessed for structural and func-
tional integrity. Using a polarographic
technique to measure respiratory capacity,
it was found that Day 1 mitochondria from
both controls and tumour-bearing animals
showved signs ofdamage and impaired respira-
tory fuinction. This effect was believed to be
caused by the presence of anaesthetic mole-
cules in the mitochondrial membranes. On
Day 6 all mitochondria were respiring
properly; no evidence of membrane disrupt-
tion was apparent. From Day 12 onwards,
however, by which time tumours had become
palpable, mitochondria from rats injected
wvith the tumour cells would not consume 02
unless magnesium ions (MgCl2) were added
to incubation media. Over this period oftime,
control animal mitochondria were still respir-
ing normally. Both types of mitochondria
wvere structurally intact. Kidney mitochond-
ria required by far the greatest amount of
magnesium for normal activity; in some
cases 10 mM MgCl2. The liver's requirement
never exceeded 3 mM MgCl2. The quantity
of magnesium ions necessary to restore
normal mitochondrial function increased
with tumour size. These results suggest that
host tissue mitochondria of the tumour-
bearing animals became increasingly more
deficient in magnqsium ions with tumour
growth, magnesium ions are essential for
normal iespiratory activity and magnesium
repletion in vitro, at least, restores normal
mitochondrial function.
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STUDIES ON THE COMPOSITION OF
HUMAN BREAST CYST FLUID. P. L.
YAP, W. R. MILLER, M. M. ROBERTS, B.
FREEDMAN, C. L. MIRTLE, A. D. PRYDE &
D. B. L. MCCLELLAND, Blood Transfusioni
Service, University Department of Clinical
Surgery and University Department of Thera-
peutics and Clinical Pharmacology, Royal
Infirmary? Edinburgh EH3 9HB
An inereased risk of breast carcinoma exists
in women with gross cystic disease of the
breast (GCD), suggesting that the 2 diseases
share a common aetiology. We have therefore
studied cyst fluid in an effort to discover its
origin.
Wide variations in the concentration of
IgA, IgG, lactoferrin, lysozyme, albumin and
dehydroepiandrosterone sulphate (DHAS)
were found in 96 cyst fluids obtained from 75
patients with GCD. Sedimentation-coefficient
determinations performed on the 19 cyst
fluids with the highest IgA concentrations
indicated that 10 contained mainly i1S
(secretory) IgA and resembled external
mammary secretions such as colostrum and
milk. These cysts also contained high con-
centrations of DHAS (80-9 + 28-9 mg/l; mean
+ s.e.) but low concentrations of IgG and
albumin. The remaining 9 cyst fluids resem-
bled serum, with the IgA mainly of the 78
(serum) type, and these evsts contained low
concentrations of DHAS (5-9 + 1-9 mg/l) but
high concentrations of IgG and albumin.
Other cyst fluids not analysed by ultra-
centrifugation contained low concentrations
of all the proteins measured. No relationship
wvas observed between the concentrations of
the substances studied, and clinical factors.
The differing compositioni of' cyst fluid
suggests that components of the fluid mayr
be derived from either serum or breast
sources. There may therefore be more than
one mode of cyst formation.
CHARACTERIZATION OF HAMSTER
NK CELLS. D. M. TEALE, R. C. REES,
A. CLARK & C. W. POTTEP., Department of
Virology, UntiverSity of Sheffield illedical
School. Sheffield S10 2RX
The importance of NK cells in tumour
immunology has previously been reviewed
(Herberman & Holden, 1978, Adv. Cancer
Res., 27, 305), and their association with
large granular lymphocytes has been des-
cribed in the human, rat and mouse (Timonen
et al., 1981, J. Exp. Med., 153, 569). In this
report w-e describe the existence ofa cytotoxic
cell population, in hamster peripheral blood,
capable of lysing NK-susceptible target cells
in a 4h Cr-release assay. These cells proved
to be non-adherent to nylon-wool, non-
phagocytic and capable of lysing xenogeneic
targets. When separated on Percoll Dis-
continuous Density Gradients cvtotoxicitv
was associated with fractions enriched foi
large, sometimes granular, lymphocytes. In
addition, cells with the morphology of large
lymphocytes A-ere shown to bind to NK-
sensitive target cells. NK activity was onlly
demonstrable in spleen and peripheral blood,
with low levels in peritoneal-exudate cells,
and activity was shown not to be age-
restricted.
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